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The development of portal hypertension and ascites in cirrhosis is associated with a
variety of circulatory abnormalities. The aims of this thesis were to assess the
haemodynamic changes of cirrhosis and their clinical consequences, and investigate
the circulatory and clinical effects of therapies used in the management of portal
hypertension and ascites.
Portal, systemic, cardiopulmonary and renal haemodynamics of 96 patients with
alcohol related cirrhosis were measured. Their inter-relationship and predictive value
for variceal haemorrhage and survival during a mean follow-up of 19 months was
investigated. Severity of liver disease was related to the hepatic venous pressure
gradient (HVPG), azgos blood flow (AzBF) and systemic hypotension. During
follow-up, HVPG predicted survival and variceal bleeding.
Propranolol and isosorbide-5-mononitrate are widely used in the prophylaxis of
variceal haemorrhage, but recent reports have suggested they may compromise renal
function. Renal blood flow (RBF), HVPG, AzBF and systemic haemodynamics were
measured in 26 cirrhotic patients before and after each drug or combination therapy.
Despite significant changes in the other parameters, no fall in RBF was detected.
The novel vasodilating beta-blocker carvedilol offers potential in the treatment of
portal hypertension, but little data currently exist. Portal, cardiopulmonary and
systemic haemodynamics and renal function were assessed in 17 cirrhotic patients
after acute and chronic therapy. Although carvedilol had a continued portal
hypotensive effect after 1 month with no detrimental effect on liver blood flow or
renal function, a significant minority of patients were unable to tolerate chronic
therapy.
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Adenosine-antagonism offer a new therapeutic approach to cirrhotic ascites and renal
dysfunction. The effects on renal and systemic haemodynamics and renal function
were assessed following administration of FK352 (a novel adenosine-1 antagonist) to
12 cirrhotic patients with ascites. An improvement in natriuresis, diuresis and RBF
was detected.
The mechanism of an improvement in renal function following transjugular
intrahepatic portosystemic stent-shunt (TIPSS) procedure remains unclear. The acute
effects of TIPSS insertion on RBF, portal and cardiopulmonary haemodynamics
were studied in 11 cirrhotic patients. Despite dramatic changes in portal pressure and
cardiopulmonary parameters, no effect on RBF was detected.
The long-term clinical effects of TIPSS remain poorly described. The outcome of
TIPSS procedure undertaken in 130 consecutive patients at our institution with a
mean follow-up of 18 months are reported. Rates of variceal rebleeding,
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Patients with cirrhosis and portal hypertension exhibit a hyperdynamic circulation
characterised by a raised cardiac output (CO) and low systemic vascular resistance
(SVR). However, there is evidence of paradoxical renal vasoconstriction in addition
to reduced sodium and water excretion, which can lead to ascites formation and
impaired renal function. The aims of this thesis were to assess the inter-relationship
and prognostic value of the circulatory abnormalities observed in cirrhosis, and to
investigate the haemodynamic, renal and clinical effects of pharmacological and
radiological interventions in the management ofportal hypertension and ascites.
1 a The haemodynamic abnormalities in cirrhosis and the development of
portal hypertension, ascites and renal dysfunction.
The development of portal hypertension appears critical in the initiation of the
subsequent circulatory and haemodynamic changes in cirrhosis. However, the exact
mechanisms behind these circulatory abnormalities and their relationship to the
degree of portal hypertension and risks of variceal bleeding and death remain
unclear.
la i Pathophysiology of Portal Hypertension.
Increased hepatic resistance
The initiating factor in the development of portal hypertension is increased resistance
to portal blood flow. In Western countries, the commonest cause is cirrhosis, where
the main resistance to flow occurs in the hepatic sinusoids. Alternatively, resistance
to flow in the portal or splenic veins or in the hepatic veins leads to pre-hepatic or
post-hepatic portal hypertension respectively (see table 1).
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Collateral vessels open and partially decompress the portal system. They arise most
commonly in the retroperitoneal area, but are most visible and problematic when they
occur at the gastro-oesophageal junction. In addition, collateral vessels arise at the
peri-anal, peri-umbilical, splenorenal, ovarian, and choledochal regions, in the
peritoneum and at areas of surgical anastamoses or ileostomy/colostomy sites.
Normally 100% portal venous blood reaches the hepatic veins, but in cirrhosis this
can be reduced to 13% (Mclndoe 1928).
However, despite formation of these collaterals, portal hypertension is maintained by
increased splanchnic arterial flow leading to increased portal blood flow (figure 1).
As for any vascular system, according to Ohm's law, changes in pressure are defined
by the equation:
P = Q x R
where P is the portal pressure, Q is the splanchnic blood flow and R is the resistance
of the portal venous system. Thus an increase in either vascular resistance or



























Alcoholic central hyaline sclerosis
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Figure 1. (over page)
Schematic representation of the haemodynamic changes seen in portal hypertension
and possible targets for pharmacological intervention:
1) Beta-1 blockade (to reduce cardiac output).
2) Beta-2 blockade or vasoconstrictors (to reduce splanchnic blood flow).
3) Vasodilators (to reduce intrahepatic resistance).
4) Beta-2 blockade (to reduce variceal/collateral flow).
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Figure 1
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Stellate cells (analogous to tissue pericytes) are found in the perisinusoidal space of
disse. Following liver injury, these cells are transformed into contractile
myofibroblasts which are central to the initiation of fibrogenesis (Friedman 1993).
They express smooth muscle alpha-actin and produce collagen. Stellate cells also
regulate sinusoidal resistance and flow in response to a variety of vasoactive
substances, particularly endothelin and nitric oxide (NO) (Rockey 1997). Therefore,
at least part of the resistance to portal venous flow is under dynamic control.
Circulating plasma endothelin levels are increased in cirrhosis, and endothelin causes
a direct constriction of the hepatic sinusoid, probably via contraction of stellate cells
(Zhang et al 1994, Rockey et al 1996). Increased endothelin receptor density has also
been reported in the cirrhotic liver (Gandhi et al 1996). Nitric oxide can be produced
by the stellate cells themselves, and exogenous or endogenous NO can prevent
endothelin induced contraction of these cells, and can relax pre-contacted cells
(Kawada et al 1993, Rockey et al 1995). The exact contibution of these and other
substances such as carbon monoxide to the regulation of intrahepatic portal
hypertension remains to be elucidated.
Increased splanchnic inflow
The resistance to portal flow is the "backward" component of portal hypertension.
The "forward" component is the increased splanchnic inflow which occurs secondary
to the peripheral vasodilatation seen in these patients. The low SVR and the
associated raised CO lead to the characteristic hyperdynamic circulation of cirrhosis
(Groszmann 1994). It has been suggested that the main site of this low SVR is in fact
the splanchnic circulation (Marato et al 1993).
In addition to its potential role in the regulation of sinusoidal flow, NO has been
implicated in the systemic circulatory abnormalities of cirrhosis. It has been proposed
that vasodilatation results from increased levels of NO secondary to the raised
endotoxin and cytokine levels seen in cirrhosis. However, this remains unproven and
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studies have reported variable circulatory effects following administration of NO
synthetase inhibitors to cirrhotic patients (Whittle et al 1992). Elevated levels or
increased sensitivity to a number of other vasodilatory substances have also been
reported in cirrhosis (see table 2).
Vascular hyporeactivity has also been well documented in cirrhosis and portal
hypertension (Hadoke et al 1997). It is unclear whether this is secondary to an
attenuated response to vasoconstrictors, defective postreceptor signal pathways or
decreased basal cytosolic calcium levels (Tsai et al 1997).
It seems likely that the vasodilated circulation of cirrhosis is due to a disturbed
balance between vasodilatory substances and vasoconstrictors (eg. endothelin, the
renin-angiotensin-aldosterone and sympathetic nervous systems (RAAS and SNS),
and anti-diuretic hormone). The relative contributions of the parenchymal liver
disease itself and the intrahepatic, porto-systemic and intrapulmonary shunts to
alterations in this balance remain unclear.
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Table 2.














la ii Pathophysiology of Cirrhotic ascites and renal dysfunction.
Underfill and overflow hypotheses
Patients with cirrhotic ascites have evidence of impaired sodium and water excretion
in addition to their dilated systemic and constricted renal circulations (Henriksen
1995). The traditional "underfill" hypothesis of ascites formation proposed that
transudation of fluid into the peritoneal cavity occurred secondary to
hypoalbuminaemia and obstruction to blood and lymph flow caused by portal
hypertension. The resulting diminished effective plasma volume caused activation of
vasoconstrictors such as the RAAS, the SNS and antidiuretic hormone (ADH) to help
maintain blood pressure. However, this theory does not explain the fact that cardiac
output is classically high and sodium retention present in cirrhosis even before
ascites develops.
Therefore the "overflow" hypothesis was developed, suggesting that renal sodium
and water retention was the primary event occurring as a result of an autonomic
reflex in response to portal hypertension. The consequence was increased CO and
eventually ascites formation. However this hypothesis does not explain the activation
ofRAAS, SNS and ADH seen in cirrhotic patients.
Peripheral vasodilatation hypothesis
To explain these findings and contradictions, the alternative "peripheral
vasodilatation" hypothesis was conceived (Schrier et al 1988). This suggests that
arterial vasodilatation is the initiating event, leading to effective arterial underfilling
which triggers neuro-humoral factors such as the RAAS, SNS and ADH causing
retention of sodium and water. The arterial vasodilatation is thought to be due to
cirrhosis and portal hypertension causing impaired liver clearance and extra hepatic
shunting of splanchnic vasodilators (fig. 2). A number of putative vasodilators have
been proposed to account for this perpheral vasodilatation in cirrhosis, although no
specific causal relationship has been identified (table 2).
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Figure 2.













SODIUM & WATER RETENTION;
RENAL VASOCONSTRICTION.
(Footnote: RAAS: renin-angiotensin-aldosterone system; SNS: sympathetic
nervous system; ADH: antidiuretic hormone.)
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Humeralfactors
Elevated levels of aldosterone, plasma renin activity (PRA) and angiotensin II have
been reported in cirrhotic patients, suggesting a major role for the RAAS in the
circulatory abnormalities of cirrhosis. Sodium excretion is inversely related to PRA,
and higher levels of angiotensin II are found in patients with ascites compared with
non-ascitics (Tobe et al 1993). Plasma noradrenaline levels are also raised in
cirrhotic patients with ascites and are inversely related to renal blood flow suggesting
that activation of the SNS also contributes to sodium retention and renal
vasoconstriction (Henriksen et al 1984).
Raised ADH levels and decreased delivery of fdtrate to the diluting segments reduces
free water clearance in cirrhosis (Schedl et al 1960), and recent reports of ADH
inhibition with opiod receptor agonists are of interest (Moreau et al 1996). Raised
levels of endothelin-1 have also been reported in cirrhotic patients with ascites, and
endothelin antagonists are under evaluation in this situation. Increased levels of
adenosine have been shown to reduce sodium and water excretion in cirrhosis (Llach
et al 1993) and adenosine-antagonism appears to improve renal sodium and water
handling in animal studies (Kuan et al 1993). Therefore adenosine antagonism offers
a novel therapeutic approach in cirrhosis.
27
Renal vascular and tubular changes
The pathogenesis of the renal dysfunction in cirrhosis is complex and poorly
understood. In particular the paradoxical renal vasoconstriction in the face of
systemic vasodilatation remains largely unexplained. The renal vasculature is
particularly sensitive to angiotensin II mediated vasoconstriction (Arroyo et al 1991).
Activation of the RAAS, the SNS and ADH secondary to splanchnic and peripheral
arterial vasodilatation can reduce renal perfusion and sodium and water excretion as
described above.
A number of studies have confirmed that renal sodium and water retention are early
features of the renal dysfunction in cirrhosis and precede the development of ascites
or a fall in the glomerular infiltration rate (GFR) (Jimenez et al 1985). This early
sodium retention has been shown to correlate with the degree of hyperaldosteronism
in cirrhotic patients (Arroyo et al 1979), however as water retention progresses, the
reduced free water clearance leads to hyponatraemia and hypo-osmolarity. In the
absence of excess diuretic therapy, the hyponatraemia seen in cirrhosis is due to
water excess rather than sodium deficiency which therefore has implications for
management. As described above, increased levels of ADH, endothelin and
adenosine may contribute to the renal vascular and tubular abnormalities of cirrhosis.
Hepatorenal Syndrome
The hepatorenal syndrome (HRS) is characterised by uraemia, oliguria,
hyponatraemia and low urinary sodium in the absence of renal histological changes
in a patient with chronic liver disease. This syndrome is the end of the spectrum of
renal abnormalities seen in cirrhotic patients and the definition has recently been
updated by an International Working Party of Hepatologists (Arroyo et al 1996, see
table 3).
Patients with hepatorenal syndrome have evidence of profound activation of the SNS
and RAAS and raised levels of endothelin-1 leading to intense renal vasoconstriction
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and reduced GFR (Arroyo et al 1983, Forrest et al 1996). The renal autoregulatory
system and the protective intrarenal vasodilators including prostaglandins fail to
maintain renal perfusion in response to the intrarenal vasoconstriction and systemic
hypotension.
The hepatorenal syndrome occurs in patients with poor hepatic reserve who often
have severe jaundice and hepatic encephalopathy and are a major management
problem. Such patients have a grave prognosis and survival is uncommon beyond




International Ascites Club's diagnostic criteria for the diagnosis of Hepatorenal
Syndrome.
MAJOR CRITERIA:
- Chronic/acute liver disease with advanced liver failure and portal hypertension.
- Low GFR (creatinine clearance <40ml/min.)
- Absence of shock/sepsis/nephrotoxic drugs.
- Absence of excessive gastrointestinal or renal fluid losses (weight loss > 500g/day
in absence or >lkg/day in presence ofperipheral oedema).
- No sustained improvement in renal function following diuretic withdrawal and
plasma expansion with 1.5 1 isotonic saline.
- Proteinuria <500mg/l and no evidence of obstructive uropathy/parenchymal renal
disease.
ADDITIONAL CRITERIA:
- Urine volume <500ml/day.
- Urine sodium <10 mmo1/1.
- Urine osmolality > plasma osmolality
- Urine red blood cells <50 per high powered field.
- Serum sodium <130mmol/l.
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1 b. Clinical sequelae of portal hypertension.
lb i Variceal Haemorrhage
Although portal hypertension contributes to the development of ascites and hepatic
encephalopathy, its most important complication is variceal haemorrhage.
Longitudinal studies have suggested that most patients with cirrhosis will eventually
develop varices (Christensen et al 1981). The rate of variceal bleeding in patients not
receiving therapy in contolled clinical trials ranges from 15% to 68% (median 32%),
with bleeding occuring most commonly within 2 years of follow-up (Pagliaro et al
1994, et al, Burroughs et al 1986). The mortality of a first variceal haemorrhage
approaches 50%, and between 47% and 84% of survivors will have a recurrent bleed
during a mean follow-up of 1-2 years (Pagliaro et al 1989). Reported mortality
figures from recurrent bleeding range from 20% to 70% (Pagliaro et al 1989).
Therefore effective primary and secondary prophylactic therapy for variceal bleeding
is worthwhile. For primary prophylaxis, identification of patients at high risk of
bleeding would allow clinicians to target therapy to these patients, and avoid
unecessary treatment of the large number ofpatients who will not bleed.
lb ii Risk factors for variceal bleeding
The portal pressure in an individual is dynamic rather than fixed. It demonstrates
circadian changes with highest pressures nocturnally, and increases post-prandially,
with alcohol intake, and in response to coughing, sneezing and exercise (Alvarez et
al 1996, Garcia-Pagan et al 1996). Such variations may combine with local factors in
the vessel walls to contribute to a surge in pressure which can lead to a variceal
bleed. However, the exact mechanisms responsible for variceal bleeding remain
unclear.
31
A number of clinical, endoscopic and haemodynamic parameters have been shown to
predict variceal haemorrhage. The risk of a first bleed has been shown to increase
with the severity of liver disease, endoscopic assessment of variceal size and the
presence of red markings on the varices (NIEC 1988).
A "bleeding threshold" of a 12mmHg pressure difference between the portal vein and
inferior vena cava has also been identified, with bleeding very unlikely at lower
pressure gradients (Garcia-Tsao et al 1985). In addition, in patients who have had a
variceal haemorrhage, the risk of rebleeding is low if a pressure gradient fall of 20%
or greater is achieved (Feu et al 1995). Although the degree of portal hypertension as
measured by the hepatic venous pressure gradient (HVPG) independently predicts
bleeding (Merkel et al 1992), when the HVPG rises above 12mmHg there is no linear
relationship between HVPG and bleeding risk.
There have been suggestions that the HVPG can predict mortality in patients with
cirrhosis (Merkel et al 1992, Armonis et al 1997). Therefore it is possible that
measurement of the HVPG or other haemodynamic parameters can be used in
conjunction with the Childs-Pugh score to assess prognosis.
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lb iii Cirrhotic Ascites.
The probability of survival 1 and 5 years after the first episode of cirrhotic ascites
has been estimated at 50% and 20% respectively (Arroyo et al 1986) which
emphasises the prognostic importance of ascites. In addition, the associated
metabolic abnormalities such as hyponatraemia and renal impairment are often
exacerbated by diuretic therapy.
Spontaneous bacterialperitonitis
Spontaneous bacterial peritonitis (SBP) is defined as infected ascitic fluid occuring in
patients with ascites, in the absence of bowel perforation ot intra-abdominal abscess
2
formation. Clinically an ascitic fluid polymorphonucleocyte count >250cells/mm ,
even in the absence of positive ascitic fluid culture is highly suggestive of SBP. The
occurrence of SBP is associated with a one year survival of 30%, therefore such
patients should be considered for liver transplantation (Altman et al 1995).
Refractory ascites
Approximately 10-20% patients with cirrhotic ascites are refractory to treatment with
sodium restriction and diuretics (Gerbes 1993). It has recently been suggested that
the definition of refractory ascites should include the two distinct conditions of
"diuretic resistant" and "diuretic intractable" ascites (Arroyo et al 1996, table 4).
Alternative therapeutic strategies include large volume paracentesis with intravenous
colloid replacement (Gines et al 1988), TIPSS procedure (Ochs et al 1995), and the
less popular peritoneo-venous shunts and extracorporeal ascitic concentration
devices. Due to the associated advanced liver disease and limited success of
alternative therapies, such patients should also be considered for transplanatation.
Hepatorenal syndrome
As previously described, the hepatorenal syndrome is the end of the spectrum of
renal abnormalities in cirrhosis. This syndrome occurs in patients with poor hepatic
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reserve who often have severe jaundice and hepatic encephalopathy and are a major
management problem. Such patients have an ominous prognosis without liver
transplantation, following which all renal abnormalities disappear.
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Table 4.
Definitions and Diagnostic Criteria of Subtypes of Refractory Ascites
Diuretic-resistant Ascites:
Ascites that cannot be mobilised or the early recurrence ofwhich cannot be
prevented because of lack of response to sodium restriction and intensive diuretic
therapy.
Diuretic-intractable Ascites:
Ascites that cannot be mobilised or the early recurrence ofwhich cannot be
prevented because of the development of diuretic-induced complications that
preclude the use of an effective diuretic dosage.
Diagnostic criteria:
Treatment period required: patients must be on intensive diuretic treatment for at
least one week.
Lack of response: mean weight loss < 200g/day during last 4 days of intensive
diuretic treatment and urinary sodium excretion <50mmol/day.
Dietary sodium restriction: a 50mmol sodium diet.
Intensive diuretic treatment: spironolactone 400mg/day plus frusemide 160mg/day
(or equivalent doses of other diuretics).
Early ascitic recurrence: within 4 weeks of initial mobilization.
Diuretic-induced complications:
- development of encephalopathy in absence of other precipitating factors
- increase in serum creatinine by >100% to above 200mmol/l
- decrease in serum sodium by >10mmol/l to <125mmol/l.
- decrease in serum potassium to <3mmol/l or increase >6mmol/l despite appropriate
measures to normalize potassium levels.
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1 c. Beta blockers and nitrates in the management of portal hypertension and
their effects on the kidney.
The most widely used drugs in the prevention of variceal haemorrhage are
propranolol and other nonselective beta-blockers. Recent reports have also assessed
nitrates in this situation. Propranolol reduces portal pressure and collateral blood
flow in cirrhosis and numerous studies have confirmed its efficacy as prophylaxis
against portal hypertensive related gastrointestinal bleeding (Pascal et al 1987,
Lebrec et al 1988, Hayes et al 1990, Conn et al 1991, Poynard et al 1991, D'Amico
et al 1995). However, approximately 40% patients will not have a portal hypotensive
response to beta-blockade (Garcia-Tsao et al 1985).
Nitrates such as isosorbide-5-mononitrate (ISMN) are long acting venodilators that
reduce portal pressure and hepatic vascular resistance (Hayes et al 1988, Navasa et al
1989, Garcia-Pagan et al 1990). They reduce the risk of variceal bleeding (Angelico
et al 1993, Bertoni et al 1994), and are often used as alternative therapy for patients
who are intolerant to beta-blockade. Recent reports have suggested that the
combination of propranolol and nitrates may be the optimum portal hypotensive
therapy (Garcia-Pagan et al 1991, Vorbioff et al 1993, Merkel et al 1997).
Ideally, haemodynamic assessement of the reduction in portal pressure in response to
drug therapy should be undertaken by measurement of the hepatic venous pressure
gradient (HVPG). This is particularly important in patients with alcoholic cirrhosis in
whom a spontaneous fall in of > 20% is possible with abstinence (Vorbioff et al
1996). Although a reduction in the resting pulse rate by 25% is often used to guide
the dosage of beta-blockers, the splanchnic haemodynamic effects of beta-blockers
are unpredictable and correlate poorly with the systemic effects.
36
lc i Primary prophylaxis of variceal bleeding
Beta-blockers
Nine controlled studies incorporating a total of 999 patients and summarised in 4
meta-analyses (Hayes et al 1990, Poynard et al 1991, Pagliaro et al 1992, D'Amico
et al 1995) have confirmed the efficacy of beta-blockers over placebo in the
prevention of a first variceal haemorrhage. Most investigators have studied
propranolol in this role, although nadolol has been used in some studies. The risk of
bleeding is reduced by approximately 45% with beta-blocker therapy and in most
studies there is a trend towards improved survival (Lebrec et al 1997). There appears
to be a consistent benefit to patients with moderate or large oesophageal varices from
all aetiologies of liver disease. Side effects of beta-blockers were reported in 15-50%
patients, although only a minority withdrew from therapy (D'Amico et al 1995).
Two studies have compared propranolol with sclerotherapy in the prevention of a
first variceal haemorrhage (Andreani et al 1990, PROVA 1991). One showed
reduced bleeding in the propranolol group at two years (Andreani et al 1990) but no
difference was detected in the other. Propranolol is also superior to a combination of
propranolol and sclerotherapy in this situation (PROVA 1991). The benefits of band
ligation over sclerotherapy have been confirmed (Laine et al 1995), therefore trials
must compare this with propranolol in the primary prophylaxis of variceal
haemorrhage. To date only one study (published in abstract form) has compared
banding with propranolol in this situation (Sarin et al 1997). No significant
difference in the bleeding rate was detected.
Nitrates
In 1993, Angelico et al suggested that nitates may be as efficacious as beta-blockers
in the primary prophylaxis of variceal bleeding, offering an alternative to those
patients who are intolerant of beta-blockers (Angelico et al 1993). Although the
recently published long term follow-up of this study confirmed that variceal bleeding
rates were similar in both groups, an increased mortality was obseved in elderly
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patients given nitrates (Angelico et al 1997). Another recent study reported a reduced
incidence of first variceal haemorrhage in patients given a combined regime of
nitrates and beta-blockers compared with those given beta-blockers alone (Merkel et
al 1996). No effect on survival was seen. This suggests that this drug combination
may be the optimum therapy in the primary prophylaxis of variceal bleeding, but
confirmatory studies are awaited particularly in view of the possible adverse effect of
nitrates recently reported by Angelico.
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lc ii Prevention of variceal rebleeding.
Following survival from an initial variceal bleed, the majority of patients will
rebleed, the risk being highest in the first few weeks. To reduce this risk, further
treatment such as pharmacological therapy, endoscopic methods of variceal
obliteration or creation of a portosystemic shunt is required.
Beta-blockers
Similar to the situation for the primary prophylaxis of variceal haemorrhage, non¬
selective beta-blockers are the most widely used drugs in the prevention of
rebleeding after a variceal haemorrhage. Most experience is with propranolol,
although some investigators have used nadolol. A total of 828 patients in 13
randomised trials, summarised in 4 meta-analyses (Pagliaro et al 1989, Hayes et al
1990, D'Amico et al 1995, Bernard et al 1997) have confirmed the efficacy of beta-
blockers in the prevention of variceal rebleeding. Most studies suggest an
improvement in survival compared with placebo. Overall, beta-blockers appear to
reduce the risk of rebleeding by approximately 40% and mortality by 20% (Lebrec et
al 1997).
Nine randomised studies compared beta-blockers with sclerotherapy in the
prevention of variceal rebleeding, and most reported similar efficacy although the
studies showed substantial heterogeneity (D'Amico et al 1995). However,
complications were more frequent and severe with sclerotherapy. There is no clear
evidence of a benefit from combined beta blockade and sclerotherapy compared with
either treatment alone.
Beta-blockers & Nitrates
The addition of nitrates (usually ISMN) to beta-blockers improves the portal
hypotensive response (Garcia-Pagan et al 1990). A recent study reported reduced
rebleeding when this drug combination was used in comparison with endosopic
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sclerotherapy (Villanueva et al 1996). However, studies are required to compare
pharmacological therapy with band ligation for the prevention of rebleeding, since
this is now the endoscopic treatment of choice.
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lc iii Renal effects of propranolol and nitrates in cirrhosis.
Any reduction in renal function is critical in cirrhotic patients, because they are
already at risk of renal impairment due to reduced RBF, glomerular filtration rate
(GFR) and sodium and water excretion (Epstein 1988). Recent suggestions that beta-
blockers and nitrates may have deleterious renal effects in cirrhosis include reports of
reduced renal sodium excretion (Vorbioff et al 1993, Rector & Reynolds 1984,
Salmeron et al 1993) and reduced renal perfusion (Ljubicic et al 1992, Bolognesi et
al 1994, Henriksen & Ring-Larsen 1993) following administration of these drugs.
This is important in view of their increasing use in the prophylaxis of variceal
haemorrhage.
Beta-blockers
The renal effects of beta-blockers are complex due to their haemodynamic and
neurohumoral actions. In addition to their portal hypotensive action, they reduce
cardiac output and increase systemic vascular resistance, but have minimal effect on
MAP (Henriksen et al 1992). Propranolol therapy leads to increased circulating
noradrenaline which can cause sodium and water retention (Best & Halter 1985),
however reduced levels of renin, angiotensin and aldosterone (beta-1 blockade) are
also observed which increase salt and water excretion (Bernardi et al 1989).
In addition, renal vasoconstriction due to beta-2 blockade has been suggested as a
mechanism by which beta-blockers may impair RBF and GFR (Wilkinson 1982).
However, the clinical significance of these changes remain unclear and data on
cirrhotic patients are limited.
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Nitrates
Nitrates are venodilators that reduce cardiac output and MAP in cirrhosis (Navasa et
al 1989, Salmeron et al 1993, Merkel et al 1987). There has been concern that this
associated fall in blood pressure and resulting activation of the RAAS and
sympathetic nervous system may compromise renal function in patients with
advanced liver disease. Nitrate therapy has been shown to reduce renal plasma flow,
GFR, and sodium and water excretion and increase renin and aldosterone values in
cirrhosis (Salmeron et al 1993, Salerno et al 1996). Combination therapy with
propranolol and nitrates has also been shown to worsen ascites to a greater extent
than propranolol alone (Vorbioff et al 1993).
However, two recent reports have shown no effect on GFR, free water clearance,
activity of the RAAS or ascites outcome in patients given combined ISMN and
propranolol therapy, or combined ISMN and nadolol therapy compared with nadolol
alone (Morrillos et al 1994, Merkel et al 1995).
Therefore the published evidence on whether beta-blockers and nitrates have
deleterious renal effects in cirrhosis is conflicting although concern remains
regarding their safety in this patient population. It is unclear whether any adverse
renal effect is secondary to intra-renal changes or impaired renal perfusion
consequent on the systemic haemodynamic effects of these drugs.
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1 d. Alternative drug therapies for portal hypertension.
Although propranolol is the pharmacological agent used most widely in the primary
prophylaxis of variceal haemorrhage and the prevention of rebleeding, many cirrhotic
patients are unable to take this drug due to contraindications or intolerance (Silvain et
al 1985). Ever since Bathal and Grossman confirmed that vasodilator therapy
modulated the increased vascular resistance in the cirrhotic liver, nitrates and other
vasodilators have been investigated as treatments for portal hypertension (Bathal &
Grossman 1985). However, the recently reported adverse effect of nitrates on
survival in elderly patients is a major concern (Angelico et al 1997).
Although haemodynamic and clinical studies have suggested that the combination of
a beta-blocker and ISMN is the optimum therapy for portal hypertension, doubts
remains about the compliance, tolerability and renal effects of such a drug
combination in cirrhotic patients. Therefore the search continues for other drugs
which reduce portal pressure and are well tolerated in cirrhosis.
ldi Vasodilating beta-blockers
Carvedilol is a novel vasodilating non-selective beta-blocker. In addition to its non¬
selective beta-blocking effects, it is a weak alpha-1 receptor antagonist and exhibits
calcium channel antagonism (Sponer et al 1992, Zweiten 1993). Recent reports have
shown that this drug has beneficial acute effects on portal pressure in cirrhosis
(Forrest et al 1996, Sekiyama et al 1997) and may indeed have a greater portal
hypotensive effect than propranolol (Banares et al 1997).
Carvedilol has two enantiomers, R (+) and S (-). Cirrhotic patients have an increased
S- to R- ratio, resulting in more beta-blockade compared with control subjects
(Neugebauer et al 1992). The beneficial beta-blockade in cirrhotic patients with
portal hypertension may be combined with reduced intrahepatic and collateral
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resistance due to the alpha-blockade. In addition, improved RBF and GFR has been
described in hypertensive patients given carvedilol, probably due to the alpha-
antagonism (Dupont et al 1987). It remains unclear as to whether carvedilol has
beneficial haemodynamic effects after chronic administration to cirrhotic patients and
whether it can be tolerated in this patient group.
One other study assessed nipradilol, another vasodilating beta-blocker, in cirrhotic
patients (Sugano et al 1995). However, only patients with Childs A or B liver disease
were investigated and renal function was not assessed. In addition, less than two
thirds of patients had a >10% fall in HVPG following acute administration of
nipradilol, compared with 81% after carvedilol (Forrest et al 1996).
Id ii Alpha-agonists
Clonidine is a centrally acting alpha-2 adrenoreceptor agonist which reduces
sympathetic activity in cirrhosis. Studies have shown a reduction in CO, MAP and
portal pressure in cirrhotic patients given clonidine (Willett et al 1986, Albillos et al
1992, Roulot et al 1992). Its effect seems to depend on a reduction in the
portosystemic collateral circulation and the drug is relatively well tolerated.
However, in a comparative haemodynamic study in patients with large varices,
clonidine had minimal portal haemodynamic effects despite major beneficial effects
with propranolol (Tincani et al 1995).
Id iii Alpha-blockers
Prazosin, an alpha-adrenoreceptor antagonist has been investigated in cirrhotic
patients. The rationale for its use is the increased sympathetic tone present in the
splanchnic vascular bed in cirrhosis, and the direct reationship between the degree of
portal hypertension and the activity of the SNS (Willet et al 1985). A reduction in
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HVPG and improvement in hepatic perfusion with no systemic circulatory effects has
been reported (Mills et al 1984, Albillos et al 1995). However, increased sodium and
water retention was observed (Albillos et al 1995).
ldiv Vasodilators
Molsidomine is a preferential venodilator that relaxes vascular smooth muscle by
increasing intracellular concentrations of cGMP. It has been shown to have a
moderate portal hypotensive effect following acute administration to cirrhotic
patients (Vinel et al 1990, Ruiz del Arbol et al 1991). However, a recent study
reported no greater effect on HVPG with combined molsidomine and propranolol
compared with propranolol alone (Garcia-Pagan et al 1996).
ldv Other drugs
Diuretics reduce blood volume and cardiac output and can therefore be used to
reduce portal pressure (Okumura et al 1991). Five-hydroxy-tryptamine (5-HT2)
receptor antagonists and angiotensin converting enzyme inhibitors have shown portal
haemodynamic effects (Koshy et al 1992, Ibarra et al 1992), but problems with
encephalopathy and systemic hypotension have been encountered (Vorbioff et al
1989, Pariente et al 1985).
A number of other drugs including angiotensin-II blockers, endothelin receptor
antagonists, nitric oxide synthetase inhibitors and pentoxifylline have been shown to
have a portal hypotensive effect in small studies. However, little data exist and none
of these drugs have been shown to be superior to propranolol.
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1 e. The therapeutic potential of adenosine-antagonism in cirrhotic ascites and
renal dysfunction.
le i Background
Adenosine is an endogenous nucleoside produced locally by the intracellular
degradation of ATP in response to hypoxia. It has potent vasoactive properties and
may be involved in the pathogenesis and maintenance of renal failure, with intra-
renal haemodynamic and tubular effects (Spielman et al 1982, Balakrishnan et al
1996). Adenosine-1 receptors are present on the afferent renal artery and proximal
renal tubule and stimulation of these inhibit adenyl cyclase, resulting in renal
vasoconstriction and sodium and water retention in animal models (Agmon et al
1993, Takeda et al 1993). Adenosine-2 receptors are found in the vasculature of the
systemic circulation and stimulation leads to vasodilatation via activation of adenyl
cyclase (Stiles 1992).
Balakrishnan and colleagues recently reported a decline in urine flow, natriuresis,
free water clearance and GFR following administration of adenosine to healthy
subjects (Balakrishnan et al 1996). These effects are similar to the abnormalities seen
in cirrhotic patients and it has been suggested that adenosine has a major role in the
haemodynamic and particularly the renal changes of cirrhosis (Milani et al 1983,
Llach et al 1993).
le ii Effects of adenosine in cirrhosis
Increased oxygen demand and tissue hypoxia are found in cirrhosis (Martini et al
1972, Moreau et al 1988) which lead to the systemic release of vasodilating
substances including adenosine (Ohisalo 1987, Olsson & Pearson 1990). However in
the kidney, adenosine acts as a vasoconstricting metabolite, reducing renal perfusion,
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GFR and sodium excretion via adenosine-1 receptors on the afferent renal artery and
the proximal tubular cells (Balakrishnan et al 1996, Agmon et al 1993, Takeda et al
1993, Edlund et al 1994). Cirrhotic patients have an increased number of adenosine
receptors and increased sensitivity to adenosine (Hall & Granger 1986, Paul et al
1993, Hasegawa et al 1989).
Llach et al reported that increasing extracellular adenosine levels by administration
of dipyridamole to cirrhotic patients reduced sodium and free water excretion (Llach
et al 1993). In their study, renal plasma flow and GFR were also reduced in patients
with ascites and high basal renin levels. Animal studies have confirmed that
stimulation of adenosine-1 receptors on the renal artery and proximal tubule cells
leads to similar renal effects to those found in cirrhosis, with renal vasoconstriction
and sodium and water retention (Agmon et al 1993, Takeda et al 1993, Holz &
Steinhausen 1987). This suggests that adenosine-1 specific antagonism may be
beneficial in the treatment of the renal abnormalities of cirrhosis.
le iii Adenosine-antagonism in cirrhosis
Methylxanthines such as theophylline and aminophylline are non-specific adenosine-
1 and -2 antagonists. Studies have shown that they improve RBF (as measured by
thermodilution or 133-Xenon washout methods), GFR, urine volume and sodium and
water excretion in cirrhosis, with variable effects on systemic haemodynamics
(Milani et al 1983, MacMathuna et al 1990, Moreau et al 1992, Forrest et al 1997).
However, these drugs are far from ideal for use in cirrhosis because of their side-
effects which include tachycardia, gastrointestinal disturbances, arrhythmias and
convulsions. In addition, xanthines are poorly cleared in cirrhosis, and at higher
plasma levels they act via phosphodiesterase inhibition with variable clinical effects
(Fredholm 1980). However, specific adenosine-1 blockade may be beneficial in
cirrhotic patients with impaired sodium and water excretion or functional renal
impairment.
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Previous use of adenosine-1 specific antagonists in animal studies demonstrated
amelioration of the acute renal failure induced by glycerol, endotoxin and cisplatin
(Kellet et al 1989, Knight et al 1991, Knight et al 1992). Kuan reported an increased
diuresis and natriuresis, but minimal systemic effects in rats given an adenosine-1
antagonist (Kuan et al 1993). Administration of an adenosine-1 antagonist has been
shown to attenuate the oliguria, hypofiltration, and electrolyte retention induced by
adenosine in an animal model, suggesting that adenosine-1 antagonism may protect
the kidney from the undesirable haemodynamic and tubular effects of adenosine
(Barrett & Wright 1994). However, to date no study has investigated the effects of an
adenosine-1 antagonist in cirrhotic patients.
48
1 f. Transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the
management of variceal haemorrhage and cirrhotic ascites.
Since the first description of the transjugular intrahepatic portosystemic stent-shunt
procedure (TIPSS) in 1988 (Rossle et al 1988), there have been numerous reports
describing its use in the management of complications of portal hypertension.
However, much of this literature involves assessment in small numbers of patients
and therefore it has been difficult to determine the exact role of TIPSS.
1 f i Variceal haemorrhage
Acute bleeding
The first reports of TIPSS procedure were in the management of oesophageal
variceal haemorrhage (Richter et al 1990, Zemel et al 1991, Ring et al 1992,
Simpson et al 1993). The treatment of uncontrolled variceal haemorrhage or
recurrent oesophageal variceal haemorrhage remain the main indications for TIPSS
placement. Although there is a lack of prospective randomised trials, TIPSS
procedure appears preferable to shunt surgery or oesophageal transection as a rescue
procedure for uncontrolled variceal haemorrhage refractory to endoscopic therapy in
view of the less invasive technique and lower reported complications and mortality
(Jalan et al 1995). Successful TIPSS placement leads to immediate haemostasis in up
to 100% patients with uncontrolled variceal haemorrhage (McCormick et al 1994,
Jalan et al 1995, Sanyal et al 1996). However rebleeding, encephalopathy and shunt
dysfunction occur at a variable rate during follow-up (see table 5).
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Recurrent variceal haemorrhage despite adequate endoscopic therapy is also an
accepted indication for TIPSS placement, especially for patients with Childs B or C
disease in whom shunt surgery is poorly tolerated (Shiffman et al 1995). However, it
is only in the past 2-3 years that randomised trials comparing TIPSS procedure with
endoscopic therapy for the prevention of rebleeding following a variceal bleed have
been reported. Seven of these trials have been published as full papers (Cabrera et al
1996, Rossle et al 1997, Sanyal et al 1997, Cello et al 1997, Sauer et al 1997, Jalan
et al 1997, Merli et al 1998) and 3 in abstract form only (G d'EAIH 1995, Garcia-
Villarreal et al 1996, Sauer et al 1997).
In these studies, patients were randomised to receive TIPSS or definitive endoscopic
therapy a variable time (up to 11 days) following control of the initial bleed by
endoscopic or pharmacological means. All except two studies which used band
ligation (Jalan et al 1997, Sauer et al 1997), used sclerotherapy as the endoscopic
treatment. Three studies added propranolol to the endoscopic treatment arm (G
d'EAIH 1995, Rossle et al 1997, Sauer et al 1997). These studies are summarised in
table 6.
Eight of these studies found a significant reduction in rebleeding following TIPSS
compared with endoscopic therapy with the other 2 showing no difference between
the groups. There were no differences in mortality in 8 of the trials, with one finding
an increased mortality in the TIPSS group (Sanyal et al 1997) and another an
increased mortality in the sclerotherapy group (Garcia-Villarreal et al 1996). In some
trials, patients who rebled in the endoscopy group were "rescued" by TIPSS
insertion, thereby reducing the chance of demonstrating a difference in survival.
Rates of encephalopathy were higher in the TIPSS group in most studies, but was
generally easy to manage.
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Shunt insufficiency and the subsequent need for surveillance of the stent remain a
major limitation of TIPSS (see below) and must be taken into account when
comparing TIPSS with other treatment modalities. Little data exist regarding the cost-
effectiveness of the various treatments for variceal haemorrhage, although two of the
TIPSS vs endoscopic therapy trials for prevention of rebleeding (Jalan et al 1997,
Cello et al 1997) concluded that there were no significant differences in total costs on
long-term follow-up. Although TIPSS procedure appears promising in preventing
rebleeding from oesophageal varices, further data are required to further define its role
in this situation.
Gastric varices.
Endoscopic methods for treating bleeding gastric varices remain unsatisfactory.
Recent reported benefits of gastric variceal injection of bovine thrombin or tissue
adhesives appear promising but require comfirmation with larger studies (Ramond et
al 1989, Williams et al 1994). In view of the perceived benefits of TIPSS over shunt
surgery, TIPS
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1 f ii Refractory ascites
In most series, refractory ascites is the second most common indication for TIPSS
placement after variceal haemorrhage. Over the past 3 years, numerous abstracts and 8
published papers (Ferral et al 1993, Villarreal et al 1993, Ochs et al 1995, Wong et al
1995, Somberg et al 1995, Quiroga et al 1995, Crenshaw et al 1996, Forrest et al
1996) have assessed the efficacy of TIPSS for refractory ascites. The findings are
broadly similar and indicate that TIPSS improves renal function and urinary sodium
excretion. Most patients have at least a partial improvement in their ascites with
reduced diuretic requirements.
The mechanism of ascites reduction following TIPSS placement remains unclear.
Possibilities include a reduction in the activity of the RAAS despite worsening of the
hyperdynamic circulation (Wong et al 1997) and a hepatorenal reflex directly linking
portal pressure and renal perfusion (Jalan et al 1997).
Most studies assessing TIPSS procedure for refractory ascites report a high incidence
of hepatic encephalopathy and a high mortality due to the advanced liver disease
present in these patients. In view of their poor prognosis, any patient with refractory
ascites should also be considered for orthotopic liver transplantation.
Two studies (Ochs et al 1995, Lebrec et al 1996), have reported results of randomised
trials comparing TIPSS with paracentesis. Lebrec et al reported that TIPSS procedure
was effective in the control of refractory ascites, but only in patients with Childs C
disease (Lebrec et al 1996). Survival was actually lower in patients treated with
TIPSS, possibly due to a reduction in hepatic perfusion. They concluded that the
improvement in ascites following TIPSS placement was due to neurohumeral factors
controlling naturesis, which depended on hepatic sinusoidal pressure. Ochs and
colleagues reported that TIPSS was more effective than paracentesis in the control of
refractory ascites with a reduced period of hospitalisation (Ochs et al 1995). No
difference in survival between the two groups was observed.
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In addition, one study presented in abstract form randomised patients with refractory
ascites to receive either TIPSS or a peritoneovenous shunt (Zervos et al 1996). The
authors found that both treatments were equally effective in palliating ascites but no
difference in survival was detected. Patients treated with peritoneovenous shunts had
fewer days in Intensive Care.
Currently TIPSS procedure should probably not be considered a routine treatment for
refractory ascites, and its use for this indication is best limited to controlled trials.
These studies should compare TIPSS placement with paracentesis or peritoneovenous
shunt insertion and should also assess quality of life issues.
lfiii Hepatorenal syndrome.
Patients with hepatorenal syndrome have a poor prognosis without orthotopic liver
transplantation. Several short reports describing the use of TIPSS in a small number of
such patients have suggested it may improve renal function, reduce the need for
haemodialysis and prolong the waiting time to liver transplantation (Lake et al 1993,
Spahr et al 1995, Sturgis et al 1995). However mortality is very high in this patient
group due to their advanced liver disease and the use of TIPSS can only provide at
best a temporary reprieve.
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If iv Complications of TIPSS procedure
Hepatic encephalopathy
One of the major concerns that was anticipated about TIPSS placement is the
increased risk of hepatic encephalopathy due to the portosystemic shunting of blood
and reduced hepatic sinusoidal perfusion. New or worsening encephalopathy has been
reported in 15-29% patients in the large TIPSS cohort studies (table 5). Unlike the
chronic debilitating encephalopathy reported by the early shunt surgery series, post-
TIPSS encephalopathy has been relatively easy to manage by protein restriction and
lactulose therapy. However for the minority of patients who develop refractory
encephalopathy, successful treatment by shunt reduction or occlusion has been
reported (Hauenstein et al 1995, Haskal et al 1995, Rose et al 1995).
Studies that have prospectively assessed the development of encephalopathy
following TIPSS placement have suggested that the incidence is highest in the first 3
months after shunt placement and improves thereafter, presumably due to gradual
narrowing of the stent (Sanyal et al 1994, Riggio et al 1996). Using multivariate
analysis, encephalopathy following TIPSS procedure has been shown to be predicted
by its presence prior to the procedure, hypoalbuminaemia, non-alcohol aetiology of
cirrhosis, advanced age, female gender and low post-procedural PPG (Sanyal et al
1994, Jalan et al 1995, Somberg et al 1995, Riggio et al 1996). Such patients must be
carefully assessed prior to and following TIPSS procedure, and perhaps should have
narrower stents placed and be given prophylactic lactulose and protein restriction.
It remains difficult to achieve the optimal balance between the reduction in portal
pressure required to minimize the risk of variceal bleeding, maintain hepatic perfusion
and avoid post-procedural encephalopathy.
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Shunt insufficiency
The frequent occurrence of shunt insufficiency and therefore the need for repeated
assessment of shunt patency during follow-up is probably the major limitation of
TIPSS. The major cohort studies describe shunt insufficiency in 29-33% patients
during follow-up, with consequent risks of variceal rebleeding or ascites
reaccumulation (table 5). A prospective study which carefully assessed shunt patency
during follow-up revealed a 1 year shunt insufficiency rate of 53% (Lind et al 1994).
Patency can be maintained in the vast majority ofpatients by a combination of balloon
angioplasty, shunt extension or parallel TIPSS placement (LaBerge et al 1995), but
the challenge is to detect the shunt insufficiency before clinical consequences occur.
It must be remembered that reports of shunt insufficiency following TIPSS procedure
depends to a large extent on both the frequency and method of assessing shunt
patency and the definition of "shunt insufficiency" used. A variety of different
definitions have been used in the literature, but the most clinically appropriate one
appears to be:
any narrowing of the shunt leading to a rise in the PPG to >12 mmHg, above which
the risk of variceal bleeding increases (Groszmann et al 1990), or a 20% rise in
immediate post TIPSS PPG for those patients with a low initial portal pressure.
The pathogenesis of shunt dysfunction remains poorly understood. Early shunt
occlusion is usually due to thrombosis within the stent, but longer term shunt
insufficiency is usually related to the development of pseudo-intimal hyperplasia
causing stenosis within the stent or the hepatic vein (LaBerge et al 1993). It has been
suggested that the creation of a transient biliary venous fistula by transection of a bile
duct at the time of the TIPSS procedure may lead to shunt stenosis or occlusion due to
the thrombogenic nature of bile (Haskal et al 1994, Jalan et al 1996).
Direct portography remains the "gold standard" in the assessment of shunt patency
following TIPSS procedure (Sanyal et al 1997). Although several studies have
suggested that duplex sonography is highly sensitive and specific at detecting shunt
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stenosis (Ferral et al 1993, Chong et al 1993, Foshager et al 1995, Dodd et al 1995),
other authors have reported poor detection of shunt dysfunction by ultrasonography as
compared with portography (Hasegger et al 1994, Ferguson et al 1995, Bartolone et al
1996). One report highlighted the possible benefits of magnetic resonance
angiography in the assessment of TIPSS patency (Eustace et al 1994), but currently
this has limited availability.
A number of studies have suggested benefit from heparin or phenprocoumon in the
reduction of early shunt occlusion following TIPSS placement (Krause et al 1994,
Sauer et al 1995). However, the best hope of reducing the need for continual shunt
assessment is probably the development of covered stents which have shown
improved patency in swine (Nishimine et al 1995). Until such stents are available, the
cost, time and invasive nature of direct portography must be weighed against the
possible deficiencies of ultrasonography in detecting shunt dysfunction.
Haemodynamic effects
Following TIPSS placement, there is a worsening of the hyperdynamic cirrhotic
circulation with increased cardiac output and decreased systemic vascular resistance
(Azoulay et al 1994, Colombato et al 1996, Van Der Linden et al 1996). It is unclear
as to how permanent these haemodynamic changes are. They are thought to occur as a
result of the increased venous return to the heart from the decompressed splanchnic
circulation.
The effects of these systemic haemodynamic changes on the renal circulation remain
poorly understood. Although TIPSS placement has been shown to improve natriuresis
and ascites control, any worsening of the systemic vasodilatation might be expected to
further reduce renal perfusion. Alterations in the concentrations of humeral factors or
the presence of an hepato-renal reflex may over-ride such an effect.
A recent study suggested that the major haemodynamic effect of TIPSS placement is
the development of pulmonary hypertension, since this correlated with the decreased
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PPG (Van der Linden et al 1996). In this study, transient shunt occlusion also returned
all haemodynamic parameters except pulmonary artery pressure to baseline. The
authors postulated that both mechanical and neurohumeral factors were involved in
these changes. The clinical implication is that TIPSS should be used with caution in
patients with known right heart failure or pulmonary hypertension.
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Chapter 2.
THE METHODOLOGY OF THE HAEMODYNAMIC
MEASUREMENTS IN CIRRHOTIC PATIENTS
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The haemodynamic catheters were placed via a 7.5 trench gauge right femoral venous
introducer sheath (Baxter Healthcare Corporation, USA), inserted after infiltration of
local anaesthetic (5-10 ml. 2% lignocaine). All catheters were positioned under
fluoroscopic guidance. Heart rate and mean arterial pressure (MAP) were recorded
using a Merlin patient monitoring system (Hewlett Packard Europe, Geneva,
Switzerland).
2 a Azgos blood flow
Azgos blood flow (AzBF) was measured using a double thermister reverse
thermodilution catheter (Webster Laboratories, California, U.S.A.). The catheter was
positioned in the azgos vein and real time AzBF measured by transfering the
thermister signals through a custom built interface and processing them in an IBM
compatible PS2-286 microcomputer system as previously described (Hayes et al
1993). Measurements were taken over 30 seconds with the patient breathing normally
at rest.
2 b Renal blood flow
Unilateral renal blood flow (RBF) was measured using the same reverse
thermodilution, double thermister catheter described above for AzBF measurement.
The catheter was positioned in the left renal vein (unless otherwise stated) since this is
longer than the right which allows easier positioning to ensure the proximal thermister
is within the lumen of the renal vein. The position was confirmed by injection of 5mls
dilute contrast media (Conray 280, May & Baker Ltd., Dagenham, U.K.). The
thermister signals were transfered through the microcomputer system as described
above to give real time measurements of unilateral real time RBF.
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2 c Hepatic venous pressure gradient
A Sidewinder II torque balloon catheter (Cordis Corporation, U.S.A.) was positioned
in the right hepatic vein. Free and wedged hepatic venous pressure (FHVP and
WHVP) were measured in triplicate to give mean values, and hepatic venous pressure
gradient (HVPG) was calculated as:
HVPG = WHVP - FHVP.
2 d Cardio-pulmonarv haemodynamics
Right heart catheterisation was undertaken using a Swan-Ganz catheter (Baxter
Healthcare Corporation, U.S.A.). Right atrial pressure (RAP) was measured, then the
catheter was positioned in the pulmonary artery to measure mean pulmonary artery
pressure (PAP) and pulmonary capillary wedge pressure (PCWP). With the catheter
then free in the pulmonary artery, cardiac output (CO) was measured by the standard
thermodilution technique and systemic vascular resistance (SVR) calculated as:
SVR = 79.96 x (MAP-RAP) / CO.
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2 e Estimated hepatic blood flow
Via a peripheral vein, an intravenous bolus of lOmg indocyanine green (ICG) was
given prior to an infusion of 0.2mg/min ICG. Following an equilibration period of 40
mins, 3 simultaneous samples were taken from the right hepatic vein (using the
Sidewinder II balloon catheter descibed above for HVPG measurement) and right
femoral vein to calculate estimated hepatic blood flow (HBF), (provided the hepatic
extraction of ICG was > 10%):
HBF = (ICG Clearance/ICG Extraction) / (1-Haematocrit)
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Chapter 3
ANALYSIS OF HAEMODYNAMIC PARAMETERS IN
ALCOHOL-INDUCED CIRRHOSIS




The prognosis of cirrhotic patients depends largely on the severity of the liver disease.
However, it has been suggested that haemodynamic assessment of the systemic,
cardiopulmonary and particularly the portal circulation may offer additional indicators
ofprognosis (Gluud et al 1988, Armonis et al 1996).
The aim of this study was to clarify the relationship between systemic,
cardiopulmonary and portal haemodynamic parameters in patients with alcohol-




3 b i Patients
From November 1992 to September 1996, 96 patients with alcohol-related cirrhosis
underwent haemodynamic assessment either as baseline measurements prior to acute
pharmacological intervention trials or as part of detailed assessment of their liver
disease. Cirrhosis was diagnosed by liver biopsy or by clinical assessment (varices or
ascites in the absence of other causes and in the prescence of chronic biochemical
derangement of liver function tests). Full patient characteristics are shown in table 7.
Twenty-four patients had suffered a previous variceal bleed and were on long-term
variceal obliteration programmes with band ligation. Three patients were in a similar
programme as part of a study assessing band ligation in the primary prophylaxis of
variceal haemorrhage. No patient was encephalopathic and none had suffered a
variceal bleed in the 10 days prior to haemodynamic assessment. All patients were
haemodynamically stable at the time of study and none were taking haemodynamic
altering medications except for diuretic therapy (n=51).
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Table 7.












3b ii Haemodynamic measurements
Ethical approval was given by Lothian Ethics Committeee and all patients gave
informed written consent. On the day of study, a full clinical examination was
undertaken and blood taken for measurement of serum bilirubin and albumin, and
prothrombin time. Due to the complexities of multiple catheter placement, all
haemodynamic measurements were not undertaken at each study.
Heart rate and MAP were recorded in all patients. Hepatic venous pressure gradient
(HVPG) was measured in 82 patients and AzBF and RBF in 62 and 42 respectively.
Right atrial pressure (RAP), CO and SVR were also measured in 28 patients.
Patients were followed up at 3-monthly intervals or earlier if complications arose.
Mean±SEM follow-up to most recent clinical review, death or liver transplantation
(n=2) was 19.3±1.5 months and episodes of endoscopically proven variceal
haemorrhage during follow-up were recorded.
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3b iii Data Analysis
Results are expressed as mean±SEM. Relationship between variables was assessed
using Spearmans correlation, and comparisons between groups analysed by unpaired
Students t-test and Mann-U-Whitney test for parametric and non-parametric data
respectively.
Patients were grouped into Childs Class A/B and Childs Class C for survival analysis,
into HVPG<12mmHg and >12mmHg for bleeding analysis and into HVPG<16mmHg
or >16mmHg for both bleeding and survival analysis. These groups were chosen
because it has been suggested that variceal bleeding does not occur at
HVPG<12mmHg (Garcia-Tsao et al 1985), and that HVPG of 16mmHg may be a
threshold value above which bleeding and death is more likely (Merkel et al 1992).
Survival and bleeding were compared between groups using Kaplan-Meier method
with log rank test.
Cox's regression was used to test the univariate and multivariate significance of the
haemodynamic parameters described above in addition to serum albumin, bilirubin,
prothrombin time, the presence of ascites, the CPS, diuretic therapy and the occurence
of a previous variceal bleed in predicting variceal bleeding and death.
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3 c Results
3c i Baseline values
The baseline values of the haemodynamic measurements are shown in table 8. Both
the HVPG and AzBF correlated with CPS (r=0.38, p=0.001 and r=0.29, p<0.05
respectively; figs. 3 and 4) but not with other haemodynamic parameters. CPS was
also related to heart rate, MAP, CO and SVR (r=0.38, p<0.001; r=-0.28, p<0.01;
r=0.40, p<0.05; r=-0.44, p<0.05 respectively). CO and SVR also both correlated with
heart rate (r=0.55, p<0.005 and r=-0.62, p<0.005 respectively) but not with other
haemodynamic measurements. There was no relationship between RBF and any other
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Figure 3.
Graph showing correlation between Childs-Pugh Score and hepatic venous pressure
gradient (HVPG) (r=0.38, p=0.001).
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Azygos Blood Row (rrl/rrin)
Figure 4.
Graph showing correlation between Childs-Pugh Score and Azygos blood flow
(r=0.29, p<0.05).
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3 c ii Variceal bleeding
During follow-up, 16 patients suffered a variceal haemorrhage (only one of whom had
a baseline HVPG of <12mmHg). Variceal bleeding occurred in 7 (29.2%) patients
who had previously bled and 9 (12.5%) who had not (p=NS). Baseline HVPG was
higher in those patients who subsequently bled compared with those who did not
(18.7±1.2 vs 16.3±0.7mmHg; p<0.02) and bleeding was more likely to occur in those
with a baseline HVPG>12mmHg compared with those with HVPG<12mmHg
(p<0.05; fig. 5) and also in those with HVPG>16mmHg compared with those with
HVPG<16mmHg (p<0.05). Variceal bleeding was only predicted in the univariate or
multivariate analysis by HVPG (p<0.01).
Baseline CO was higher in those patients who bled during follow-up compared with
those who did not (10.7±0.7 versus 6.7±0.3 1/min; p<0.01), but AzBF, RBF, SVR,
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Figure 5.
Kaplan-Meier analysis comparing variceal bleeding during follow-up between
patients with HVPG<12mmHg and those with HVPG>12mmHg (p<0.05).
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3 c iii Survival
During follow-up, 38 patients died. Survival was significantly greater in patients with
Childs grade A or B compared with Childs C disease (p<0.0001) (fig. 6), and in those
with baseline HVPG <16mmHg compared with HVPG >16mmHg (p=0.001) (fig. 7).
Baseline CPS and HVPG were higher in patients who died during follow-up
compared with those who survived (10.3±0.3 versus 8.2±0.3 (p<0.001); and 19.2± 1.0
versus 15.1±0.7mmHg (p=0.001) respectively). Baseline AzBF, RBF, CO, SVR or
MAP was not different between those who died and survived on follow-up.
Variables predicting death in the univariate analysis were CPS (p<0.0001),
prothrombin time (p<0.0001), HVPG (p=0.0001), presence of ascites (p<0.001),
serum albumin (p<0.001), serum bilirubin (p<0.05), and diuretic therapy (p<0.05). No
other haemodynamic parameter predicted death. On multivariate analysis, only the


















Kaplan-Meier analysis comparing cumulative survival between patients with Childs
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Figure 7.
Kaplan-Meier analysis comparing cumulative survival between patients with
HVPG<16mmHg and those with HVPG>16mmHg (p=0.001).
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3 d Conclusions
This large study indicates a strong relationship between severity of liver disease and
the associated haemodynamic changes including a fall in MAP and SVR, and a rise in
HVPG, CO and AzBF in patients with alcoholic cirrhosis. Measurement of HVPG is
also shown to have strong prognostic value in such patients.
Death and variceal bleeding were more likely in patients with HVPG>16mmHg than
in those with lower HVPG, and bleeding extremely uncommon in patients with
HVPG<12mmHg. Perhaps most significantly, HVPG was the only haemodynamic or
clinical parameter (including CPS) which predicted bleeding on multivariate analysis,




ACUTE RENAL, PORTAL AND SYSTEMIC




Beta-blockers and nitrates are the drugs most commonly used in the prophylaxis of
variceal haemorrhage. However, several recent studies have suggested that these drugs
may compromise renal function in cirrhosis. The aim of our study was to investigate
the effect of propranolol, ISMN and the combination of both drugs on renal blood




All patients gave informed written consent, and the study was approved by the
Lothian Ethics Committee. Twenty-six patients (12 female, mean age 51. 1±1.9 years
(range 33-70), mean CPS 9.2±0.6) with cirrhosis were studied. Eighteen patients had
ascites at the time of study which was clinically graded as mild, moderate or severe
(see table 9). Diagnosis of cirrhosis was based on liver biopsy (20 patients) or the
presence of chronic liver biochemical abnormalities and endoscopically proven
varices (6 patients). Cirrhosis was alcohol related (ALD) in 21 patients, secondary to
primary biliary cirrhosis in 2 patients and primary sclerosing cholangitis, sarcoid and
alpha-1-antitrypsin deficiency in 1 patient each.
No patient had biochemical evidence of renal dysfunction prior to study (serum urea >
6.6 mmol/1 or serum creatinine > 150 umol/1) and none were receiving vasoactive
medication at the time of study. In addition, no patient had suffered a gastrointestinal
haemorrhage within the previous 4 months.
4b ii Haemodynamic measurements
Studies were undertaken in the Department of Medicine catheter laboratory, on fasted
patients in the supine position. HVPG was measured, then unilateral (left) RBF and
AzBF in each patient. The thermodilution catheter was then left in position for the
duration of the study.
When recruited for the study, patients were matched for age and CPS for each
therapeutic regimen (table 9). Nine patients were then given 80 mg oral propranolol, 8
patients 20 mg oral ISMN and 9 patients both therapies. One hour later AzBF was
again recorded, then the reverse thermodilution catheter was manouevred back into
the initial position in the left renal vein and repeat measurement of RBF undertaken.
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Finally, measurement ofHVPG was repeated. The sheath was then removed and firm
pressure applied until haemostasis was obtained. Heart rate and MAP were also
recorded for the duration of the study and for 4 hours thereafter. In all cases, the
duration of the study was less than 3.5 hours.
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Table9. Characteristicsofpa ientsgiv npropranolol,isosorbide-5-mono itrate(ISMN)combi ati nt erapy. Propranolol
ISMN
Propranolol/ISMN
Age(yrs): Childs-Pughscore: No.withasci es(mildormoderate/severe): SerumCr atinine(umol/1),eanrange): Aetiology( LD/other):
(n=9) 52.7±2.3 9.2+1.0 5/0 83.1(6 -136) 8/1
(11=8) 50.5±2.8 9.4±1.5 4/1 92.1(65-142) 6/2




4b iii Data Analysis
Results are expressed as mean±SEM or range were indicated. For parametric data,
paired Student's t-test and Pearson's correlation were used. Wilcoxon signed ranked
test and Kendall correlation were used for non-parametric variables. A p-value of <
0.05 was taken to be significant.
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4 c Results
4c i Baseline values and systemic haemodynamic changes
All patients completed the study without difficulty and no side effects were observed
or reported. There was no statistical difference between the three therapeutic groups
with regard to baseline RBF or other haemodynamic parameters. Baseline RBF did
not correlate with CPS, HVPG or ascites severity. Changes in heart rate and MAP for
each therapy group at one hour following medication are shown in table 10.
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Table10. Systemichaemodvnamiceff ctsfacutedministrationpr pranol l.I MNdco bi edth py Propranolol preost Heartrate(bpm):81.6±3.97 7+4.21 MAP(mmHg)82.6±3.478 2 3
1 p<0.005versuspre-drugalue
ISMNPropranolol/ISMN
preostr t 86.8±3.591.0+ .379 9 4 84 4. 84.513.376.9+3.618.1 4.66 7+ .
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4 c ii Splanchnic and renal haemodynamic effects of propranolol
Following administration of propranolol, there was a fall in HVPG from 16.3±2.2 to
12.9±1.9 mmHg (p=0.05) and in AzBF from 471.5±85.8 to 293.4±42.6 ml/min
(p<0.01) (fig. 8). There was no effect on RBF (454.1±77.3 versus 413.9±60.3 ml/min)
(fig- 9).
4 c iii Splanchnic and renal haemodynamic effects of ISMN
ISMN therapy led to a fall in FIVPG from 14.9±1.9 to 11.0±1.3 mmHg (p<0.01), but
no effect on either AzBF (573.4±183.1 versus 576.0±145.1) ml/min) (fig. 8) or RBF
(302.5±49.4 versus 301.7±58.8 ml/min) (fig. 9).
4 c iv Splanchnic and renal haemodynamic effects of combination therapy
Following administration of the combination of propranolol and ISMN, HVPG fell
from 15.1±1.8 to 8.9±1.1 mmHg (p=0.002) and AzBF fell from 612.5±187.6 to
358.2±57.0 ml/min (p<0.05) (fig. 8). Again, there was no effect on RBF (419.2±62.6
versus 415.1±61.1 ml/min) (fig. 9).
When the 18 patients with ascites were considered alone, there remained no effect on
RBF of any therapy when these patients were grouped together, or when analysed in
treatment subgroups.
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We undertook this study to assess the acute effect of propranolol, ISMN and the
combination of both drugs on RBF in cirrhotic patients. Despite the anticipated drop
in MAP with ISMN and combination therapy, and the significant changes in HVPG
and AzBF with these drugs, no effect on RBF was detected with either drug alone or
in combination.
Any effect on renal function following administration of these drugs to cirrhotic
patients does not appear to occur secondary to an acute fall in RBF.
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Chapter 5.
ACUTE AND CHRONIC HAEMODYNAMIC AND
RENAL EFFECTS OF CARVEDILOL,
A VASODILATING BETA-BLOCKER IN CIRRHOSIS
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5 a Introduction
Carvedilol is a novel vasodilating non-selective beta-blocker with weak alpha-1
receptor and calcium channel antagonism. Recent reports have shown that acute
administration of carvedilol can reduce portal pressure in cirrhosis (Forrest et al 1996,
Sekiyama et al 1997), but no information exists as to the chronic effects of carvedilol
in this patient population. The aim of our study was to assess the acute and chronic




All patients gave informed written consent to the study which was approved by the
Lothian Medicine and Oncology Ethics Committee. Seventeen patients (mean age
55.2±2.8 years) with known cirrhosis and current or previously documented
oesophageal varices were studied. Sixteen patients had alcohol related cirrhosis, and
one Primary Biliary Cirrhosis. Eight patients had Childs-Pugh grade A, five grade B
and four grade C liver disease.
Eleven patients had ascites (6 moderate, 5 mild). Seven patients had previously
suffered a variceal bleed and had undergone obliteration of their varices by band
ligation. Eight patients had undergone band ligation as primary prophylaxis against
variceal haemorrhage as part of an ongoing study, and two had grade I oesophageal
varices for which they had received no treatment.
5b ii Study Protocol
Patients underwent assessment of their portal and systemic circulations prior to and 60
minutes following 25mg oral carvedilol. They then received 12.5mg carvedilol daily
(at 0900), increased to 25mg after 3 days if tolerated for four weeks. At this stage,
repeat assessment of their portal and systemic circulations were undertaken prior to
rechallenge with 25mg carvedilol. The last morning dose (on the day of the second
invasive procedure) had been omitted. In addition their renal function was assessed at
baseline and after 4 weeks carvedilol therapy. Patients compliance with drug therapy
was assessed by questioning and a tablet count.
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5b iii Haemodynamic measurements
Haemodynamic measurements were undertaken with the patient in the fasted state in
the supine position. Cardiac output (CO) and SVR were measured, then FHVP and
WHVP to calculate HVPG. In addition, HBF was measured using the ICG clearance
method described earlier.
All the above measurements were repeated 60 minutes following administration of
25mg oral carvedilol. Heart rate and MAP were measured at 15 minutes during the
study.
Following 4 weeks carvedilol therapy, these parameters were again measured prior to
and 60 minutes following re-challenge with 25mg oral carvedilol.
5b iv Assessment of renal function
Prior to commencement of the study, a 24 hour urine collection was obtained for
measurement of urine volume, urine sodium excretion and creatinine clearance.
Following 4 weeks carvedilol therapy, a further 24 hour urine collection was obtained
to repeat these analyses.
5b v Data Analysis
Results are expressed as mean±SEM. Paired Students t-test and Pearson's correlation
were used for parametric data, and Wilcoxon signed rank test and Spearman




Seven patients were unable to complete 4 weeks carvedilol therapy and return for the
second study. Two had an immediate hypotensive response to the first dose of 25mg
carvedilol with asymptomatic falls in blood pressure to 60/40 and 65/35 mmHg
respectively, maximal at 90-120 minutes following drug administration. However,
both had a spontaneous rise in blood pressure within 2 hours with no untoward
effects, but they received no further carvedilol. One other patient had an
asymptomatic gradual fall in BP to 85/50 after 8 days of therapy despite keeping the
dose of carvedilol at 12.5mg, therefore the drug was discontinued.
Three patients resumed alcohol drinking, stopped therapy and failed to attend for the
repeat study. One other patient changed employment during the study period and was
unable to take time off to attend for the repeat study and therefore discontinued
carvedilol after 3 weeks without experiencing any side-effects.
Of the 10 patients who completed 4 weeks of carvedilol therapy and attended for the
second haemodynamic study, 8 were able to take 25mg daily with no ill effects and 2
were changed to the lower dose (12.5mg daily) due to mild hypotension and dizziness
(n=l) or mild breathlessness (n=l). One further patient had an asymptomatic BP of
90/50 at the baseline haemodynamic measurements at 4 weeks, and he was therefore
not rechallenged with the drug. No untoward effects were reported and his BP rose
spontaneously after discontinuation of the drug.
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5c ii Splanchnic haemodynamic response
Following acute administration of carvedilol, there was a mean fall in HVPG of
20.8% from a baseline value of 16.3±1.2 to 13.2±1.3mmHg (p<0.001), and a
continued effect at 4 weeks compared with baseline (mean fall of 16.3% to
12.9±1.7mmHg) (p=0.001) (fig. 10). Following rechallenge at 4 weeks, there was a
further slight fall in HVPG to 11.2+1.5mmHg (p<0.05 compared to the baseline value
at 4 weeks) (fig. 10).
Thirteen (76.5%) patients had an acute fall in HVPG of 10% or more and 7 (41.2%) a
fall of 20% or more. After 4 weeks therapy, 6 (60%) patients had a fall in HVPG of
10% or more compared with baseline, and 4 (40%) a fall of 20% or more. The FHVP
did not change significantly from baseline at any time point, and the fall in HVPG
was accounted for by a drop in WHVP (table 11). There was no difference in the
reduction in HVPG between the patients who had suffered a previous variceal bleed,
and those who had not.
There was no change in HBF after acute or chronic administration of carvedilol or on
rechallenge of the drug (table 11).
Figure 10 (over page)
Graph showing reduction in hepatic venous pressure gradient (HVPG) following acute




























5c iii Systemic haemodynamic response
There was a fall in HR after acute and chronic drug administration, but no effect on
rechallenge at 4 weeks (table 11). Similarly, MAP fell acutely and after 4 weeks
therapy, but there was also a further fall on rechallenge (fig. 11). Cardiac output fell
after acute administration of carvedilol, but the drop in CO after 4 weeks therapy
failed to reach significance, and there was no further effect on rechallenge (table 11).
The acute and chronic changes in CO did not correlate with the drop in HVPG or
WHVP. There were no effects on RAP or SVR after acute or chronic carvedilol
administration, or on rechallenge at 4 weeks (table 11).
5c iv Effect on renal function
There were no changes in urine volume, natriuresis or creatinine clearance following 4
weeks carvedilol therapy (table 12).
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WHVP(mmHg) FHVP(mmHg) HBF(ml/min) HR(bpm) RAP(mmHg) CO(1/min) SVR(dynes,cm)
21.1+1.4 4.8+0.5 1052.8+201.8 77.4+3.5 2.8+0.5 6.8+0.7 1016.3+78.1
17.8+1.6* 4.6+0.7 1109.8+236.3 75.1+3.31 2.1+0.5 6.3+0.5° 1019.2+68.9
17.4+1.2° 4.5+0.8 964.0+332.8 65.1+3.2* 1.2+0.6 6.1+0.6 1073.4+125.4
14.9±1.8°4 3.7+0.9 999.7+327.4 62.1+3.6* 1.1+1.0 6.1+0.7° 1068.7+137.6
(°p<0.05;1 p<0.005;* <0. 01comparedwithbaselinvalufacutt dy;♦pO.OSco paredbas lchro ic ) 102
Figure 11 (over page)
Graph showing reduction in mean arterial pressure (MAP) following acute and














Table showing no difference in urine volume, natriuresis and creatinine
clearance before and after 4 weeks carvedilol therapy-
baseline 4 weeks
Urine volume (ml/day) 1668.7±214.8 1880.9±309.6
Sodium excretion (mmol/day) 126.2±25.7 151.9+33.5
Creatinine clearance (ml/min) 114.6±27.9 190.5+49.7
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5 d Conclusions
These results confirm the beneficial effect on HVPG of acute administration of
carvedilol and show a consistent portal hypotensive effect following chronic therapy.
No detrimental effect on hepatic blood flow or renal function was observed. However,




HAEMODYNAMIC AND RENAL EFFECTS OF FK352
(A NOVEL ADENOSINE-1 ANTAGONIST)
IN CIRRHOTIC PATIENTSWITH ASCITES
6 a Introduction
It has been suggested that adenosine plays a role in the renal abnormalities of
cirrhosis, acting via adenosine-1 receptors on the renal artery and proximal tubule
cells.
FK352 is a novel pyrazolopyridine derivative, which has been characterised in vitro as
a highly selective adenosine-1 receptor antagonist. In animal studies, it has been
shown to increase renal blood flow, diuresis and natriuresis, and its safety profile has
been confirmed in healthy volunteers. However, adenosine-1 antagonists have never
previously been investigated in patients with cirrhosis.
The aim of this study was to investigate the effects of FK352 on renal and systemic




Twelve patients (8 men) with alcohol-induced cirrhosis and ascites were studied. The
mean age was 51.3±2.4 years and mean CPS 8.2±0.5 (8 Childs class B, 4 Childs class
C). Cirrhosis was confirmed by biopsy in 9 patients and by the combination of
oesophageal varices and chronic derangement in biochemical liver function tests in
the absence of portal vein thrombosis in 3. All patients had earlier confirmation of
ascites by ultrasonography and at the time of study, ascites was clinically graded as
moderate (n=7) or mild (n=5). None of the patients were taking vasoactive
medications and all were on dietary salt restriction.
Ten patients were on diuretic therapy prior to the study. Eight were taking
spironolactone at a mean dose of 119mg/day (1 of whom was also taking 40mg
ffusemide daily) and 2 were taking amiloride at a mean dose of 6.7mg/day (1 of
whom was also taking 40mg ffusemide daily). Spironolactone was stopped 1 week,
and amiloride and ffusemide 3 days prior to the study. No patient had biochemical
evidence of renal impairment (defined as serum urea > 6.6 mmol/1 or serum creatinine
>150 mmol/1). Patients abstained ffom alcohol, cigarettes and caffeine containing
substances for 24 hours prior to the study.
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6b ii Study protocol
The study was approved by the Lothian Ethics Committee and all patients gave
informed written consent. This was a Phase II open labelled pilot study, designed
primarily to assess the efficacy and safety of FK352. A dose escalation was built into
the study to identify any obvious trend towards a dose-response.
On the morning of the study, patients received a light breakfast (2 slices of toast and
half a pint of milk). At 0800, they were required to drink 1 litre of water, then
transferred to the Haemodynamic Suite where they remained supine until completion
of the study. A urinary catheter was inserted and a loading dose of />-aminohippuric
acid (PAH) (450mg) and inulin (3.5g) administered via a peripheral vein. This was
followed at 0900 by a constant infusion ofPAH (16mg/min) and inulin (20mg/min).
A single bolus injection of FK352 (lOmg for the first 4 patients, 25mg the next 4
patients and 50mg the final 4 patients) was administered over a 2 minute period
through a separate peripheral vein at 1200. PAH and inulin infusions were continued
for 120 minutes following drug administration.
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6b iii Plasma and urine analyses
Sixty minutes following commencement of the PAH and inulin infusions, 30 minute
urine collections were obtained for the 2 hours prior to and the 2 hours following
administration of FK352. Patients were required to drink 100 mis water during each
of these 30 minutes periods. The urine collections were used to measure flow rate (V)
and concentrations of PAH and inulin. Plasma was sampled at the mid-point of these
30 minute urine collections to measure PAH and inulin concentrations and therefore
calculate inulin clearance (estimated GFR) and PAH clearance (estimated renal
plasma flow (ERPF)) for each 30 minute period:
clearance = (Urine concentration) x V / (Plasma concentration).
Four patients also had renal venous PAH concentrations measured prior to and
following FK352 to measure the PAH extraction coefficient { = (Peripheral PAH
concentration - Renal vein PAH concentration) / (peripheral PAH concentration)}. In
these 4 patients, this was used to give the corrected ERPF:
corrected ERPF = ERPF/PAH extraction coefficient.
In addition, plasma and urine osmolality, sodium and potassium concentration were
also measured to calculate the sodium excretion rate (UNaV, where UNa is the urine
concentration of sodium), potassium excretion rate and free water clearance for each
30 minute period:
free water clearance = V - (Urine osmolality) x V / (Plasma osmolality).
Plasma and urine was also collected at 15 minutes prior to and 15, 45 and 105 minutes
following administration of FK352 to measure plasma angiotensin II, renin activity
(PRA), adrenaline, noradrenaline and plasma and urine cAMP levels. At the end of
the study, the PAH and inulin infusions were discontinued and the urinary catheter
removed.
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6b iv Laboratory analysis
Blood samples for PRA, angiotensin II, adrenaline, noradrenaline and cAMP
determinations were collected on ice. The supernatant serum from all blood samples
and the urine samples for cAMP measurement were stored at -70 degrees centigrade
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until analysis. PRA was measured by I radioimmunoassay of angiotensin I
generation (Biodata Diagnostics, Roma, Italy), and angiotensin II by radioisotope
assay with solid phase separation step (Nichols Institute Ltd., Newport, U.K.).
Catecholamines were measured by high performance liquid chromatography and
cAMP by radioimmunoassay (Incstar Ltd., Wokingham, U.K.). PAH and inulin were
measured using high performance liquid chromatography with fluorometric detection
and spectrophotometric technique respectively as previously described (Li Kam Wa et
al, 1993).
6b v Haemodynamic measurements
Right heart catheterisation was undertaken to measure CO and SVR, 30 minutes prior
to and 120 minutes following administration of FK352. Using the reverse
thermodilution catheter, unilateral RBF was measured 15 minutes prior to and 15, 45,
75 and 105 minutes following administration of FK352, with the thermodilution
catheter left in position between recordings. During the study, continuous
electrocardiograph monitoring was employed and heart rate and MAP recorded at 15
minute intervals.
Following completion of the study (<6 hours in all cases), the femoral sheath was
removed and pressure applied until haemostasis was obtained. The patient was then
transferred to the ward and monitoring of heart rate and MAP was undertaken for a
further 4 hours. The patients were observed overnight and reviewed at 1 week for
clinical and biochemical assessment.
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6b vi Data Analysis
Data are expressed as mean values ±SEM. In view of the repeated measurements on
each patient, the drug effect was analysed by AUC based on percentage change from
the mean baseline value. If the AUC was significant (p<0.05), the Students t-test was
carried out to compare the mean pre-drug level with the value at each post-dose time
point using the Bonferroni correction for multiple comparisons.
Therefore, the parameters with 4 post-dose time points (V, UNaV, potassium
excretion rate, free water clearance and RBF) had a significance level of
0.05/4=0.0125, and those with 3 post-dose time points (PAH and inulin clearance and
hormone parameters) had a significance level of 0.05/3=0.0167. The relationship
between RBF and ERPF and the corrected ERPF was assessed using Spearman
correlation with a significance level of p<0.05.
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6 c Results
All patients tolerated the drug well and completed the study without difficulty. No
clinical or biochemical abnormalities were detected at 24 hours or at the 1 week
review. No dose response was detected, therefore all results were analysed for the 12
patients together.
6c i Changes in Renal Function
Following FK352 administration, UNaV increased by a mean of 199.9±43.0%
(p<0.001) from a baseline mean of 185.9±62.6 to a maximum of 563.11139.1
pmol/min and remained elevated for at least 2 hours (figure 12). Urine flow rate
increased by 51.2117.5% (p<0.02) from a mean of 6.4910.80 to a maximum of
12.4312.25 ml/min immediately following drug administration before returning
towards baseline (figure 13). There was a slight rise in free water clearance by
92.7153.8% from a mean of 3.5610.56 prior to FK352 to 7.1711.60 ml/min
immediately following drug administration before returning towards baseline.
However this did not reach statistical significance (p=0.11).
There was no change in potassium excretion rate following FK352 with a rise of
10.0+6.8% from a baseline of 60.8419.88 pmol/min. Similarly, no change was
observed in PAH or inulin clearance over the study period, with a change of
3.8110.6% and -3.813.8% from baseline values of 592.2160.8 ml/min and
113.8112.8 ml/min respectively. In the 4 patients in whom it was measured, the PAH
extraction coefficent ranged from 0.21-0.81, with a mean change in the corrected
ERPF following FK352 of-1.3112.6% from a baseline value of 454.8+150.3ml/min.
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Figure 12.
Graph showing changes in absolute sodium excretion (UNaV) following
administration ofFK352 (AUC p<0.001).
{Application of the Bonferroni correction for multiple comparisons at individual post-
dose time points gives significance level of p=0.0125. Therefore the individual
significant values are: *p<0.001 and 1 p<0.005 vs. mean pre-FK352 value}.
115
Figure 13.
Graph showing changes in urine flow rate following administration of FK352 (AUC
p<0.02).
{Application of the Bonferroni correction for multiple comparisons at individual post-
dose time points gives significance level of p=0.0125. Therefore the only individual
significant value is 1 p<0.005 vs. mean pre-FK352 value)
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6c ii Haemodynamic changes
Real time unilateral RBF increased by 42.3±12.5% (p<0.01) from 445.4±99.1 to a
maximum of 634.0± 109.2 ml/min following FK352 (figure 14). There was no
correlation between RBF and ERPF, but RBF correlated with the corrected ERPF
(p<0.05). There was no change in heart rate or MAP during the study. Similarly,
cardiac output (6.42±0.45 1/min pre- and 6.38±0.47 1/min post-FK352) and systemic
vascular resistance (1025.3±92.7 dynes.s/cm5 pre- and 1020.2±102.0 dynes.s/cm5
post-FK352) remained unchanged.
6c iii Plasma and urine analytes
Plasma cAMP, Angiotensin II and PRA increased following FK352 by a mean of
10.8+3.2% (p<0.01), 36.9±11.3% (p<0.01) and 247.9±82.6% (p<0.02) respectively,
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Figure 14.
Graph showing change in unilateral renal blood flow following FK352 administration
(AUC p<0.01).
{Application of Bonferroni correction for multiple comparisons at individual post-
dose time points gives significance level of p=0.0125. Therefore the only individual
significant value is: # p=0.011 vs. mean pre-FK352 value}.
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6 d Conclusions
We have demonstrated an improvement in urine flow and natriuresis following
administration of an adenosine-1 specific antagonist (FK352) to cirrhotic patients with
ascites. There was also a significant increase in RBF as measured by the reverse
thermodilution technique, but no change in ERPF or GFR as measured by PAH or
inulin clearance respectively. Unlike most diuretics, a trend to an increase in free
water clearance was also observed.
This is the first use of this drug in cirrhotic patients and it would appear that
adenosine-1 antagonism can ameliorate some of the haemodynamic and renal tubular
abnormalities seen in cirrhotic patients with ascites.
Acknowledgement: I would like to thank Fugisawa Pharmaceutical Company Ltd. for
provision of FK352, Data Analysis and Research Limited (Lanarkshire, U.K.) for
statistical analysis, and Dr. A. Cumming (Department of Renal Medicine, Royal
Infirmary ofEdinburgh) for specialist advice on the running of this study.
Chapter 7






Insertion of TIPSS dramatically reduces portal pressure and has significant systemic
haemodyanamic effects. Although TIPSS procedure worsens the peripheral
vasodilatation observed in cirrhosis, it also reduces the severity of ascites, increases
sodium excretion and may temporarily improve renal function in patients with the
hepato-renal syndrome. These findings suggest a link between the renal abnormalities
of cirrhosis and portal hypertension.
Portal venous infusion of glutamine in an animal model has been shown to reduce
RBF, which was reversed by renal denervation and section of the hepatic vagal fibres
(Lang et al 1991). The authors proposed the existence of an hepato-renal reflex with
afferent hepatic vagal and efferent renal sympathetic fibres. In addition, an acute
increase in portal pressure caused by TIPSS occlusion in cirrhotic patients has been
shown to cause an immediate reduction in RBF which correlated with the increase in
the PPG (Jalan et al 1997).
Due to its immediate effect on portal pressure, TIPSS procedure provides a model to
investigate the relationship between portal hypertension and RBF. The aim of this
study was to assess the effect on RBF and other haemodynamic parameters of an




The study was approved by the local ethics committee and all patients gave informed
written consent. Eleven unselected cirrhotic patients undergoing elective TIPSS
placement for recurrent oesophageal variceal haemorrhage (n=9) or refractory ascites
(n=2) were studied. All patients were haemodynamically stable at the time of the
TIPSS procedure and none had suffered a gastrointestinal haemorrhage within the
previous 48 hours. In addition, no patient was receiving vasoactive medications and
none were ventilated.
Ten patients had alcohol related cirrhosis, mean age was 55.4±3.9 and mean CPS was





Age (mean±SEM) 55.4 ±3.9









7b ii Haemodynamic measurements
On transfer to the catheter suite, intravenous midazolam and pethidine were
administered and a reverse thermodilution catheter positioned via a femoral introducer
sheath to measure baseline unilateral RBF. This catheter was kept in this position for
the duration of the study.
A right internal jugular introducer sheath was then inserted (using 5mls 2% lignocaine
local anaesthesia), and right heart catheterisation undertaken to measure RAP, PAP,
PCWP, CO and SVR. This catheter was then removed.
TIPSS placement was undertaken in the routine manner as previously described in
detail (22). One (n=6) or two (n=5) Wallstents were inserted to reduce the PPG below
12mmHg or reduce it by 20% if the initial PPG was <12mmHg (1 patient). Ten
millimetre stents were used in 7 patients and 12mm stents in 4. Successful and
uncomplicated stent placement was achieved in all patients.
With the reverse thermodilution catheter remaining in position, measurement of RBF
was repeated at 5, 15, 30, 45 and 60 minutes following stent insertion. Thirty minutes
following stent placement, right heart catheterisation was repeated to remeasure RAP,
PAP, PCWP, CO and SVR. After these measurements were completed, all catheters
and introducers were removed and pressure applied to obtain haemostasis.
Electrocardiography, pulse rate and oximetry were monitored continuously during the
study, and MAP recorded at 15 minute intervals. After completion of the study,
patients were transfered to the ward for further routine observation.
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7b iii Data Analysis
Results are expressed as mean±SEM. Paired Students t-test for parametric and
Wilcoxon Signed Rank test for non-parametric data were used to analyse changes in
haemodynamic parameters. Pearson and Spearman correlation tests were used to
assess the relationship between parametric and non-parametric data respectively. A
significance level of 0.05 was chosen.
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7 c Results
7 c i Splanchnic and renal haemodynamics
The PPG fell from 21.7±2.1 to 5.5±1.1 mmHg (p<0.001) following TIPSS insertion.
Compared with the baseline value of 252.5±54.2 ml/min, there was no change in RBF
at any time following TIPSS placement (figure 15). Values of unilateral RBF at 5, 15,
30, 45 and 60 minutes were 202.5±34.3, 229.5±35.8, 272.9±55.9, 262.6±46.5 and
290.7±49.7 ml/min. respectively. There was actually a slight decrease in unilateral
RBF/CO % from 4.5±1.0 to 3.7±0.7 % after TIPSS insertion.
Figure 15 (over page)















7c ii Systemic haemodynamics
The CO rose from 6.1±0.9 to 8.0±1.0 1/min. (p=0.001) and SVR fell from
1283.6±104.4 to 950.2±97.7 dynes.sec/cm5 (p=0.003) thirty minutes after stent
placement (figure 16).
The RAP rose from 2.3±1.1 to 7.8±1.0 mmHg (p<0.001), PAP from 11.8±2.0 to
24.5±1.9 mmHg (p<0.001) and PCWP from 7.8±2.0 to 17.8±1.6 mmHg (p=0.001)
following T1PSS placement. The fall in PPG correlated only with the fall in SVR
(p<0.05) and rise in CO (p<0.05) (figure 17). TIPSS insertion had no effect on heart
rate or MAP. There were no significant differences between the haemodynamic
changes observed in patients treated with 10mm or 12mm stents. Full haemodynamic
changes are shown in table 15.
Figure 16 (over page!
Graph showing increase in cardiac output (p=0.001) and decrease in systemic vascular













Fall in POrto-atrial Pressure Gradient (mrrHg)
30
Figure 17. Graph showing correlation between fall in porto-atrial pressure gradient
and rise in cardiac output (p<0.05) following TIPSS placement.
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7 d Conclusions
We have shown that following elective TIPSS procedure in cirrhotic patients, there is
no acute effect on RBF despite a dramatic reduction in PPG. We also confirm the
immediate increases in CO, PAP, PCWP and fall in SVR after shunt placement.
Therefore a suggested hepato-renal reflex does not lead to an immediate rise in RBF
following an acute fall in portal pressure. In addition, the reported improvement in










Although TIPSS procedure appears effective for acute and recurrent variceal bleeding
refractory to endoscopic treatment and may improve ascites, the current literature on
this procedure is limited both by short duration of follow-up and small patient
numbers. This is important since shunt patency after TIPSS placement may decrease
with time, and encephalopathy following surgical shunts was often delayed.
From 1991 until August 1995, we carried out 130 TIPSS procedures in our unit. The





From 1991 to 1995, TIPSS procedure was attempted in 130 patients, with successful
placement of the stent in 119 cases (91.5%). Patient characteristics are shown in tables
16 and 17. Over the same time period, a total of 220 patients were treated for variceal
haemorrhage at our institution.
The aetiology of portal hypertension was alcoholic cirrhosis (ALD) in the majority of
patients and most patients had Childs-Pugh grade C liver disease at the time of TIPSS
procedure (table 16). Four patients were non-cirrhotic (1 each with amyloid,
idiopathic portal hypertension, polycystic disease and nodular regenerative
hyperplasia).
The most common indication for TIPSS placement was oesophageal variceal bleeding
(table 17). These patients had either continued bleeding despite 2 sessions of
sclerotherapy or were part of a trial comparing band ligation with TIPSS in the
prevention of rebleeding. Five (3.8%) patients had ectopic varices (2 rectal, 2 stomal
and 1 duodenal) and the indictation for TIPSS placement was painful splenomegaly,
hypersplenism and embolization of a spontaneous shunt in 1 patient each. Thirty-five
procedures were carried out as an emergency, with 19 receiving assisted ventilation








Aetiology of Liver Disease (%):
Alcoholic cirrhosis 84 (64.6%;
Cryptogenic cirrhosis 12 (9.2)
Primary biliary cirrhosis 11 (8.5)
Hepatitis C 5 (3.8)
Hepatitis B 5 (3.8)
Cystic Fibrosis 3 (2.3)
Primary sclerosing cholangitis 2(1.5)
Autoimmune hepatitis 2(1.5)
Other 6 (4.6)









Oesophageal varices 73 (56.2)
Gastric varices 26 (20.0)
Refractory ascites 17(13.1)
Portal hypertensive gastropathy 6 (4.6)
Ectopic varices 5 (3.8)
Other 3 (2.3)
Emergency procedure (%): 35 (26.9)
Clinical features:
Artificially ventilated 19 (14.6%)
Haemodynamic compromise 10(7.7%)
Ascites 86 (66.2%)
Hepatic encephalopathy 44 (33.8%)
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8b ii TIPSS procedure
The technique of TIPSS placement was based on the original method described by
Richter (Richter et al 1990) and is described in detail elsewhere (Chalmers et al
1992). Routine pre-procedural mesenteric angiography was undertaken in the first 32
patients to guide portal vein puncture and in 27 subsequent patients, Doppler
ultrasonography was used to identify the site of portal vein bifurcation. In the last 71
patients however, no routine imaging was undertaken to localize the portal vein pre-
TIPSS, although ultrasonography was used prior to the procedure to exclude portal
vein thrombosis. These changes have evolved as a result of ongoing audit at our unit.
Once successful puncture of the portal vein was achieved, 2-3 Palmaz stents (Johnson
& Johnson) (24 patients), or 1-2 Wallstents (Schneider U.S. Stent Division) (106
patients) were inserted to reduce the PPG to less than 12mmHg. Three patients
subsequently had Angiomed stents (Angiomed, Karlsruhe, Germany) inserted to
reduce the shunt size. In 2 patients in whom a thrombus was noted within the portal
vein at the end of the procedure, a catheter was left within the shunt for regional
infusion of low dose streptokinase for 24 hours.
Prophylactic antibiotics (cefotaxime and amoxycillin) were administered 1 hour prior
to procedure and continued for 48 hours thereafter.
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8b iii Clinical follow-up
After discharge, patients were reviewed at 6-weeks, then at 3-monthly intervals.
Encephalopathy was assessed clinically at each visit, but prophylactic lactulose and
protein restriction were not routinely applied. Variceal rebleeding was defined as
endoscopically proven variceal haemorrhage occurring more than 24 hours after
TIPSS insertion. Non-variceal sources of gastrointestinal bleeding were documented
at endoscopy.
Mean follow-up (defined as time to death, most recent clinical review or liver
transplantation) for all patients was 10.7±1.0 months, and for survivors (up to October
1995) 18.0±1.3 months.
8b iv Shunt surveillance
Doppler ultrasonography was performed prior to discharge to ensure shunt patency.
Routine portography was undertaken at 1-3 months and six-monthly thereafter to
assess shunt function, or earlier in the event of rebleeding or reaccumulation of
ascites. Early in our experience however, several shunts were left 6-12 months before
initial angiographic assessment.
All shunt complications were confirmed angiographically with occlusion defined as
absent flow through the shunt. Pseudo-intimal hyperplasia, hepatic vein stenosis,
portal vein and shunt thrombosis were defined by the angiographic appearance in
conjunction with either a 20% rise in PPG, or an increase in PPG to 12mmHg or
more. Primary shunt patency was defined as the (pre-intervention) absence of any of
the above shunt complications.
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8b v Data analysis
Results are expressed as mean±SEM or range where indicated. Paired students t-test
was used to determine statistical significance and Kaplan-Meier method used for rates
of variceal rebleeding, primary shunt patency and survival.
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8 c Results
8c i Shunt procedure
TIPSS placement was successful in 91.5% patients (table 18). The procedure failed in
11 patients (10 of whom had variceal haemorrhage) because a main branch of the
portal vein could not be punctured. Four of these patients subsequently underwent
shunt surgery and 5 had further endoscopic therapy. Thirty-day mortality in the failed
TIPSS group with variceal haemorrhage was 70%.
Two procedure related deaths occurred from intra-peritoneal haemorrhage due to
extrahepatic tear of the portal vein or puncture of the liver capsule. One patient
developed an epidural haemorrhage which was diagnosed following the procedure but
the exact relationship to TIPSS placement was unclear. Other complications included
portal vein thrombosis in 2 patients (successfully treated by local streptokinase
infusion), portal vein dissection in 1 (successfully managed by stenting) and shunt
dislocation or migration into the splenic vein in 2. There were no clinically significant
groin or neck haematomas.
8c ii Shunt dysfunction
A total of 63 episodes of shunt complications were observed in 45 patients (table 18).
Twenty-nine of these were clinically significant, associated with variceal rebleeding
or reaccumulation of ascites, with the others detected on routine surveillance. Fifty
percent of the shunt complications occurring less than 1 month post TIPSS were
associated with variceal rebleeding, as were 41.7% of those occurring from 1-3
months, 35% from 3-12 months and 23.5% from 12-24 months. No shunt
complications occurring >2 years following TIPSS placement was associated with
variceal rebleeding.
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Taking follow-up as most recent angiographic TIPSS assessment, pre-intervention
shunt patency was 58.1% at 1 year and 21.4% at 2 years (see table 18 and figure 18).
The causes of shunt dysfunction are described in table 18. No Palmaz stent had
primary patency at 2 years. All shunt complications but one (in a patient who was
transferred to an endoscopic banding programme and remains well) were successfully





Successful TIPSS procedure (%): 119 (91.5)
PPG pre-TIPSS (mmHg): 17.5±0.5
PPG post-TIPSS (mmHg): 8.6 ±0.2
Pre-intervention shunt patency (%):
6 months 47(71.2)
1 year 25 (58.1)
2 years 3 (21.4)
Shunt complications 63 episodes in 45
(37.8%) patients:
pseudo-intimal hyperplasia 29
hepatic vein stenosis 13





Kaplan-Meier analysis of patients free of variceal rebleeding and patients with
primary shunt patency during follow-up.
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8c iii Clinical follow-up
Control ofAcute Bleeding
Thirty-five patients had TIPSS procedure for acute variceal haemorrhage uncontrolled
despite sclerotherapy with or without balloon tamponade. The procedure was
technically successful in 32 of these patients and the other 3 patients died: 2 from
massive variceal haemorrhage and 1 shortly after oesophageal transection.
Fourteen of the remaining patients died during the index hospital admission: 3 each
from acute on chronic liver failure, sepsis and end stage liver failure, 2 from continued
bleeding (1 from an autopsy proven sclerotherapy ulcer and 1 with disseminated
intravascular coagulation and acidosis), 2 from cardiac arrests/myocardial infarcts,
and one from a procedure related intra-peritoneal bleed. Two further patients had
subsequent variceal rebleeds, both related to shunt insufficiency which was
successfully treated by angioplasty and shunt extension.
Recurrent Variceal Bleeding
TIPSS procedure was successful in reducing recurrent variceal haemorrhage. There
were 24 episodes of variceal re-bleeding in 13.4% patients (see figure 18 and table
19), all of which were associated with shunt insufficiency and responded to dilatation
or further stenting. None of the 5 patients who underwent TIPSS placement for
ectopic variceal haemorrhage had a recurrent bleed. Non-variceal haemorrhage
occurred in 7.6% patients (see table 19).
Ascites
Eighty-six patients had ascites prior to TIPSS placement and this was the primary
indication in 17 patients (7 ofwhom had established hepato-renal syndrome; see table
19). The ascites improved (reduced or no diuretic requirement) in 65.1% of these
patients, but reaccumulated in 14. This was associated with shunt insufficiency in 11
patients and spontaneous bacterial peritonitis (SBP) in 2, but was responsive in all
cases to shunt revision and antibiotics respectively. Of the 17 patients who underwent
TIPSS procedure for refractory ascites, improvement occurred in 11 and 2 have
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subsequently undergone successful liver transplantation. Those with biochemical
evidence of renal dysfunction tended to respond less well after TIPSS insertion.
Other Indications
TIPSS procedure was performed for intractable bleeding from portal hypertensive
gastropathy in 6 patients. Four of these have not required further transfusion and the
other two have required one admission each for transfusion. Both of these patients had
evidence of shunt dysfunction due to neo-intimal hyperplasia in association with a
raised PPG, which was successfully treated by angioplasty or shunt extension. TIPSS
placement resulted in an improvement in platelet count from 13000/1 to 50000/1 in one
patient with hypersplenism. Another patient had a large spontaneous shunt
successfully embolized via the TIPSS for amelioration of intractable hepatic
encephalopathy.
Hepatic Encephalopathy
Forty-four patients were clinically encephalopathic prior to TIPSS procedure and this
resolved in 54.5% after the procedure. Twenty (16.8%) patients developed new or
worsening spontaneous encephalopathy during follow-up (15 within the first 6
months). A further 12.6% developed encephalopathy secondary to sepsis or bleeding
during follow up (see table 19). Reduction in shunt size was performed because of
encephalopathy in 4 patients (successful in 3), with all others responding to simple
medical therapy.
Sepsis
Fourteen patients developed clinically significant infections in the week following
TIPSS placement (7 pulmonary, 2 SBP, 2 related to central venous catheter, 1
cellulitis and 2 of unknown origin). Sepsis was the cause of death in 2 patients during
the index admission: 1 with pre-existing staphylococcal and fungal septicaemia and





Variceal rebleeding: 24 episodes in 16 (13.4%) patients
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Sepsis post TIPSS: 14(11.8%)
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Liver Function
Approximately one third of patients exhibited a transient deterioration in their liver
function tests in the first week following TIPSS placement, with rises particularly in
bilirubin and alanine aminotransferase levels. Three patients died with clinical
features of acute liver failure, characterized by hypotension, renal failure and
hypoglycaemia. Two of these patients also had evidence of raised intra-cranial
pressure on extra-dural pressure recordings or computed tomography. Childs-Pugh
score did however improve at 3-6 months to 7.6±0.3 (p=0.019) largely due to a
reduction in ascites.
Transplantation
Thirteen patients underwent orthotopic liver transplantation following TIPSS
procedure. Transplant was undertaken a mean of 7.1±1.6 months following stent
placement, and 11 of these patients remain alive and well.
Mortality
Of the 119 patients with successful TIPSS placement, 52 have died and 13 have been
transplanted. Procedure related mortality was 1.5% and mean time to death was
6.0±1.2 months (range 0.03-45.3). Mean follow-up of survivors is 18.0±1.3 months
(range 2.0-43.5). Thirty-day mortality was 21.8% (84.6% of whom had Childs C
disease) and six month survival 69.2%. One and two year survival is 62.3% and
46.5% respectively. Mortality was dependent on Childs grade at time of TIPSS
procedure (see figure 19).
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Figure 19.
Kaplan-Meier analysis ofpatient survival post-TIPSS by Childs grade.
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8 d Conclusions.
This large study indicates that following variceal haemorrhage, TIPSS procedure is
associated with low rebleeding rates provided shunt patency can be maintained during
follow-up. The definitive role of this procedure in the management of variceal
bleeding will be determined from randomised trials comparing TIPSS placement with
endoscopic and pharmacological therapies.
Shunt dysfunction remains the major limitation of TIPSS procedure, and regular shunt
surveillance is required, preferably with direct portography to identify shunt
insufficiency and allow therapeutic intervention. Post-TIPSS encephalopathy is
significant, but is generally easy to manage with lactulose and protein restriction.
Although TIPSS placement reduces ascites, its place in the management of patients
with refractory ascites remains unclear, and it should not be performed for this





The questions stimulating this thesis were:
a) what is the relationship between the haemodynamics of cirrhosis and prognosis?
b) what are the haemodynamic, renal and clinical effects of pharmacological and
radiological interventions for portal hypertension and ascites?
9 a Haemodynamics of cirrhosis
The haemodynamic changes in cirrhosis have long been recognised, but the
relationship between the systemic, renal and portal circulations in these patients
remains poorly understood. The splanchnic circulation is thought to be the main site
of reduced vascular resistance in cirrhosis (Marato et al 1993), and the alterations in
systemic haemodynamics are thought to arise secondary to splanchnic vasodilators
gaining access to the systemic vasculature via collateral vessels and reduced hepatic
clearance (Schrier et al 1988). The vasodilated splanchnic and systemic circulations
lead to activation of neurohumoral systems causing sodium and water retention and
renal vasoconstriction which can lead to ascites formation and functional renal
abnormalities (Bosch et al 1980, Schrier et al 1988).
9a i Relationship between systemic and splanchnic haemodynamics and severity
of liver disease
We have shown that the severity of the hyperdynamic circulatory disturbances
observed in cirrhosis is related to the degree of hepatic impairment, with heart rate,
MAP, CO and SVR all correlating with the CPS. However, perhaps surprisingly RBF
was not related to the CPS.
The HVPG is an indirect measurement of portal pressure which accurately reflects the
pressure gradient between the portal and hepatic veins in patients with sinusoidal
portal hypertension such as alcoholic cirrhosis, but not in those with pre- or post-
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sinusoidal portal hypertension (Boyer et al 1977). Although we found no relationship
between HVPG or collateral flow as measured by AzBF and systemic haemodynamic
parameters, we found that both HVPG and AzBF correlate with CPS, which is
consistent with earlier reports (Braillon et al 1986).
9a ii Prognostic value of haemodynamic parameters for bleeding and survival
Bleeding
Recently, a number of studies have assessed the prognostic value of HVPG
measurement in cirrhosis, with some authors suggesting it should be used much more
frequently in such patients (Armonis et al 1996). In addition, early reports of a
"bleeding threshold" of an HVPG of 12mmHg, below which variceal bleeding did not
occur, have subsequently been confirmed (Garcia-Tsao et al 1985, Groszmann et al
1990, Vorbioff et al 1996). In our study, only one patient with an HVPG <12mmHg
went on to have a variceal bleed. However this patient had their haemodynamic study
when abstinent from alcohol, then subsequently returned to drinking prior to their
variceal haemorrhage. Active drinking has previously been shown to increase the
HVPG and therefore the risk of variceal bleeding (Vorbioff et al 1996). Obviously
other patients in our study may have returned to or continued drinking during follow-
up, but abstinence is difficult to assess in this patient group. Therefore we did not
analyse this factor with regard to its effect on patient outcome.
Although a number of patients were on a band ligation surveillance programme and
others were on diuretic therapy at the time of study, endoscopic treatment of varices
does not appear to affect HVPG (Lo et al 1996), and it remains unclear whether
diuretics have an effect (Nevens et al 1996, Sogni et al 1994). There was no
difference in the HVPG between patients who were on diuretic therapy and those not
on diuretics in our study.
Using Cox's regression, we found that HVPG was the only haemodynamic, laboratory
or clinical parameter to predict bleeding on multivariate analysis. In particular, it had
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better predictive value than CPS. It is interesting that one measurement of HVPG
appears to predict variceal haemorrhage over the next two years, despite the fact that a
number of patients subsequently had pharmacological intervention as attempted
prophylaxis for variceal bleeding. This study was designed to assess the prognostic
value of a "snap-shot" baseline haemodynamic assessment and we did not evaluate
the individual benefit of any subsequently administered drugs.
Endoscopic signs such as variceal size and the presence of red spots on the varices
have also been shown to predict variceal bleeding (NIEC 1988). However, few of our
patients underwent endoscopy around the time of the haemodynamic study, therefore
we were unable to include endoscopic signs in the analysis.
Interestingly, we found no relationship between AzBF, which is a marker of collateral
flow, and the risk of bleeding. This finding has been previously reported (Cales et al
1984), and is probably explained by the fact that the azygos vein also drains
mediastinal channels in addition to the oesophageal submucosa. Presumably for
similar reasons, AzBF was not related to survival.
Survival
Unlike the findings from our study, Llach and colleagues reported that MAP
independently predicts survival on multivariate analysis in cirrhotic patients with
ascites (Llach et al 1988). However, similar to our results, a number of studies have
suggested that the measurement of HVPG predicts survival in cirrhosis above and
beyond the information given by the CPS (Merkel et al 1992, Vinel et al 1986, Gluud
et al 1988). We have confirmed Merkel and colleagues earlier report of a lower
survival in patients with HVPG>16mmHg (Merkel et al 1992). HVPG has previously
been shown to be an independent predictor of survival on multiple regression analysis
(Merkel et al 1992, Gluud et al 1988, Armonis et al 1997).
We found that HVPG and the CPS were the only haemodynamic, laboratory or
clinical parameters which predicted survival on multivariate analysis. HVPG retained
independent significant predictive value for survival even when patients with a
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previous history of variceal bleeding, or those with death due to bleeding were
omitted from analysis. The CPS is of course a composite score of five clinical and
laboratory parameters. When HVPG was compared with these individual parameters
on multivariate analysis with the exclusion of the CPS, only the prothrombin time and
the presence of ascites were superior to HVPG in predicting death. Therefore,
incorporation ofHVPG into a scoring system including some or all of the current CPS
parameters is likely to lead to an improved prognostic score.
9a iii Implications for management
Measurement of HVPG is a relatively simple and safe procedure that takes less than
twenty minutes to perform. In our group of patients, 5 had self-limiting bruising over
the femoral venous site, but no other complications were encountered. Apart from its
possible prognostic value for survival, HVPG measurement can help target therapy for
patients at high risk of bleeding and perhaps should become part of the routine
assessment ofpatients with cirrhosis, especially those with varices.
Patients with an HVPG >12mmHg who have not previously bled should receive
primary prophylaxis with beta-blockers with or without nitrates (D'Amico et al 1995).
Although band ligation is the most commonly used treatment for patients who have
suffered a variceal bleed, trials are currently underway to compare this with drug
therapy in the prevention of rebleeding. Ideally, any patient undergoing
pharmacological therapy as primary or secondary prophylaxis for variceal
haemorrhage should undergo serial measurements of HVPG, which can act as a
"splanchnic sphygmomanometer" (Armonis et al 1996). This will identify patients not
responding to treatment, who can then be offered alternative therapeutic strategies
(Groszmann et al 1990, Feu et al 1995).
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9 b Aspects of the pharmacological management of portal hvpertesion.
Propranolol and to a lesser extent ISMN are widely used in the pharmacological
management of portal hypertension, most commonly in the primary prophylaxis of
variceal haemorrhage. However, recent reports have suggested that these drugs may
compromise renal function in cirrhosis, and questions remain regarding the
tolerability of these agents in this patient population.
9b i Effects of propranolol and isosorbide-5-mononitrate on renal blood flow
There are conflicting data in the literature with regard to the renal effects of beta-
blockers and nitrates in cirrhosis, which may be due to differences in the study
populations or in the duration of treatment. The concern is greatest for those patients
with advanced cirrhosis and ascites who would be least likely to tolerate a fall in renal
perfusion and impaired renal function (Henriksen & Ring-Larsen 1993). In our study
which assessed the effects ofpropranolol and ISMN on RBF, although all patients had
normal serum creatinine levels, it is possible that some may have had a degree of renal
impairment not evident from their serum creatinine. However, when ascitic patients
alone were assessed, there was still no effect on RBF.
Generally the autoregulation in the kidney maintains a constant RBF over a wide
range of arterial blood pressures (Wilkinson 1982). Henriksen and Ring-Larsen
suggest that in cirrhosis, a pharmacologically induced fall in MAP may compromise
renal perfusion and GFR, leading to a subsequent reduction in sodium and water
excretion, partly due to a shift in this autoregulation (Henriksen & Ring-Larsen 1993).
Although we did not assess GFR or sodium and water excretion, we found no change
in RBF despite the expected changes in MAP, HVPG and AzBF following
administration of propranolol and/or ISMN. This would suggest that renal
autoregulation is intact in this patients group.
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We assessed only the acute effect of these drugs on RBF, therefore we cannot draw
conclusions regarding prolonged therapy. It is possible that administration of these
drugs to cirrhotic patients may compromise renal function by mechanisms other than a
reduction in RBF, such as neurohumoral or tubular effects. However, the main
concern ofmany studies was the possible reduction in renal perfusion consequent on
the systemic haemodynamic changes induced by these drugs.
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Beta-blockers
Beta-blockers have been shown to reduce the frusemide-stimulated increase in renal
interlobular arterial flow (Ljubicic et al 1992), and reduce estimated RBF in cirrhosis
as assessed by doppler ultrasonography (Bolognesi et al 1994). However, Bataille and
colleagues found no effect on RBF of acute propranolol therapy when given to
cirrhotic patients (Bataille et al 1984), and no difference in creatinine clearance was
detected between cirrhotic patients given diuretics alone and those given propranolol
and diuretics (Rector & Reynolds 1984).
In addition, propranolol has been reported as having no effect on GFR in cirrhosis
despite suppressing renin secretion (Wilkinson et al 1977), and Bernardi and
colleagues found that propranolol actually increased GFR and natriuresis in ascitic
cirrhotics with high sympathetic tone (Bernardi et al 1989). Other studies have
reported both decreased (Rector & Reynolds 1984) and increased (Hayes et al 1984)
natriuresis in cirrhotic patients in response to propranolol.
However, despite the anticipated reductions in heart rate, AzBF and HVPG in our
study following acute administration of propranolol, no effect on RBF was observed.
Indeed, the patients with the lower initial RBF who were given propranolol (whose
renal function would be of most concern) actually had a rise in RBF following
therapy.
Nitrates
Nitrate therapy has been shown to reduce renal plasma flow, GFR, and sodium and
water excretion and increase renin and aldosterone values in cirrhosis (Salmeron et al
1993). The fall in GFR and free water clearance was greater in those patients who had
ascites. Vorbioff et al found that 57% cirrhotic patients with ascites or a history of
ascites developed worsening of ascites when given propranolol and nitrates, compared
with no worsening of ascites in any patient given propranolol alone (Vorbioff et al
1993). Salerno et al recently reported that acute ISMN therapy in cirrhosis reduced
diuresis and natriuresis, and reduced GFR in patients with ascites (Salerno et al 1996).
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However, the same study also showed that chronic administration of ISMN did not
affect renal function if patients did not have ascites, but reduced diuresis and naturesis
in ascitic patients. No effect on GFR or renal plasma flow was detected.
However, Morrillos et al recently reported no effect on inulin clearance, free water
clearance, plasma renin activity, aldosterone concentration or ascites outcome in
cirrhotic patients given long-term propranolol and ISMN, despite a reduction in blood
pressure (Morrillos et al 1994). In addition, Merkel and colleagues found no
deterioration in renal function in cirrhotic patients given 6 months of ISMN and
nadolol compared with patients given nadolol alone (Merkel et al 1995). Although
there was a correlation between the fall in blood pressure and the rise in serum
creatinine in the group as a whole, it was only the patients given combination therapy
who had a reduction in their ascites.
We observed no change in RBF when patients were given ISMN alone or in
combination with propranolol, despite significant effects on MAP, HVPG and AzBF
consistent with previous reports in the literature (Navasa et al 1989, Garcia-Pagan et
al 1990).
Different methods ofrenal bloodflow measurement
Apart from the different study populations and treatment durations, the studies
described above differed in their method of assessing renal blood flow, with most
using doppler ultrasonography or PAH clearance techniques. Ultrasound is insensitive
in the assessment of renal blood flow, and accurate PAH clearance requires high renal
PAH extraction which does not occur in the presence of hypoxia and shunting of
blood which occurs in sepsis or cirrhosis (Brenner et al 1990). Therefore,
thermodilution methods may be more accurate in pathologiocal states.
For this reason, we used the reverse thermodilution method to measure changes in
RBF. Although this has the limitation of only measuring RBF in one kidney and
represents flow circulating during a short period of time, it has previously been used
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to measure acute RBF changes in cirrhosis in response to drug therapy (Forrest et al
1996).
In view of our desire to assess both AzBF and RBF in this study, we had to move the
thermodilution catheter out of the renal vein between the two recordings of RBF. The
initial position of the catheter in the left renal vein was recorded fluoroscopically and
the catheter re-positioned to the exact same position for the 1 hour recording of RBF
using fluoroscopic guidance. To ensure validity of these measurements, 3 other
cirrhotic patients had multiple RBF recordings made over 1 hour, with the catheter
moved in and out of the left renal vein under similar conditions. The coefficient of
variation in RBF recordings was <10 %.
In our study, the possibility of a type II error for the RBF results exists, but the
numbers studied produced significant results with regard to the other haemodynamic
parameters. Although the patients given ISMN had slightly lower baseline RBF
compared to those given propranolol or combination therapy, this difference was not
significant, and similar to the other therapeutic groups, these patients had no change in
RBF following therapy.
In summary, there appears to be no change in RBF following acute administration of
propranolol, ISMN or a combination of the two drugs to cirrhotic patients, despite the
anticipated changes in MAP, HVPG and AzBF. Therefore any effect of these drugs on
renal function in cirrhosis does not appear to be due to an acute reduction in RBF.
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9b ii Comparisons between carvedilol and beta-blockers or nitrates in the
management of portal hypertension.
We have shown that the vasodilating beta-blocker carvedilol has a portal hypotensive
effect after both acute and chronic administration. The haemodynamic effects of
carvedilol were studied prior to and 60 minutes following oral administration at which
time peak plasma levels have been reported in cirrhosis (Neugebauer et al 1988).
However a significant minority of patients are intolerant of 4 weeks therapy with this
drug. The optimum dose of carvedilol in cirrhosis remains unclear, but a Japanese
group recently reported a 15% drop in HVPG following acute administration of lOmg
carvedilol to cirrhotic patients (Sekiyama et al 1997). It is possible that a lower dose
of carvedilol will allow greater long-term tolerability with only a slight reduction in
the beneficial effect on HVPG.
Splanchnic haemodynamics
Although beta-blockers remain the "gold standard" for pharmacological treatment of
portal hypertension (D'Amico et al 1995), haemodynamic studies have shown that
combination therapy with beta-blockers plus nitrates has a greater portal hypotensive
effect than beta-blockers alone (Garcia-Pagan et al 1990).
Following acute propranolol therapy, a reduction in HVPG of 12-18% has been
reported with an associated reduction in collateral flow and HBF (Bosch et al 1984,
Garcia-Tsao G et al 1986, Garcia Pagan et al 1990). Following acute administration of
combined propranolol and ISMN therapy, the HVPG has been shown to fall by a
greater degree than propranolol alone (26% vs. 14%), but also lead to a further
reduction in HBF (Garcia-Pagan et al 1990). In our study, acute administration of
carvedilol reduced the baseline HVPG by a mean of 20.8% whilst having no effect on
HBF.
We observed an acute reduction in HVPG of >10% in 76.5% patients given
carvedilol. This compares with 55% patients given propranolol acutely, although most
patients with minimal acute or chronic portal hypotensive response to beta-blokers can
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be converted to "responders" by addition of ISMN (Garcia-Pagan et al 1990, Merkel
et al 1997).
Following 4 weeks carvedilol therapy, we observed a mean fall in HVPG of 16.3%,
40% patients having a fall of 20% or more. In a previous report, chronic
administration of propranolol led to a mean fall in HVPG of 10%, compared with
19% in patients given chronic combined propranolol and ISMN therapy (Garcia-
Pagan et al 1991). In that study, HVPG fell by at least 20% in 10% of the propranolol
group compared with 50% given combined therapy. Propranolol also reduced HBF.
Therefore, chronic administration of carvedilol appears to reduce HVPG to a greater
extent than propranolol alone and similar to combined propranolol and ISMN.
However, unlike beta-blocker therapy carvedilol does not appear to compromise liver
blood flow.
Systemic haemodynamics
Acute propranolol therapy reduces heart rate and CO, and combination therapy with
nitrates leads to a further fall in CO and reduces MAP (Garcia-Pagan et al 1990). In
our study, heart rate, MAP and CO fell after acute carvedilol therapy, but no effect on
CO or SVR was seen after chronic administration. However, a continued reduction in
MAP was observed after 4 weeks carvedilol therapy.
Although this drop in MAP was similar to that reported after chronic combined
propranolol and ISMN therapy (Garcia-Pagan et al 1991), 3 patients had to
discontinue carvedilol due to hypotension and another required dose reduction due to
dizziness. In total, 41% patients were unable to complete 4 weeks carvedilol therapy,
and a further 2 patients had to be changed to a lower dose. Most studies report that 15-
40% cirrhotic patients are intolerant of long-term beta-blockers, with a larger
proportion unable to tolerate combined beta-blockers and nitrates.
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Renalfunction
As described above, there have been suggestions that propranolol may impair sodium
excretion in cirrhosis and nitrates may compromise renal blood flow and GFR (Rector
& Reynolds 1984, Salmeron et al 1993). Vorbioff and colleagues reported a
deterioration in renal function in the majority of ascitic patients given combined
propranolol and ISMN therapy (Vorbioff et al 1993), but later studies reported no
effect on renal function of this combination (Morrillas et al 1994, Merkel et al 1995).
Although we did not find an acute reduction in RBF following propranolol and ISMN
combined therapy, there remains some concern regarding chronic administration of
this drug combination in patients with advanced cirrhosis and ascites. The numbers in
our study were small, but it is reassuring that no deleterious effects of chronic
carvedilol therapy on urine volume, sodium excretion or creatinine clearance were
observed.
Therefore carvedilol appears to have a beneficial portal hypotensive effect in cirrhotic
patients following both acute and chronic therapy, with no detrimental effect on liver
blood flow or renal function. Although a significant minority of patients are unable to
tolerate chronic carvedilol therapy, lower doses may have continued beneficial effects.
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9 c Role of adenosine-1 antagonism in the management of cirrhotic ascites.
Adenosine-1 antagonists have not been previously studied in patients with cirrhosis.
We demonstrated improved renal function and RBF in cirrhotic patients following
adenosine-1 antagonism with FK352. There was an immediate isokaliuretic
improvement in urine flow rate and a tendency for free water clearance to rise
following FK352, and an increase in natriuresis which persisted for at least 2 hours.
These effects are of obvious benefit in cirrhotic patients with ascites in whom sodium
and water excretion is impaired and diuretic therapy often leads to potassium
imbalance (Naranjo et al 1979). Although we were only able to repeat right heart
catheterisation 2 hours after drug administration and may have missed an earlier
effect, minimal effects on systemic haemodynamics were observed which may reflect
the renal specificity of adenosine-1 receptors.
9c i Effect on renal sodium and water handling
Water loading and commencement of the supine position may have led to the
relatively high baseline urine volumes and RBF, but there were no significant changes
in urine flow rate, natriuresis or free water clearance during the 2 hours prior to drug
administration. Administration of FK352 was then followed by an immediate increase
in urine flow and natriuresis. Any relation of this effect to the fluid load and posture
change 4 hours earlier is improbable and inconsistent with previous reports (Bemardi
et al 1994, Madsen et al 1986).
Although the patients in our study all had clinical evidence of ascites, none had
biochemical renal impairment or true refractory ascites as defined by Arroyo and
colleagues (Arroyo et al 1996) and therefore we cannot extend our findings to these
patient groups. However, there was a consistent rise in urine flow rate, natriuresis and
RBF when only the patients with Childs grade C disease were considered, indicating a
continued benefit to patients at the more advanced end of the spectrum of liver
disease. Certainly at present, therapeutic options for patients with refractory ascites or
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hepato-renal syndrome are limited and we are keen to study the effects of this drug on
such patients.
9c ii Effects on renal blood flow and GFR
The standard methods of measuring renal blood flow and GFR are PAH and inulin
clearance respectively. However, as previously described, accurate PAH clearance
requires high renal PAH extraction, and in cirrhotic patients, this method may be
invalid (Brenner et al 1990). Therefore we measured renal venous PAH to calculate
the PAH extraction, and also used the reverse thermodilution method as a separate
indicator of changes in renal flow. The improved RBF we have shown following
FK352 is consistent with earlier results from animal studies and the improved RBF
seen in cirrhotic patients given xanthines (Milani et al 1983, Forrest et al 1997).
In normal subjects, PAH extraction should be >0.9, but in the 4 patients in whom we
measured this, the pre-FK352 PAH extraction values ranged from 0.21-0.81.
However, the number of patients studied was too small to properly assess the effect of
FK352 on corrected ERPF. Inulin clearance remains the "gold standard" for GFR
measurement and we were surprised that no rise in GFR was detected despite the
increase in RBF, diuresis and natriuresis. It is possible that FK352 leads to tubular
transport changes and improved RBF via antagonism of adenosine-1 receptors on the
tubule cells and renal vasculature respectively, with little effect on GFR which may
already be at the maximal achievable level in these patients.
9d iii Effect on RAAS and cAMP
A secondary objective of our study was to assess any hormonal change following
FK352 administration. We observed an increase in plasma angiotensin II, PRA and
cAMP, but no change in plasma catecholamines or urinary cAMP. Stimulation of
adenosine-1 receptors inhibits renin release (Arend et al 1986, Deray et al 1987) and
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suppression of this inhibition by administration of theophylline or an adenosine-1
receptor antagonist has been reported to increase PRA (Van Buren et al 1993, Erley et
al 1994).
It has been suggested that the activity of the RAAS is closely related to the impaired
natriuresis in cirrhosis (Wong et al 1997). In addition, increased local adenosine levels
have been shown to potentiate sodium and water retention and renal vasoconstriction
in cirrhotic patients with ascites and overactivity of the RAAS (Llach et al 1993).
Therefore it is of interest that following administration of FK352 to cirrhotic patients,
we observed an improvement in natriuresis and urine flow rate despite an increase in
PRA and angiotensin II. This would suggest that adenosine-1 receptor antagonism is
unique in being able to counter the detrimental effects on the kidney of overactivity of
the RAAS without a deleterious effect on the peripheral vasculature.
Stimulation of adenosine-1 receptors leads to a decrease in cAMP via adenyl cyclase
inhibition (Burnatowska & Spielman 1991) and antagonism of these receptors has
been shown to inhibit this decrease in human glomeruli (Toya et al 1993). Therefore,
adenosine-1 antagonism by FK352 may explain the observed rise in plasma cAMP
during the study. It is unclear if urinary cAMP reflects local renal production or its
excretion via the kidney, making interpretation of urine levels difficult. No effect of
FK352 on peripheral catecholamine levels were observed, which may reflect a limited
effect on systemic haemodynamics.
In summary, adenosine-1 specific antagonism in the form of FK352 appears safe and
effective in cirrhotic patients with ascites. An improvement in diuresis, natriuresis and
RBF is seen. Adenosine-1 antagonism offers a novel approach to the management of
cirrhotic ascites and the spectrum of renal abnormalities seen in cirrhosis.
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9 d_ TIPSS procedure in the management of complications of portal
hypertension.
9d i Haemodynamic and renal effects of TIPSS placement
The dramatic cardiopulmonary and systemic haemodynamic effects of TIPSS
procedure have been described in a number of recent studies. However, the
relationship of these changes to any effect on renal function remains unclear.
Effects on cardiopulmonary haemodynamics
We have confirmed previous reports of a significant rise in CO, PAP and PCWP and a
fall in SVR following TIPSS insertion. Azoulay et al reported an immediate increase
in RAP, PAP, PCWP and CO and a decrease in SVR following the procedure, and a
further worsening of the CO and SVR after 1 month (Azoulay et al 1994). Colombato
and colleagues observed an immediate rise in RAP, PAP, PCWP and cardiac index,
and a fall in SVR following TIPSS placement (Colombato et al 1996). A slight
attenuation of the rise in cardiac index was the only further change detected at 2
months.
Van der Linden et al suggested that the increase in pulmonary pressures was the major
haemodynamic alteration after TIPSS placement (Van der Linden et al 1996). Unlike
the results from our study, they found that the drop in PPG correlated with the rise in
PAP. It seems likely that the extra blood volume delivered to the right heart, mostly
from decompression of the splanchnic circulation, leads to increased pulmonary
pressures and CO. However, in addition to this volume load, the delivery of
vasodilators from the splanchnic to the systemic circulation may precipitate the
haemodynamic changes in the pulmonary, cardiac and systemic circulations.
Effects on renal function
The effect of TIPSS insertion on renal function is currently of great interest. TIPSS
procedure has been shown to improve ascites control, with a delayed natriuresis
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maximal 1 month after shunt placement (Wong et al 1995, Somberg et al 1995,
Quiroga et al 1995, Wong et al 1997). TIPSS insertion also reduces the elevated
circulating levels of plasma renin activity, aldosterone and noradrenaline over a period
of weeks to months following the procedure (Wong et al 1995, Somberg et al 1995,
Quiroga et al 1995, Jalan et al 1996, Wong et al 1997). Variable effects on glomerular
filtration rate or creatinine clearance have been reported (Wong et al 1995, Somberg
et al 1995, Quiroga et al 1995, Jalan et al 1996).
Wong and colleagues have suggested that sodium retention in cirrhosis is critically
linked to sinusoidal portal hypertension, and enhanced by increased activity of the
RAAS (Wong et al 1997). Our results suggest that any improvement in renal funtion
after TIPSS placement does not occur secondary to any reflex increase in RBF.
The validity of thermodilution techniques in the assessment of changes in RBF over a
period of weeks or months is questionable due to the difficulty in ensuring precise
replacement of the catheter in the same position in the renal vein. Therefore we only
assessed the acute changes in RBF following TIPSS placement, and may have missed
a later improvement in RBF. Other studies have reported no effect on renal plasma
flow as estimated by PAH clearance at variable intervals from 1 day to 4 months
following TIPSS insertion (Wong et al 1995, Lebrec et al 1996, Wong et al 1997).
Possibility ofa hepato-renal reflex
Studies by Lang and Jalan have suggested the presence of an hepato-renal reflex
(Lang et al 1991, Jalan et al 1997). In an animal model, Lang and colleagues infused
glutamine into the portal vein, thereby causing acute hepatocyte swelling. This was
associated with an acute reduction in RBF, which was abolished by renal denervation
or section of the hepatic vagal fibres. Stimulation of the sympathetic nerves
innervating the kidney has also been shown to reduce RBF (DiBona & Sawin 1985),
and effective renal plasma flow has improved following sympathectomy (Solis-
Herruzo et al 1987).
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Jalan and colleagues reported that occlusion of a TIPSS in cirrhotic patients was
accompanied by an immediate reduction in RBF which correlated with the rise in PPG
(Jalan et al 1997). There was a smaller but significant reduction in CO which did not
account for the reduction in RBF, and a rise in SVR. TIPSS occlusion had no effect on
renal venous or right atrial levels of angiotensin II, plasma renin activity, atrial
natriuretic peptide, adrenaline or noradrenaline.
Although we did not observe a rise in RBF following the acute reduction in portal
pressure achieved by TIPSS insertion, this does not disprove the presence of an
hepato-renal reflex. A rise in portal pressure may be only one of a variety of
mechanisms that may trigger such a reflex arc, and a fall in portal pressure may not
necessarily activate the reflex.
Renal blood flow can be affected by neural factors, the RAAS, circulating
noradrenaline, vasopressin and natriuretic peptides and intrarenal prostaglandins,
leukotrienes, kinins, endothelin, nitic oxide and adenosine (Bernardi et al 1985,
Moore et al 1992, Wong et al 1993, Llach et al 1993, Forrest et al 1996). Therefore
full assessment of the changes in RBF caused by altering portal pressure would
ideally require measurement of these parameters. However, the reported improvement
in renal function following TIPSS procedure does not appear to involve an acute
increase in RBF.
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9d ii Long-term outcome following TIPSS procedure.
Variceal bleeding
TIPSS insertion has established a position as a "rescue procedure" for uncontrolled
variceal bleeding. In our long-term study, shunt creation was successful in the vast
majority (91.4%) of the 35 patients who had TIPSS procedure for continued variceal
haemorrhage despite sclerotherapy with or without balloon tamponade. Most of these
patients had Childs C cirrhosis. Although only 2 patients had continued bleeding, the
in-patient mortality in this high risk group was 43.7%.
The options of a surgical portosystemic shunt or transection in this situation have
higher procedure-related and early mortality (Franco & Smadja 1985). In addition
transection has higher rebleeding rates and surgical shunting has higher rates of
encephalopathy whilst also compromising a subsequent liver transplant (Matory et al
1980, Grace 1994). Although a recent report suggested benefits from a small diameter
H-graft portacaval shunt compared with TIPSS placement (Rosemurgy et al 1996), it
should be noted that in many cases TIPSS procedure is performed in critically ill
patients who would not be considered fit for surgery.
It remains unclear whether patients who have suffered a first variceal bleed should be
treated with band ligation to obliteration, pharmacological therapy, TIPSS insertion or
some combination of these modalities. Cost analysis, patient compliance with various
treatments and the availability of TIPSS procedure will help determine the optimum
therapy for such patients. In our study, nine (7.6%) patients developed non-variceal
bleeding during follow-up, mostly as a result of sclerotherapy ulcers and these were
the cause of death in 2 patients. Sclerotherapy ulcers have been recognised as a major
problem by many investigators and remain a major potential cause of morbidity and
mortality no matter how effective the shunt is. The more widespread use of band
ligation should reduce the frequency of this complication (Laine et al 1995).
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Refractory ascites
Treatment of patients with refractory ascites remains a major clinical problem. Apart
from liver transplantation, the main therapeutic options are repeated large volume
paracentesis and peritoneovenous shunting. However, these are associated with
significant morbidity and prolonged in-patient management and may aggravate
functional renal failure. Although early reports described benefits of TIPSS procedure
for refractory ascites (Quiroga et al 1995, Ochs et al 1995), the only published
randomised trial comparing it with paracentesis for this indication reported a higher
mortality in the TIPSS group (Lebrec et al 1996). Results from further trials which
should include quality of life data are awaited.
The role of TIPSS procedure in the management of hepato-renal syndrome also
remains controversial. Several authors have reported improvement in functional renal
failure following the procedure (Lake et al 1993, Ochs et al 1995, Brensing et al
1996), and a preliminary study demonstrated a post-TIPSS decrease in the levels of
endothelin-1 which is thought to have a major role in the syndrome (Martinet et al
1994). However as we found in our study, results of TIPSS placement in this patient
group are generally disappointing, and they have a very poor prognosis without liver
transplantation.
Shunt dysfunction
Our recurrent variceal rebleeding rate (13.4% patients) compares favourably with
most other series (Helton et al 1993, Rossle et al 1994, Coldwell et al 1995, LaBerge
et al 1995). Similar to other investigators, we found shunt dysfunction in all patients
with variceal rebleeding (LaBerge et al 1995). There appears to be a steady attrition
rate in shunt patency with time with a primary (pre-intervention) patency of 21.4% at
2 years. Although we have previously shown that shunt dysfunction is more common
with Palmaz stents than Wallstents (Jalan et al 1994), it should be noted that our early
(often Palmaz-stented) patients were left longer than 3 months prior to initial
angiographic assessment. Therefore it is difficult to be sure of the exact timing of
shunt dysfunction in this patient group.
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Accepting this limitation, if it is believed important to assess the stent prior to a 20%
risk of dysfunction, it would be necessary to check the shunt at 2 months and then
approximately 6 monthly thereafter. It would appear that early shunt dysfunction is
more likely to be associated with variceal rebleeding than that occurring later post
TIPSS, therefore even closer shunt assessment in the first few months after placement
may be neccessary.
When shunt insufficiency was detected, intervention maintained shunt patency in all
but one patient, although the majority of stents treated with balloon dilatation required
repeat dilatation on follow-up. This procedure would appear to have only a temporary
effect and the long-term benefits of and exact indications for dilatation remain
unclear. The current limitations of ultrasonographic methods of shunt assessment
mean that direct portography remains the "gold standard" for surveillance (Ferguson
et al 1995, Bartolone et al 1996). This is a major limitation of TIPSS procedure but as
stated above, the development of new covered stents may address this problem.
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Encephalopathy
In our study, new or worsening spontaneous encephalopathy was seen in 16.8% of our
patients and a further 12.6% had new or worsening encephalopathy secondary to
sepsis or bleeding following TIPSS placement. However, considering that 33.6%
patients were encephalopathic prior to the procedure (often because of a recent bleed),
it is difficult to determine the exact role of the shunt in the development of
encephalopathy in this group. In all but 4 patients (who went on to shunt reduction),
the encephalopathy responded to simple medical therapy such as lactulose and protein
restriction. This contrasts with the often debilitating encephalopathy seen in around
one third of patients after non-selective surgical shunts and is likely due to the small
stent diameter and intrahepatic position which encourages continued portal flow into
the liver (Franco & Smadja 1985, Lacy et al 1992).
A reduced incidence of encephalopathy has been reported in narrow portocaval H-
grafts and selective splenorenal shunts although the associated risks of surgery and
subsequent problems with transplantation must be considered (Langer et al 1985,
Johansen 1992). Risk factors for post-TIPSS encephalopathy include a previous
history of encephalopathy, advanced age, female gender, hypoalbuminaemia, non-
alcohol aetiology of cirrhosis, and low post-procedural PPG. These must be carefully
assessed prior to and following TIPSS procedure, and consideration should be given
to smaller stent placement and prophylactic use of lactulose and protein restriction in
such patients.
Liverfunction
Similar to other investigators, we found a transient deterioration in liver function tests
in a third of patients, probably secondary to reduced hepatic perfusion (Rossle et al
1993). Three patients died soon after TIPSS procedure with clinical features of acute
liver failure, two of whom also had evidence of raised intra-cranial pressure. This is
unusual in patients with chronic liver disease but has been previously reported
(Crippen et al 1992). However, all three of these patients were extremely ill at the
time of TIPSS procedure, with periods of prolonged hypotension and requiring
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ventilation. The role of the shunt in their clinical deterioration is therefore difficult to
define, although any reduction in liver perfusion in such patients may be critical.
However, overall there was a significant improvement in Childs-Pugh score at 3-6
months largely due to improvement in ascites.
Mortality
Procedure related mortality in our study was 1.5% which is similar to most reported
series and compares favourably with the 10% operative mortality associated with
surgical portosystemic shunts (Henderson et al 1984). We observed a relatively high
30-day mortality of 21.8% compared with some groups (Rossle et al 1994). However,
mortality has been consistently shown to depend on Childs grade at time of TIPSS
placement and our high percentage of Childs B and C patients (38.9% and 53.2%
respectively) and high numbers of emergency procedures (26.9%) would account for
this. Our one and two year survival of 62.3% and 46.5% respectively are similar to the
recently reported series from San Francisco (LaBerge et al, 1995).
Long term survival following TIPSS procedure will depend on the underlying severity
of liver disease and improved survival due to reduced rebleeding will be difficult to
detect. However the benefits of reduced morbidity due to less variceal rebleeding and
improved control of ascites should not be underestimated. Apart from the severity of
liver disease, hyponatraemia and encephalopathy prior to TIPSS placement have been
shown to independently determine long-term survival (Jalan et al 1995). Thirteen of
our patients subsequently underwent liver transplantation and the benefits of TIPSS
procedure as a "bridge to transplantation" have previously been reported (John et al
1996). In particular, when managing variceal bleeding prior to transplantation, the
avoidance of surgery is advantageous.
In summary, TIPSS insertion is a relatively simple procedure that can be successfully
performed even on critically ill patients. It is effective in controlling both acute and
recurrent variceal haemorrhage and problematic portal hypertensive gastropathy, and
may improve ascites contol. Unlike most surgical portosystemic shunts, TIPSS
procedure does not compromise subsequent liver transplantation.
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However, shunt dysfunction is common and appears to increase linearly with time.
Both variceal rebleeding and reaccumulation of ascites usually occur in the presence
of shunt dysfunction. Therefore regular surveillance by portography is required, and
this probably represents the major limitation of this procedure. Post-TIPSS
encephalopathy is significant but is generally easy to manage. Trials are underway to
compare TIPSS placement with pharmacological or endoscopic therapy in the
prevention of variceal rebleeding and with paracentesis for refractory ascites. Such
trials must include data on quality of life and costs to help define the role of TIPSS
procedure in these situations.
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EPILOGUE:
Thoughts for future research.
The work presented in this thesis answers some questions but poses others. It is my
aim to continue to be involved in studies arising from this research, and I outline some
potential projects below.
Haemodynamics of cirrhosis:
It is clear that there is a close relationship between the severity of liver disease and
HVPG in cirrhosis, and this measurement also predicts subsequent variceal bleeeding
and death. Serial measurements ofHVPG will allow accurate assessment of bleeding
risk in patients undergoing drug therapy for portal hypertension, and the effect of
abstinence in patients with alcohol related liver disease. The evolution of a scoring
system containing CPS parameters, HVPG and possibly other measurements may
provide a more accurate indication of prognosis in cirrhotic patients.
Drug therapy for portal hypertension:
Although propranolol remains the drug of choice in the management of portal
hypertension, recent studies have shown the haemodynamic and clinical benefits of
combined beta-blocker and nitrate therapy. However, we have shown that new
therapies such as carvedilol provide similar portal hypotensive effects. We are now
assessing the chronic haemodynamic effects of lower doses of carvedilol in cirrhotic
patients. We then hope to compare carvedilol with propranolol ± ISMN in a clinical
trial to assess its value in the primary prophylaxis of variceal haemorrhage.
Adenosine-antagonism in cirrhosis:
Acute administration of an adenosine-1 antagonist improves natriuresis and diuresis in
cirrhotic patients with ascites. Future studies with such agents must assess their long-
term efficacy and tolerability. However, spironolactone remains a cheap and effective
first line diuretic for cirrhotic patients with ascites, therefore we hope to study the
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effects of adenosine-1 antagonists in patients with refractory ascites or hepatorenal
syndrome, where current therapy is limited.
TIPSS:
The role of TIPSS procedure in the prevention of variceal rebleeding remains unclear.
Further trials are required to define the exact role of TIPSS, endoscopic therapy and
pharmacological agents in the prevention of variceal rebleeding. TIPSS procedure
does not appear beneficial in the treatment of refractory ascites. However further
studies may identify a subset of patients who may benefit from this procedure in
comparison with paracentesis or peritoneo-venous shunts. Quality of life and cost
issues and must also be taken into account in such studies.
The dramatic haemodynamic changes and alterations in sodium and water
homeostasis observed after TIPSS procedure provide a useful model to investigate the
pathophysiology and treatment of the circulatory and renal changes of cirrhosis. In
addition, the measurement of humeral factors and vasoactive substances in the
splanchnic, renal and systemic vascular beds will also help elucidate the mechanisms
behind the haemodynamic abnormalities seen in cirrhosis.
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Longterm follow up of transjugular intrahepatic
portosystemic stent shunt (TIPSS) for the
treatment of portal hypertension: results in 130
patients





















portosystemic stent shunts (TIPSS) are
increasingly being used to manage the
complications of portal hypertension.
This study reports on the follow up on 130
patients who have undergone TIPSS.
Patients and Methods—One hundred and
thirty patients (81 male), mean (SD) age
54*7 (12-5) years underwent TIPSS. The
majority (64*6%) had alcoholic cirrhosis
and 53*2% had Childs C disease. Indi¬
cations were: variceal haemorrhage
(76-2%), refractory ascites (13-1%), portal
hypertensive gastropathy (4*6%), others
(6-1%). Shunt function was assessed by
Doppler ultrasonography and two then six
monthly portography and mean follow up
for survivors was 18*0 months (range
2-43-5).
Results—The procedure was successful in
119 (91-5%). Sixty three episodes of shunt
dysfunction were observed in 45 (37-8%)
patients. Variceal rebleeding occurred in
16 (13-4%) patients and was always asso¬
ciated with shunt dysfunction. Twenty
(16-8%) patients had new or worse spon¬
taneous encephalopathy after TIPSS and
11 (64-7%) patients had an improvement
in resistant ascites. Thirty day mortality
was 21-8% and one year survival 62-5%.
Conclusion—TIPSS is an effective treat¬
ment for variceal bleeding, resistant
ascites, and portal hypertensive gastro¬
pathy. Rebleeding is invariably associated
with shunt dysfunction, the frequency of
which increases with time, therefore
regular and longterm shunt surveillance is
required.
{Gut 1996; 39: 479-485)
Keywords: transjugular intrahepatic portosystemic
stent shunt, portal hypertension, varices, ascites.
Since their introduction into clinical practice in
1989,1 transjugular intrahepatic portosystemic
stent shunts (TIPSS) are being increasingly
used in the management of both variceal
haemorrhage and refractory ascites.
Variceal haemorrhage is the most dramatic
complication of portal hypertension, occurring
in 30% patients with cirrhosis during their
lifetime.2 Mortality from the first bleed
approaches 50%3 and 70-100% patients have
recurrent bleeding. Immediate control of
bleeding can be achieved in 90% of patients by
balloon tamponade,4 vasoactive drug therapy,5
sclerotherapy,6 variceal band ligation7 or
surgery,8 9 with the greatest reduction in re¬
bleeding rates achieved by surgical shunts.10
The main limitations of shunt surgery are its
high perioperative mortality and frequency of
debilitating postoperative encephalopathy,
which approaches 30% in some series.11 TIPSS
has been shown to control active variceal
haemorrhage and reduce rebleeding rates while
having lower procedure related complications
and probably less post-treatment encephalo¬
pathy12 compared with surgical shunts. Follow
up of patients with TIPSS is however limited,
which is important as encephalopathy follow¬
ing surgical shunts commonly was delayed and
shunt patency after TIPSS may decrease with
time.
Refractory ascites is associated with ad¬
vanced liver disease and a poor prognosis.13
The current therapeutic options of repeated
paracentesis and a peritoneovenous shunt are
far from ideal and associated with significant
morbidity and prolonged hospital stay and do
not affect survival.14 TIPSS permits better
control of ascites and improves renal sodium
excretion15 although the mortality seems
unchanged in the limited reported data. TIPSS
has also been used and found to be effective in
the control of other conditions such as portal
hypertensive gastropathy, splenomegaly,16
Budd-Chiari syndrome,17 and hepatic hydro-
thorax.18 The present available literature is
limited both by short duration of follow up and
small patient numbers. Up until August 1995,
we had carried out 130 TIPSS procedures in
our unit and the aim of this paper is to present




From 1991 to 1995, TIPSS insertion was
attempted in 130 patients, with successful
placement of the stent in 119 cases (91-5%).
Table I shows the details of the patients. Eighty
one patients were male with mean (SD) age of
54-7 (12-5) years (range 9 to 83 years). Over
the same period, a total of 220 patients were
treated for variceal haemorrhage at our
institution.
480 Stanley, Jalan, Forrest, Redhead, Hayes
table i Patient characteristics (n=130) before TIPSS
Sex (M/F) 81/49
Age (y)
mean (SD) 54-7 (12-5)
range 9-83
Aetiology of liver disease (%)
alcoholic cirrhosis 84 (64-6)
cryptogenic cirrhosis 12 (9-2)
primary biliary cirrhosis 11 (8-5)
hepatitis C 5 (3-8)
hepatitis B 5 (3-8)
cystic fibrosis 3 (2-3)
primary sclerosing cholangitis 2(1-5)
autoimmune hepatitis 2(1-5)
other 6 (4-6)






oesophageal varices 73 (56-2)
gastric varices 26 (20-0)
refractory ascites 17 (13-1)
portal hypertensive gastropathy 6 (4-6)
ectopic varices 5 (3-8)
other 3 (2-3)
Emergency procedure (%) 35 (26-9)
Clinical features (%)
artificially ventilated 19 (14-6)
haemodynamic compromise 10 (7-7)
ascites 86 (66-2)
hepatic encephalopathy 44 (33-8)
The aetiology of portal hypertension was
alcoholic cirrhosis (ALD) in 84 (64-6%)
patients, with other aetiologies shown in
Table I. One patient had a! antitrypsin
deficiency and one Budd-Chiari syndrome.
Four patients were non-cirrhotic (one each
with amyloid, idiopathic portal hypertension,
polycystic disease, and nodular regenerative
hyperplasia). Most cirrhotic patients (53-2%)
had Childs-Pugh grade C disease at time of
TIPSS with a mean (SD) overall Childs-Pugh
score of 9-9 (2-7).
The indication for TIPSS was oesophageal
variceal bleeding in 73 (56-2%) patients who
had either continued bleeding despite two
sessions of sclerotherapy or were part of a trial
comparing band ligation with TIPSS in the
prevention of rebleeding (see Table I). The
indication was ectopic varices in five (3-8%)
patients (two rectal, two stomal, and one duo¬
denal) and painful splenomegaly, hypersplen-
ism and embolisation of a spontaneous shunt in
one patient each. Thirty five procedures
(26-9%) were carried out as an emergency with
19 (14-6%) patients receiving assisted ventila¬
tion and 23 (17-7%) patients treated with
balloon tamponade prior to TIPSS.
STUDY DESIGN
The technique of TIPSS placement was based
on the original method described by Richter19
and is described in detail elsewhere.20 Routine
pre-procedural mesenteric angiography was
undertaken in the first 32 patients to guide
portal vein puncture and in 27 subsequent
patients, Doppler ultrasonography was used to
identify the site of portal vein bifurcation. In
the last 71 patients however, no routine
imaging was undertaken to localise the portal
vein pre-TIPSS, although ultrasonography was
used prior to the procedure to exclude portal
vein thrombosis. These changes have evolved
as a result of ongoing audit at our unit.
Once successful puncture of the portal vein
was achieved, 2-3 Palmaz stents (Johnson and
Johnson) (20 patients), or 1-2 Wallstents
(Schneider US Stent Division) (99 patients)
were inserted to reduce the portal pressure
gradient (defined as: (portal pressure) -
(inferior vena-caval pressure)) to less than 12
mm Hg. Three patients subsequently had
Angiomed stents (Angiomed, Karlsruhe,
Germany) inserted to reduce the shunt size. In
two patients in whom a thrombus was noted
within the portal vein at the end of the
procedure, a catheter was left within the shunt
for regional infusion of low dose streptokinase
for 24 hours. Prophylactic antibiotics (cefo¬
taxime and amoxycillin) were given one hour
before the procedure and continued for 48
hours thereafter and Doppler ultrasonography
was performed prior to discharge to ensure
shunt patency. Routine portography was
undertaken at one to three months and six
monthly thereafter to assess shunt function, or
earlier in the event of rebleeding or reaccumu-
lation of ascites. Early in our experience how¬
ever, several shunts were left six to 12 months
before initial angiographic assessment.
Encephalopathy was assessed clinically after
six weeks then at three monthly intervals
during outpatient review. Prophylactic lactu¬
lose and protein restriction were not routinely
applied. Variceal rebleeding was defined as
endoscopically confirmed variceal haemor¬
rhage occurring more than 24 hours after
TIPSS insertion. All shunt complications were
confirmed angiographically with occlusion
defined as absent flow through the shunt.
Pseudo-intimal hyperplasia, hepatic vein
stenosis, portal vein and shunt thrombosis
were defined by the angiographic appearance
in conjunction with either a 20% rise in portal
pressure gradient or an increase in portal
pressure gradient to 12 mm Hg or more.
Primary shunt patency was defined as the (pre-
intervention) absence of any of the above shunt
complications. Mean (SD) follow up (defined
as time to death, most recent clinical review or
liver transplantation) for all patients was 10-7
(1 TO) months and for survivors (patients alive
up to October 1995) 18-0 (1T9) months.
STATISTICAL ANALYSIS
Results are expressed as mean (SD) or range
where indicated. Paired Student's t test was
used to determine statistical significance and
Kaplan-Meier method used for rates ofvariceal
rebleeding, primary shunt patency, and survival.
Results
Tables II and III summarise the results.
SHUNT PROCEDURE
TIPSS placement was successful in 119
(91-5%) patients. The procedure failed in 11
patients (10 of whom had variceal haemor¬
rhage) because a main branch of the portal vein
could not be punctured: four of these patients
subsequently underwent shunt surgery and five
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table ii Results of TIPSS procedure and shunt
complications
Successful TIPSS procedure (%) 119 (91-5)
PPG before TIPSS mean (SD) (mm Hg) 17-5 (5-9)
PPG after TIPSS (mm Hg) 8-6 (3-4)
Pre-intervention shunt patency (%):
6 months 47(71-2)
1 year 25 (58-1)
2 years 3 (21-4)
Shunt complications: 63 episodes in
45 (37-8) patients:
pseudo-intimal hyperplasia 29
hepatic vein stenosis 13
portal vein/shunt thrombosis 5
occlusion 16
PPG=portal pressure gradient.
had further endoscopic therapy. Thirty day
mortality in the failed TIPSS group with
variceal haemorrhage was 70-0%.
Two procedure related deaths occurred from
intraperitoneal haemorrhage because of an
extrahepatic tear of the portal vein in one and
puncture of the liver capsule in the other. One
patient developed an epidural haemorrhage,
which was diagnosed after the procedure but
the exact relation to TIPSS placement was
unclear. Other complications included portal
vein thrombosis in two patients (successfully
treated by local streptokinase infusion), portal
vein dissection in one (successfully managed by
stenting), and shunt dislocation or migration
into the splenic vein in two. There were no
clinically significant groin or neck haema-
tomas. Mean (SD) portal pressure gradient
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Figure I: Kaplan-Meier analysis ofpatients free of variceal rebleeding and with primary
shunt patency duringfollow up.
was reduced from 17-5 (5-9) mm Hg pre-
TIPSS to 8-6 (3-4) mm Hg (p<0-001) after
successful stent placement.
A total of 63 episodes of shunt complications
were seen in 45 patients (see table II). Twenty
nine of these were clinically significant (asso¬
ciated with variceal rebleeding or reaccumu¬
lation of ascites), with the others detected on
routine surveillance. Fifty per cent of the shunt
complications occurring less than one month
after TIPSS were associated with variceal re¬
bleeding, as were 41-7% of those occurring
from one to three months, 35% from three to
12 months, and 23-5% from 12-24 months.
None of the shunt complications occurring
more than two years after TIPSS were asso¬
ciated with variceal rebleeding. Taking follow
up as most recent angiographic TIPSS assess¬
ment, pre-intervention shunt patency was
71-2% at six months, 58-1% at one year, and
21-4% at two years (see Table II and Fig 1).
No Palmaz stent had primary patency at two
years. All shunt complications but one (in a
patient who was transferred to an endoscopic
banding programme and remains well) were
successfully treated by balloon dilatation, local
thrombolysis, shunt extension or parallel shunt
placement (nine patients). The causes of shunt
dysfunction are described in Table II.
CLINICAL FOLLOW UP
Control ofacute bleeding
Thirty five patients had TIPSS for acute
variceal haemorrhage uncontrolled despite
sclerotherapy with or without tamponade.
Eighteen of these patients were mechanically
ventilated and 10 were haemodynamically
unstable at time of TIPSS. The procedure was
technically successful in 32 of these patients and
the other three patients died: two from massive
haemorrhage and one shortly after oesophageal
transection. Fourteen of the remaining patients
died during the index hospital admission: three
each from acute on chronic liver failure, sepsis,
and end stage liver failure, two from continued
bleeding (one from a sclerotherapy ulcer
confirmed at necropsy and one with
disseminated intravascular coagulation and
acidosis), two from cardiac arrests/myocardial
infarct, and one from a procedure related
intraperitoneal bleed. Two further patients had
subsequent variceal rebleeds, both related to
shunt insufficiency and successfully treated by
angioplasty and shunt extension.
Recurrent variceal bleeding
TIPSS was successful in reducing recurrent
variceal haemorrhage. There were 24 episodes
of variceal re-bleeding in 16 (13-4%) patients
(see Fig 1), all of which were associated with
shunt insufficiency and responded to dilatation
or further stenting. Five patients underwent
TIPSS for ectopic variceal haemorrhage (two
rectal, two stomal, and one duodenal) and
none of these patients have had a recurrent
bleed. Non-variceal haemorrhage occurred in
nine (7-6%) patients (see Table III).
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Ascites
Eighty six patients (66-2%) had ascites prior to
TIPSS and this was the primary indication in
17 patients (seven of whom had established
hepatorenal syndrome) (see Table III). The
ascites improved (reduced or no diuretic
requirement) in 56 (65-1%) of the 86 patients,
but reaccumulated in 14. This was associated
with shunt insufficiency in 11 patients and
spontaneous bacterial peritonitis in two, but
was responsive in all cases to shunt revision and
antibiotics respectively. Of the 17 patients who
had TIPSS performed for refractory ascites,
improvement occurred in 11 and two have
subsequently undergone successful liver trans¬
plantation. Those with biochemical evidence
of renal dysfunction tended to respond less well
after TIPSS insertion.
Other indications
TIPSS was performed for intractable bleeding
from portal hypertensive gastropathy in six
patients. Four of these have not required
further transfusion and the other two have
required one admission each for transfusion.
Both of these patients had evidence of shunt
dysfunction due to pseudo-intimal hyperplasia
in association with a raised portal pressure
gradient, which was successfully treated by
angioplasty or shunt extension. TIPSS resulted
in an improvement in platelet count from
13 000/1 to 50 000/1 in one patient with hyper-
splenism. Another patient had a large
spontaneous shunt successfully embolised via
the TIPSS for amelioration of intractable
hepatic encephalopathy.
Sepsis
Fourteen (11-8%) patients developed clinically
significant infections in the week after TIPSS
(seven pulmonary, two spontaneous bacterial
peritonitis, two related to central venous
catheter, one cellulitis, and two of unknown
origin). Sepsis was the cause of death in two
patients during the index admission: one with
pre-existing staphylococcal and fungal septi¬
caemia and one with cystic fibrosis and pre¬
existing lung sepsis. All other infective episodes
responded to antibiotics.
Liverfunction
Approximately one third of patients exhibited
a transient deterioration in their liver function
tests in the first week after TIPSS, usually with
doubling of bilirubin and alanine amino¬
transferase values. Three patients died with
clinical features of acute liver failure, character¬
ised by hypotension, renal failure, and hypo-
glycaemia. Two of these patients also had
evidence of raised intracranial pressure on
extradural pressure recordings or computed
tomography. Childs-Pugh score did however
improve at three to six months to 7-6 (2-1)
(p=0-019) largely because of a reduction in
ascites.
Transplantation
Thirteen patients have undergone orthotopic
liver transplantation after TIPSS. Transplant
was undertaken a mean of 7-1 (5-4) months
after TIPSS and 11 of these patients remain
alive and well.
Hepatic encephalopathy
Forty four (33-8%) patients were clinically
encephalopathic prior to TIPSS and this
resolved in 24 (54-5%) after the procedure.
Twenty (16-8%) patients developed new or
worsening spontaneous encephalopathy during
follow up (15 within the first six months). A
further 15 (12-6%) patients developed en¬
cephalopathy secondary to sepsis or bleeding
during follow up (see Table III). Reduction in
shunt size was performed because of en¬
cephalopathy in four patients (successful in
three), with all others responding to simple
medical treatment.
Childs grade
C — B— A —
o.o
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Follow up after TIPSS (months)
Figure 2: Kaplan-Meier analysis ofpatient survival after
TIPSS by Childs grade. (Childs A, n=12; Childs B, n=44;
Childs C, n=61. At 12 months, n=9, 23, and 14
respectively.)
Mortality
Of the 119 patients with successful TIPSS
placement, 52 have died and 13 have under¬
gone transplantation. Procedure related
mortality was 1-5% and mean time to death
was 6-0 (8-9) months (range 0-03-45-3). Mean
follow up of survivors is 18-0 (11-9) months
(range 2-0-43-5). Thirty day mortality was
21-8% (84-6% of whom had Childs C disease)
and six months survival 69-2%. One and two
year survival is 62-3% and 46-5% respectively.
Mortality was dependent on Childs grade at
time of TIPSS (see Fig 2).
Discussion
This is only the second study with large
numbers of patients and longterm follow up
and our results are similar to the two year
follow up of 90 patients reported by Laberge
et al.21 Shunt insertion was achieved with a
reduction in the portal pressure gradient to
below 12 mm Hg in 91-5% patients. Our
recurrent variceal rebleeding rate (13-4%
patients) and rate of new or worsening
spontaneous encephalopathy (16-8% patients)
compares favourably with most other
series.12 21-23
TIPSS has established a position as a 'rescue
procedure' for uncontrolled variceal bleeding.
Of the 35 patients who had TIPSS for
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continued variceal haemorrhage despite sclero¬
therapy with or without balloon tamponade,
shunt creation was successful in the vast
majority (91-4%). Most (77-1%) of these
patients had Childs C cirrhosis. Although only
two patients had continued bleeding the
inpatient mortality in this high risk group was
43-7%. The options of a surgical portosystemic
shunt or transection in this situation have
higher procedure related and early mortality.24
In addition transection has higher rebleeding
rates25 and surgical shunting has higher rates of
encephalopathy26 while also compromising a
subsequent liver transplant. It should be noted
that in many cases TIPSS is performed in
critically ill patients who would not be con¬
sidered fit for surgery.
Similar to other investigators,21 we found
shunt dysfunction in all patients with variceal
rebleeding. There seems to be a steady attrition
rate in shunt patency with time (Table II and
Fig 1) with a primary (pre-intervention)
patency of 21-4% at two years. We have pre¬
viously shown that shunt dysfunction is more
common with Palmaz stents than Wallstents,27
although it should be noted that our early (often
Palmaz stented) patients were left longer than
three months prior to initial angiographic
assessment, therefore especially in this group it
is difficult to be sure of the exact timing of shunt
dysfunction. Accepting this limitation, if it is
believed important to assess the TIPSS prior to
a 20% risk of dysfunction, it is necessary to
check the shunt at two months and then
approximately six monthly thereafter. It would
seem that early shunt dysfunction is more likely
to be associated with variceal rebleeding than
that occurring later after TIPSS, therefore even
closer shunt assessment in the first few months
after placement may be neccessary.
Although intervention maintained shunt
patency in all but one patient when insuf¬
ficiency was detected, most stents treated with
balloon dilatation required repeat dilatation on
follow up. This procedure would seem to have
only a temporary effect and the longterm
benefits of and exact indications for dilatation
remain unclear. The current limitations of
ultrasonographic methods of shunt assess¬
ment28 mean that direct portography remains
the 'gold standard' for surveillance. This is an
important limitation of TIPSS but hopefully
the development of new covered stents will
tackle this problem.
An ability to identify early shunt dysfunction
and minimise encephalopathy together with a
low incidence of rebleeding makes TIPSS an
alternative to sclerotherapy in the treatment of
recurrent variceal bleeding. Trials are currently
underway to compare these two treatments in
this situation. In the case of gastric variceal
haemorrhage where current endoscopic treat¬
ments are unsatisfactory, we believe TIPSS to
be the treatment of choice, as indicated by the
comparatively large proportion of patients in
our series with gastric varices.
Nine (7-6%) patients developed non-
variceal bleeding during follow up, mostly as a
result of sclerotherapy ulcers and these were
the cause of death in two patients. Sclero¬
therapy ulcers have been recognised as a major
problem by many investigators and remain a
major potential cause of morbidity and
mortality no matter how effective the shunt is.
The alternative of band ligation should reduce
the frequency of this complication.29
New or worsening spontaneous encephalo¬
pathy was seen in 16-8% patients and a further
12-6% had new or worsening encephalopathy
secondary to sepsis or bleeding after TIPSS.
Considering however that 33-6% patients were
encephalopathy prior to TIPSS, it is difficult
to determine the exact role of the shunt in the
development of encephalopathy in this group.
In all but four patients (who went on to shunt
reduction), the encephalopathy responded to
simple medical treatment such as lactulose and
protein restriction. This contrasts with the
often debilitating encephalopathy seen in
around one third of patients after non-selective
surgical shunts" and is probably because of the
small stent diameter and intrahepatic position
that encourages continued portal flow into the
liver.30 A reduced incidence of encephalopathy
has been reported in narrow portocaval
H-grafts31 and selective splenorenal shunts32
however the associated risks of surgery and
subsequent problems with transplantation must
again be considered. Recent reports indicate
that increasing age and a previous history of
encephalopathy are the main predictors of en¬
cephalopathy after TIPSS33 and perhaps these
patients should have narrower stents placed.
Treatment of patients with refractory ascites
remains a major clinical problem. Apart from
liver transplantation, the main therapeutic
options are repeated large volume paracentesis
and peritoneovenous shunting, both of which
are associated with significant morbidity and
prolonged inpatient management and may
aggravate functional renal failure. Recent
reports14 15 describe the benefits of TIPSS for
refractory ascites although data are limited. The
mechanism of action seems to be a combina¬
tion of reduced portal pressure gradient and
increased natriuresis, probably secondary to
increased effective circulating plasma volume
and neurohumeral factors. Survival is poor in
patients with refractory ascites and any trial
assessing TIPSS in this situation would need to
assess quality of life and cost-benefit factors.
The place of TIPSS in the treatment of
hepatorenal syndrome also remains contro¬
versial. Several authors have reported improve¬
ment in functional renal failure15 34 and a
preliminary study35 showed a decrease after
TIPSS in the levels of endothelin 1, which is
thought to have an important role in the
syndrome. However as we found in this study,
results are generally disappointing in this group
of patients and they have a very poor prognosis
without liver transplantation.
Similar to other investigators,36 we found a
transient deterioration in liver function tests in
a third of patients probably secondary to
reduced hepatic perfusion. Three patients died
soon after TIPSS with clinical features of acute
liver failure, two of whom had evidence of
raised intracranial pressure. This is unusual in
patients with chronic liver disease but has been
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reported.37 All three of these patients were
extremely ill at the time of TIPSS, however,
with prolonged hypotension and requiring
ventilation. The role of TIPSS in their clinical
deterioration is therefore difficult to define,
although any reduction in liver perfusion in
such patients may be critical. Overall however
there was a significant improvement in Childs-
Pugh score at three to six months largely due
to improvement in ascites.
Procedure related mortality was 1-5%,
which is similar to most reported series and
compares favourably with the operative mor¬
tality associated with surgical portosystemic
shunts of around 10%.38 We found a relatively
high 30 day mortality of 21-8% compared with
some groups,22 however mortality has been
consistently shown to depend on Childs grade
at time of TIPSS and our higher percentage of
Childs B and C patients (38-9% and 53-2%
respectively) and higher numbers of emergency
procedures (26-9%) would account for this.
Our one and two year survival of 62-3% and
46-5% respectively are similar to the recently
reported series from San Francisco.21
Longterm survival after TIPSS will depend
on the underlying severity of liver disease and
improved survival due to reduced rebleeding
will be difficult to detect. However the benefits
of reduced morbidity, as a result of improved
control of ascites and less variceal rebleeding
should not be underestimated. We have
previously shown that besides severity of liver
disease, hyponatraemia and encephalopathy
prior to TIPSS independently determine long-
term survival.39 Thirteen of our patients sub¬
sequently underwent liver transplantation and
the benefits of TIPSS as a 'bridge to trans¬
plantation' have been previously reported.40 In
particular the ability to avoid surgery in the
treatment of variceal bleeding before trans¬
plant is important.
In conclusion, TIPSS is a comparatively
simple procedure that can be successfully per¬
formed even on critically ill patients. It is
effective in the treatment of both acute and
recurrent variceal haemorrhage (especially
where they are not amenable to sclerotherapy),
refractory ascites, and portal hypertensive
gastropathy. Unlike surgical portosystemic
shunts, it has the advantage of not compro¬
mising subsequent liver transplantation. Shunt
dysfunction however is common and seems to
increase linearly with time and variceal re¬
bleeding and reaccumulation of ascites usually
occur in the presence of shunt stenosis or
occlusion. Regular surveillance by portography
is therefore necessary and this represents an
important limitation ofTIPSS. Post-procedure
encephalopathy is significant but generally
easily treated and bleeding from sclerotherapy
ulcers remains an important cause ofmorbidity
and mortality. Trials are currently underway to
compare TIPSS with sclerotherapy or banding
in the treatment of first variceal haemorrhage
and with paracentesis for refractory ascites,
which will help define its exact role in these
situations.
We thank Fiona Miller for technical assistance and data
collection.
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SUMMARY
In the 8 years since its introduction into clinical
practice, initial enthusiasm for the transjugular
intrahepatic portosystemic stent-shunt (TIPSS) has
been tempered by a more critical appraisal of its role in
the management of portal hypertension. TIPSS has
established its role as a rescue procedure for variceal
haemorrhage uncontrolled by endoscopic means and
as a treatment for ectopic or recurrent variceal
bleeding. Randomized trials comparing TIPSS with
endoscopic methods in the secondary prophylaxis of
oesophageal variceal haemorrhage have shown
reduced rebleeding after TIPSS but no effect on
survival. Its exact role in this situation awaits further
assessment, including quality of life and cost analyses,
and consideration of the current limited availability of
the technique.
Experience of TIPSS in patients with refractory ascites
or hepatorenal syndrome has been disappointing. Little
data currently exist, but results of further randomized
studies comparing TIPSS with paracentesis for
refractory ascites are awaited. Ideally these should be
multicentre studies, and should include quality of life
data for this poor prognostic group.
Development of shunt insufficiency remains a major
problem and occurs in « 50% patients at 1 year. The
need for continued shunt surveillance by Doppler
sonography and direct portography is the major
limitation of TIPSS, but hopefully the development of
covered stents will address this problem.
INTRODUCTION
Following the introduction of the transjugular intra¬
hepatic portosystemic stent-shunt procedure (TIPSS) into
clinical practice in 1989,1 there have been numerous
reports describing its use in the management of the
complications of portal hypertension. Much of this
t literature involves assessment in small numbers of
patients and therefore it has been difficult to determine
the exact role of TIPSS. However, several recent
' randomized studies have compared TIPSS with estab¬
lished treatments for both variceal haemorrhage and
refractory ascites. These provide valuable data with
which to critically judge the role of TIPSS in these
Correspondence to: Dr A. J. Stanley, Department of Medicine, Royal
Infirmary of Edinburgh, Lauriston Place, Edinburgh EH3 9YW, UK.
settings. In the light of these and other recently published
studies, this review seeks to examine the current role of
TIPSS in the management of portal hypertension and to
assess its complications and limitations.
TIPSS PROCEDURE
The techniques of TIPSS placement are generally based
on the original method described by Richter et al.1 Many
centres use pre-procedural Doppler ultrasonography to
exclude portal vein thrombosis (see below) and in some
cases to localize the portal vein bifurcation.
Following midazolam and pethidine premedication, a
sheath is introduced over a guidewire into the inferior
vena cava via a right internal jugular approach. Using a
stiff hydrophilic guidewire, the middle or right hepatic
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Figure 1. (a) Initial portogram prior to emergency TIPSS insertion showing oesophageal varices and Sengstaken balloon in situ, (b)
Portogram of same patient just following TIPSS placement with shunting of portal blood through TIPSS and resolution of varices.
vein is selected under fluoroscopic guidance and the
sheath is advanced into the selected vein. A transjugular
needle is then passed down the sheath and used to direct
the puncture of the portal vein. Following this, the
guidewire is passed into the portal system and the whole
sheath is then advanced and portal venography carried
out (Figure 1A).
Following measurement of the portal pressure gradient
(PPG, defined as the difference between portal venous
pressure and inferior vena caval pressure), the track is
dilated with an angioplasty balloon. A self-expanding
metal stent (8-12 mm diameter) is then inserted into the
parenchymal channel, portography is repeated and the
final PPG measured (Figure IB). The most commonly
used stents are the Wallstents (Schneider, US Stent
Division) or the Palmaz stents (Johnson & Johnson). The
PPG should be reduced to below 12 mmHg,2 although in
the rare occurrence of a low initial PPG, the aim should
be a reduction in baseline PPG by 20%.
When the procedure is being undertaken for uncon¬
trolled variceal haemorrhage, varices can be embolized
with steel coils or particulate matter and indeed this is
routinely done in some centres. Some units also inject
intravenous heparin at the time of stent insertion, but the
benefits of these interventions are unclear.
As with any technique, TIPSS is operator-dependent
and a learning curve exists, which is the main reason
why TIPSS is likely to remain limited to specialist units.
In experienced hands, the procedure can be completed
successfully in 90% patients, usually within 2 h.
VARICEAL HAEMORRHAGE
The first reports of TIPSS were in the management of
oesophageal variceal haemorrhage.1,3 The treatment of
uncontrolled variceal haemorrhage or recurrent oeso¬
phageal variceal haemorrhage remain the main indica¬
tions for TIPSS procedure (Table 1). TIPSS placement
appears preferable to shunt surgery or oesophageal
transection as a rescue procedure for uncontrolled
variceal haemorrhage refractory to endoscopic therapy,
in view of the less invasive technique and lower reported
complications and mortality,4 although no prospective
randomized studies have been performed. Indeed, suc¬
cessful TIPSS placement leads to immediate haemostasis
in up to 100% patients with uncontrolled variceal
haemorrhage.4"6
Recurrent variceal haemorrhage despite adequate endo¬
scopic therapy is also an accepted indication for TIPSS
placement, especially for patients with Childs B or C
disease in whom shunt surgery is poorly tolerated.7
Several large cohort studies have reported variceal
rebleeding rates of 13-18 % during a follow-up period of
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Table 1. Four major series reporting TIPSS
insertion
Rossle7
Number of patients 100
Childs C patients (%) 22
Emergency procedure (%) 10
Mean follow-up (months) 12
Rebleeding (%) 18
Encephalopathy (%) 15
Shunt dysfunction (%) 33
Mortality-30 day(%) 3
Mortality-overall (%) 10














(months) Rebleeding (%)* H. enceph. (%)* Survival (%)*
Rossle et a/.$12 26/28 8 8 vs. 26$ 19 vs. 4 92 vs. 96
Sanyal et al.13 40/39 - 22 vs. 15 22 vs. ? 73 vs. 90$
G d'EAIHt14 32/33 12 41 vs. 61 - 50 vs. 48
Cello et al.15 21/19 12 0 vs. 37§ 52 vs. 42 81 vs. 84 (30 day)
Jalan et al. II16 31/27 16 10 vs. 50** 22 vs. 8 81 vs. 89 (30 day)
Riggio et al." 38/43 19 21 vs. 51$ (1 yr) 50 vs. 16§ 83 vs. 85 (1 yr)
Sauer et al.'f18 42/41 18 9 vs. 44$ (1 yr) 29 vs. 10$ 77 vs. 85 (1 yr)
Garcia-Villarreal et al.19 18/19 15 11 vs. 47§ 26 vs. 22 94 vs. 56§
Cabrera et al20 31/32 15 23 vs. 52$ 33 vs. 13$ 80 vs. 84
* results expressed as TIPSS group vs. endoscopy group,
f used concomitant propranolol in sclerotherapy arm.
If used band ligation as endoscopic therapy.
$ P < 0.05
§ PcO.Ol
** P < 0.001
5-14 months after TIPSS placement for variceal haem¬
orrhage8"11 (Table 2).
However, it is only in the past 2-3 years that
randomized trials comparing TIPSS procedure with
endoscopic therapy for the secondary prophylaxis of
oesophageal variceal haemorrhage (i.e. to reduce
rebleeding) have been reported, eight in abstract form12"19
and one as a full paper.20 In these studies, patients were
randomized to receive TIPSS or definitive endoscopic
therapy a variable time (up to 1 week) following control
of the initial bleed by endoscopic or pharmacological
means. All except one study16 (which used band ligation),
used sclerotherapy as the endoscopic treatment and
three studies12,14'18 added propranolol to the endoscopic
treatment arm. These studies are summarized in Table 2.
Seven of these studies found a significant reduction in
rebleeding following TIPSS compared with endoscopic
therapy, with the other two showing no difference
between the groups. There were no differences in
mortality in seven of the nine trials, with one finding an
increased mortality in the TIPSS group13 and another an
increasedmortality in the sclerotherapy group.19 In some
trials, patients who rebled in the endoscopy group were
'rescued' by TIPSS insertion, thereby reducing the
chance of demonstrating a difference in survival.
Encephalopathy occurred more often in the TIPSS group
in most studies, but was generally easy to manage.
Shunt insufficiency and the subsequent need for sur¬
veillance of the stent remains a major limitation of TIPSS
(see below) and must be taken into account when
comparing TIPSS with other treatment modalities,
although long-term surveillance is also necessary in
endoscopic treatment. In addition, little information
exists regarding the cost-effectiveness of the various
treatments for variceal haemorrhage, although one
abstract concluded that preventing variceal bleeding by
TIPSS placement is about one-third more expensive than
by endoscopic sclerotherapy.21 Although TIPSS
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Table 3. Indications for TIPSS
Definite indications:
Acute oesophageal variceal bleeding refractory to endoscopic therapy
Recurrent oesophageal variceal bleeding
Gastric or ectopic variceal haemorrhage
Bleeding from portal hypertensive gastropathy
Unproven indications:
Refractory ascites or hepatic hydrothorax






procedure appears promising in this situation, further
information on its cost-effectiveness and advances in
shunt patency and surveillance methods will help clarify
its role in preventing oesophageal variceal rebleeding.
Gastric and ectopic varices
Endoscopic methods for treating bleeding gastric varices
remain unsatisfactory. In view of the perceived benefits of
TIPSS over shunt surgery, TIPSS placement has been
advocated by some as the treatment of choice for gastric
variceal haemorrhage.22,23 Although one study
suggested TIPSS was less successful for gastric than
oesophageal variceal haemorrhage,24 other studies have
confirmed its efficacy in this group of patients.25'26
However, no randomized trials have been carried out to
compare TIPSS with surgery or endoscopic treatments
such as bovine thrombin sclerotherapy in the man¬
agement of gastric variceal haemorrhage; ideally these
should be undertaken.
The situation is similar with regard to ectopic varices.
TIPSS has been shown to be effective for the management
of bleeding rectal, intestinal and stomal varices27"30 and
recurrent urinary conduit bleeding.31
REFRACTORY ASCITES
In most series, refractory ascites is the second most
common indication for TIPSS placement after variceal
haemorrhage. Over the past 3 years, numerous abstracts
and eight published papers32-39 have assessed the efficacy
of TIPSS for refractory ascites. The findings are broadly
similar and indicate that TIPSS improves renal function
and urinary sodium excretion, and most patients have at
least a partial improvement in their ascites, with reduced
diuretic requirements. However, most studies report a
high incidence of hepatic encephalopathy and high
mortality, due largely to the advanced liver disease
present in these patients. Several studies therefore recom¬
mended TIPSS for patients with refractory ascites and
Childs grade B but not grade C disease. In view of their
poor prognosis, patients with refractory ascites should
also be considered for orthotopic liver transplantation.
Two studies,40'41 (one in abstract form41), have reported
results of randomized trials comparing TIPSS with
paracentesis. Lebrec et al.i0 found that TIPSS procedure
was effective in the control of refractory ascites, but only
in patients with Childs C disease. Survival was actually
lower in patients treated with TIPSS, possibly due to a
reduction in hepatic perfusion. They concluded that the
improvement in ascites following TIPSS placement was
due to neurohumeral factors controlling naturesis, which
depended on hepatic sinusoidal pressure. Ochs et al.41
found that TIPSS was more effective than paracentesis in
the control of refractory ascites, with a reduction in the
period of hospitalization. They found no difference in
survival between the two groups.
In addition, one study, presented in abstract form,
randomized patients with refractory ascites to receive
either TIPSS or a peritoneovenous shunt.42 The authors
found that both treatments were equally effective in
palliating ascites but no difference in survival was
detected. Patients treated with peritoneovenous shunts
had fewer days in intensive care.
Currently TIPSS procedure should not be considered a
routine treatment for refractory ascites. In view of the
high mortality in these patients, future studies assessing
the role ofTIPSS in this condition should measure quality
of life and in-patient stay. These studies will probably
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need to be multicentre and prospectively randomize
patients to compare TIPSS placement with paracentesis
or peritoneovenous shunt insertion for the management
of refractory ascites.
HEPATORENAL SYNDROME
Patients with hepatorenal syndrome (HRS) have a poor
prognosis without orthotopic liver transplantation. Sev¬
eral abstracts and case reports,43-48 describing the use of
TIPSS in a small number of patients with HRS, have
suggested it may improve renal function, reduce the need
for haemodialysis and prolong the waiting time to liver
transplantation. However, mortality remained very high
in this patient group due to their advanced liver disease,
and the use ofTIPSS can only provide at best a temporary
reprieve.
OTHER INDICATIONS
Budd-Chiari syndrome can be treated by thrombolysis
of the occluded vein, the creation of a surgical shunt,
stent insertion in the hepatic vein or inferior vena cava,
or by liver transplantation.49 Recently, several reports
have described successful treatment of Budd-Chiari
syndrome by TIPSS placement.50-52 These reports confirm
that in this condition, TIPSS procedure reduces ascites,
collateral blood flow and intestinal congestion. In ad¬
dition, unlike shunt surgery, TIPSS is not compromised
by an enlarged caudate lobe and is less invasive.
Although portal vein thrombosis was initially con¬
sidered a relative contraindication to TIPSS insertion,
two recent reports indicate that this procedure can be
successfully undertaken in such patients.53-54 However,
one of these reports included patients with non-cavern¬
ous portal vein thrombosis only and used concomitant
local thrombolysis.54 Data remains scarce on the use of
TIPSS for this indication and the exact nature and site of
the portal vein occlusion, together with local expertise,
must be taken into account before considering it as a
treatment for portal vein thrombosis.
In addition, TIPSS has been shown to be of benefit in the
management of patients with bleeding secondary to
portal hypertensive gastropathy.55 TIPSS has also been
used effectively in the management of cirrhotic hydro-
thorax,56-58 hypersplenism59 (see below), veno-occlusive
disease60 and the hepatopulmonary syndrome.61
The presence of TIPSS in patients who have had this
procedure as treatment for their portal hypertension
allows relatively easy access to the portal vein by
transjugular puncture via the stent. Portal venous blood
sampling and portal haemodynamic assessment can
therefore be undertaken for research purposes, particu¬
larly at the time of portographic shunt surveillance.
'BRIDGE TO TRANSPLANTATION'
Insertion ofTIPSS has been shown to have less associated
morbidity and mortality than portocaval shunt surgery
and has less potential to compromise subsequent ortho¬
topic liver transplantation.62 A number of studies have
assessed the possible benefits of TIPSS insertion on
subsequent transplantation.63-65 Most authors agree that
although prior TIPSS insertion for variceal bleeding or
refractory ascites does not compromise surgery at the
time of transplantation, elective TIPSS procedure prior to
operation does not facilitate surgery and should not be
undertaken unless indicated to treat a defined com¬
plication such as variceal haemorrhage.
CONTRAINDICATIONS TO TIPSS PROCEDURE
Absolute contraindications to TIPSS placement (Table
4) include severe right heart failure or pulmonary
hypertension, since the procedure exacerbates these
conditions and may lead to clinical decompensation (see
below). Due to the reduction in sinusoidal perfusion
following TIPSS placement, which may result in a
temporary deterioration in liver function, TIPSS should
not be used in patients with acute or severe progressive
liver disease unless essential for the control of life-
threatening variceal bleeding.7 The procedure should
also be avoided in the presence of polycystic liver disease
due to the risks of severe haemorrhage. In addition,
occlusion of the jugular or caval veins precludes stent
placement.
Relative contraindications include active systemic or
intrahepatic sepsis, severe hepatic encephalopathy not




A 1-2% procedure-related mortality has been reported
in the large TIPSS series.8-11 This compares favourably
with perioperative mortality for shunt surgery, especially
when it is considered that many patients undergoing
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Table 4. Contraindications to TIPSS
Absolute:
Severe right heart failure or pulmonary hypertension
Severe acute or progressive liver failure
Polycystic liver disease
Supra-hepatic inferior vena-caval or bilateral internal and external jugular venous
occlusion
Relative:
Systemic or hepatic sepsis
Severe hepatic encephalopathy (not related to bleeding)
Portal vein thrombosis
Hepatocellular carcinoma
TIPSS as a rescue procedure for refractory variceal
bleeding would not be fit for surgery.5
Most series report procedure-related complications of
around 10%. These include intraperitoneal haemor¬
rhage, hepatic arterial puncture, biliary leaks or haem¬
orrhage, liver capsule haematoma, stent dislocation or
migration into the splenic vein or pulmonary artery,
portal vein dissection, portal vein or hepatic arterial
thrombosis and endocarditis.66-69 Due to the risks of
hypoxaemia and dysrhythmias during the procedure,
continuous oxygen saturation and ECG monitoring is
essential during TIPSS placement. Many studies describe
a transient worsening of liver function in approximately
one-third of patients in the weeks following TIPSS
procedure. This may further compromise liver function,
as discussed above.
Several studies have assessed prognostic markers for
TIPSS placement.70-74 These have shown that poor
outcome following the procedure has been can be
predicted by a high Childs-Pugh and APACHE II score,
raised serum creatinine and low serum sodium, prior
encephalopathy, non-viral aetiology, advanced age and
female gender.
refractory encephalopathy, successful treatment by
shunt reduction or occlusion has been reported.75-77
Studies that have prospectively assessed the develop¬
ment of encephalopathy following TIPSS placement have
suggested that the incidence is highest in the first 3
months after shunt placement, thereafter improving,
presumably due to gradual narrowing of the stent.78,79
Using multivariate analysis, encephalopathy following
TIPSS procedure has been shown to be predicted by its
presence prior to the procedure, hypoalbuminaemia,
non-alcohol aetiology of cirrhosis and female gender.70,80
A recent prospective study also identified advanced age
and low post-procedural PPG as predictors of encepha¬
lopathy following TIPSS insertion.78 Such patients must
be carefully assessed prior to and following TIPSS
procedure, and should perhaps have narrower stents
placed and be given prophylactic lactulose and protein
restriction.
It remains difficult to achieve the optimal balance
between the reduction in portal pressure required to
minimize the risk of variceal bleeding and that pressure
required tomaintain hepatic perfusion and lessen the risk
of post-procedural encephalopathy.
HEPATIC ENCEPHALOPATHY
One of the major concerns that was anticipated about
TIPSS placement is the increased risk of hepatic en¬
cephalopathy due to the portosystemic shunting of blood
and reduced hepatic sinusoidal perfusion. New or
worsening encephalopathy has been reported in 15-29 %
patients in the large TIPSS cohort studies8-11 (Table 1).
Unlike the chronic debilitating encephalopathy reported
by the early shunt surgery series, post-TIPSS encepha¬
lopathy has been generally easily managed by medical
measures such as protein restriction and lactulose.
However, for the minority of patients who develop
SHUNT INSUFFICIENCY
The frequent occurrence of shunt insufficiency and
therefore the need for repeated assessment of shunt
patency during follow-up is probably themajor limitation
of TIPSS. The major cohort studies describe shunt
insufficiency in 29-45 % patients during follow-up, with
the consequent risks of variceal rebleeding or ascites
reaccumulation.8-11 A prospective study assessing shunt
patency during follow-up revealed a 1 year shunt
insufficiency rate of 53%.81 Patency can be maintained
in the vast majority of patients by a combination of
balloon angioplasty, shunt extension or parallel TIPSS
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Figure 2. Portogram showing patent parallel TIPSS and initial
blocked TIPSS lateral to it with metal coils used to embolize
oesophago-gastric varices.
placement (Figure 2),10 but the challenge is to detect the
shunt insufficiency before clinical consequences occur.
It must be remembered that any report of shunt
insufficiency following TIPSS procedure depends to a
large extent on both the frequency and method of
assessing shunt patency and the definition of 'shunt
insufficiency' used. A variety of different definitions have
been used in the literature, but the most clinically
appropriate appears to be: any narrowing of the shunt
leading to a rise in the PPG to 12 mmHg (above which
the risk of variceal bleeding increases2) or a 20% rise in
immediate post-TIPSS PPG (for those patients with a low
initial portal pressure).
The pathogenesis of shunt dysfunction remains poorly
understood. Early shunt occlusion is usually due to
thrombosis within the stent, but longer-term shunt
insufficiency is usually related to the development of
pseudo-intimal hyperplasia causing stenosis within the
stent or the hepatic vein.82 It has been suggested that the
creation of a transient biliary venous fistula by tran¬
section of a bile duct at the time of the TIPSS procedure
may lead to shunt stenosis or occlusion due to the
thrombogenic nature of bile.83,84
There is debate as to whether duplex sonography is as
effective as the ' gold standard' direct portography in the
assessment of shunt patency following TIPSS procedure.
Several studies have suggested that duplex sonography is
highly sensitive and specific at detecting shunt stenosis,
with maximum flow velocity within the shunt being the
best parameter of shunt function.85-89 However, other
authors found poor detection of shunt insufficiency by
ultrasonography as compared with portography and
therefore suggest that intermittent direct portography is
essential to assess shunt function during follow-up.90-92 A
recent report highlighted the possible benefits ofmagnetic
resonance angiography in the assessment of TIPSS
patency,93 but currently this has limited availability.
A number of studies have suggested benefit from
heparin or phenprocoumon in the reduction of early
shunt occlusion following TIPSS placement.94,95 How¬
ever, the best hope of reducing the need for continual
shunt assessment is probably the development of covered
stents, which have improved shunt patency in swine.96
Until such stents are available, the cost, time and invasive
nature of direct portography must be weighed against
the possible deficiencies of ultrasonography in detecting
shunt dysfunction.
HAEMODYNAMIC EFFECTS
Following TIPSS placement, there is an immediate
worsening of the hyperdynamic cirrhotic circulation,
with increased cardiac output and associated decreased
systemic vascular resistance.97,98 How permanent these
haemodynamic changes are remains unclear. Initially at
least, this is thought to occur secondary to the increased
venous return to the right heart, largely from the
splanchnic circulation.
However, a recent study suggested that the major
haemodynamic alteration after TIPSS placement is the
development of pulmonary hypertension, since this
correlated with the decreased porto-atrial gradient.99 In
this study, transient shunt occlusion also returned all
haemodynamic parameters except pulmonary artery
pressure to baseline. The authors postulated that both
mechanical and neurohumeral factors were involved in
these changes.
In addition to the volume load, the delivery of vaso¬
dilators from the splanchnic to the systemic circulation
may precipitate the haemodynamic changes in the
pulmonary, cardiac and systemic circulations. The clini¬
cal implication is that TIPSS should be used with caution
in patients with known right heart failure or pulmonary
hypertension (see above).
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HAEMATOLOGICAL EFFECTS
Several case reports and two prospective studies100'101
have assessed the incidence of haemolysis following
TIPSS placement. These indicated that up to 30% of
patients develop haemolysis after stent insertion. This is
usually mild and transient, but can cause clinically
significant anaemia in 5-13% of cases. Post-TIPSS
haemolysis appears similar to the traumatic haemolysis
following prosthetic cardiac valve replacement or dacron
aorto-femoral bypass grafts. In such cases, turbulent flow
in contactwith a foreign surface leads to shear, producing
stress and fragmentation haemolysis.
Conn has alluded to the 'naked stent syndrome', in
which naked steel wires of the TIPSS can protrude into
the portal or hepatic veins leading to fragmentation
haemolysis.102 The transient nature of such haemolysis
may be explained by the gradual covering of the stent by
pseudointimal hyperplasia, protecting against further
haemolysis.
There is some conflict in the literature about the effect of
TIPSS on the peripheral platelet count, with the above
two prospective studies reaching differing conclusions.
Jalan et al.101 found a significant increase in platelet
count and reduction in spleen size 3 months after TIPSS
placement, whilst Sanyal et al.100 found no consistent
improvement in platelet count during 1 year follow-up
after TIPSS insertion. A recent retrospective report
described an increase in the platelet count from 1 week to
1 year following TIPSS placement in 11 patients with
hypersplenism.103 A further study of 21 patients described
a significant improvement in the platelet count within 1
week of TIPSS procedure in those patients with a post-
procedural PPG 12 mmHg.85
More data are required on this subject, but thrombo¬
cytopenia caused by hypersplenism associated with
portal hypertension remains an unproven indication for
TIPSS placement. No authors have found a significant
change in the white cell count following TIPSS pro¬
cedure.
CONCLUSION
Following the initial enthusiasm with which the intro¬
duction of TIPSS procedure was met, there has been
a more recent critical and hopefully evidence-based
appraisal of its role. It has established its place in the
treatment of uncontrolled variceal haemorrhage, recur¬
rent variceal haemorrhage and gastric or ectopic
variceal haemorrhage not responsive to endoscopic
therapy. Although TIPSS appears promising for sec¬
ondary prophylaxis following a first variceal haem¬
orrhage, further data are required to assess its role in
this situation and additional factors such as cost and
availability must be considered.
There is currently no proven advantage for the use of
TIPSS as compared with paracentesis for the manage¬
ment of refractory ascites, and TIPSS should not be used
for this indication outwith clinical trials. Improved
identification of patients at risk of post-procedural en¬
cephalopathy and haemodynamic complications will aid
patient selection. Covered stents may improve shunt
patency, which is currently the major limitation of the
procedure.
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THE LANCET
Seminar
Portal hypertension and variceal haemorrhage
Adrian J Stanley, Peter C Hayes
Portal hypertension commonly complicates cirrhosis, and
variceal haemorrhage is its worst and most life-threatening
complication. The introduction of new pharmacological
agents, endoscopic variceal band ligation, and transjugular
intrahepatic portosystemic stent-shunt (TIPSS) has
increased the therapeutic options available for this disorder.
However, despite these advances, mortality remains high.
Pathophysiology of portal hypertension
Increased resistance to portal blood flow is the initiating
factor in the development of portal hypertension. In
western countries, the most common cause is cirrhosis, in
which the main resistance to flow occurs in the hepatic
sinusoids. Alternatively, resistance to flow in the portal or
splenic veins leads to prehepatic portal hypertension and in
the hepatic veins leads to posthepatic portal hypertension.
Collateral vessels open and partially decompress the
portal system. Collateral vessels arise most commonly in
the retroperitoneal area, but are most visible and
troublesome when they occur at the gastro-oesophageal
junction. Collateral vessels also arise at the perianal,
periumbilical, splenorenal, ovarian, and choledochal
regions; in the peritoneum; and at areas of surgical
anastamoses or ileostomy or colostomy sites. However,
despite formation of these collaterals, portal hypertension is
maintained by increased splanchnic arterial flow, leading to
increased portal blood flow (figure 1).
Stellate cells (analogous to tissue pericytes) are found in
the perisinusoidal space. After liver injury, these cells are
transformed into contractile myofibroblasts that are central
to the start of fibrogenesis.1 They also regulate sinusoidal
resistance and flow in response to vasoactive substances,
especially endothelin and nitric oxide.2 Therefore, at least
part of the resistance to portal venous flow is dynamic.
This resistance to portal flow is the "backward"
component of portal hypertension. The "forward"
component is the increased splanchnic inflow, secondary to
peripheral vasodilatation. This low systemic vascular
resistance and the associated raised cardiac output lead to
the characteristic hyperdynamic circulation of cirrhosis.
Studies have suggested that the main site of low systemic
vascular resistance is the splanchnic circulation.3
Much work has gone into defining the part played by
nitric oxide in the circulatory abnormalities of cirrhosis.
Vasodilatation is proposed to result from increased
concentrations of nitric oxide, secondary to raised
concentrations of endotoxins and cytokines in cirrhosis*
although evidence suggests that increases in both the
constitutive and inducible isoforms of nitric-oxide synthase
are involved. Yet this mechanism remains unproven and
studies have reported variable circulatory effects after
administration of nitric-oxide-synthetase inhibitors to
patients with cirrhosis.4
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Figure 1: Haemodynamic changes in portal hypertension and
possible targets for therapeutic intervention
1) reduction of cardiac output by 3-1 blockade; 2) reduction of
splanchnic blood flow by 3-2 blockade or vasoconstrictors such as
a-adrenergic agonists or vasopressin analogues; 3) reduction of intra¬
hepatic resistance by vasodilators; 4) reduction of variceal or collateral
flow by 3-2 blockade, balloon tamponade, or endoscopic therapy.
The vasodilated circulation of cirrhosis is probably due to
a disturbed balance between vasodilatory (eg, nitric oxide,
glucagon, atrial natriuretic peptide, substance P, vasoactive
intestinal peptide, bile acids) and vasoconstrictive
substances (eg, endothelin, the renin-angiotensin-
aldosterone and sympathetic nervous systems, antidiuretic
hormone). The contributions of the parenchymal liver
disease itself and the intrahepatic, portosystemic, and
intrapulmonary shunts to alterations in this balance
remain unclear.
Risk of bleeding
Portal pressure in individuals is dynamic, with circadian
change. The highest pressures occur during the night, and
increase postprandially and in response to coughing,
sneezing, and exercise.5 Such variations may combine with
local factors in vessel walls to contribute to a pressure surge
that can lead to a variceal bleed. However, the exact
mechanisms that bring about variceal bleeding are unclear.
The risk of a variceal haemorrhage increases with the
severity of liver disease, variceal size, and the presence of
red markings on the varices.6 Bleeding has been identified
as unlikely with differences in pressure of less than
12 mm Hg between the portal vein and inferior vena cava.7
The risk of bleeding is also low if a reduction in pressure of
20% or more is achieved.8
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Acute variceal haemorrhage
About a third of patients with varices will bleed. Mortality
from a first bleed is around 50% and most survivors will
have a rebleed, with an associated inpatient mortality of
30%.9 Most bleeding related to portal hypertension occurs
from oesophageal varices, but bleeding can also arise from
gastric or ectopic varices, or from portal hypertensive
gastropathy or enteropathy. A suggested algorithm for the
management of suspected variceal haemorrhage is shown in
figure 2.
Initial resuscitation
Early and adequate initial resuscitation is vital.
Endotracheal intubation with or without ventilation is
commonly required to provide airway protection and avoid
aspiration, especially in patients with a major bleed or
substantial encephalopathy. Restoration of the circulating
blood volume with colloid followed by crossmatched whole
blood should be guided in most cases by regular
monitoring of central venous pressure and urine volume.
Although prompt fluid replacement is essential to protect
renal perfusion, overfilling may increase portal pressure,
leading to variceal rebleeding. Right-atrial pressure should
be kept between 0 and 5 mm Hg. Right-heart
catheterisation is an option in patients with ascites or
pre-existing cardiopulmonary disease, or haemodynamic
instability. Coagulopathy in these patients should be
treated with fresh-frozen plasma and platelet infusions,
although evidence that this treatment is beneficial is scarce.
Although a 90% success in stopping variceal bleeding
with balloon tamponade and endoscopic and
pharmacological treatment has been reported, up to 70% of
episodes of variceal haemorrhage stop spontaneously.10
Endoscopic management
Endoscopy allows accurate identification of the source of
bleeding and direct therapeutic intervention. For many
years, endoscopic sclerotherapy with sodium tetradecyl
sulphate, polidocanol, or ethanolamine has been the
therapy of choice to control bleeding from oesophageal
varices and for their eradication. However, five randomised
studies and a meta-analysis have shown that band ligation
reduces complications, speed of variceal eradication,
rebleeding rates, and bleeding-related mortality compared
with sclerotherapy.11 Band ligation did have complications
related to the overtube, required for repeated banding, but
the development of devices with multiple bands has
removed the need for the overtube.
Therefore, band ligation should now be the endoscopic
treatment of choice for oesophageal varices. However, with
active bleeding, injection sclerotherapy may achieve initial
haemostasis more easily before band ligation at subsequent
endoscopies is undertaken.12
Pharmacological management
Although drugs have been used in the management of
variceal bleeding for nearly half a century, new interest has
arisen after reports and meta-analyses that show similar
efficacy to sclerotherapy with somatostatin or its synthetic
analogue octreotide acetate in the control of acute variceal
haemorrhage.13 One report showed a reduction in early
rebleeding among patients treated with band ligation plus a
5-day infusion of octreotide acetate compared with banding
alone.14 The dose and the length of therapy vary widely in
studies and further trials are required to identify the
optimum treatment regimen.
Terlipressin, a synthetic analogue of vasopressin with a
longer biological half-life, allows bolus administration every
Figure 2: Suggested algorithm for management of variceal
haemorrhage
Vasoactive drugs: octreotide or somatostatin, or terlipressin.
4 h. It has fewer systemic side-effects than vasopressin, but
concomitant administration of nitrates to reduce ischaemic
side-effects is still recommended. Terlipressin is as effective
as somatostatin, octreotide acetate, or balloon tamponade
in controlling variceal haemorrhage and is the only drug
shown to lower mortality from variceal bleeding.15 Benefits
are seen with early therapy, with improved bleeding control
and survival in cirrhotic patients with gastrointestinal
bleeding given terlipressin and nitroglycerine as emergency
treatment in the home before transfer to hospital.16
Although pharmacological agents are useful alternatives
when early endoscopy is unavailable, any beneficial effects
are temporary. Therefore, endoscopy should be arranged as
soon as possible to confirm the source of bleeding and for
endoscopic therapy if required. When substantial bleeding
obscures the view of the endoscopist, administration of
octreotide, somatostatin, or terlipressin with nitrates may
help to achieve haemostasis before repeat endoscopy.
Balloon tamponade
Balloon tamponade with a Minnesota or Sengstaken-
Blackmore tube can be lifesaving in the presence of
substantial bleeding when carried out by experienced staff.
However, placement by inexperienced staff is associated
with a death rate of 6-20%, due largely to oesophageal
perforation and pulmonary aspiration.
The tube should be passed orally, well into the stomach
before inflation of the gastric balloon with about 300 mL
air. Firm traction maintains the position of the gastric
balloon under tension at the oesophagogastric junction.
The oesophageal balloon is only inflated if bleeding
continues and should be deflated for 30 min every 4-6 h
and not used for more than 12 h. After this time, the risk of
complications from the gastric balloon also increases.
Because 50% of patients will rebleed when the tube is
deflated, immediate definitive endoscopic therapy must be
undertaken.17
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Cabarera et al 31/32 15 23 52$ 33 13$ 80 84
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Summary of trials comparing TIPSS with endoscopic therapy for prevention of variceal bleeding
TIPSS
TIPSS is a new radiological intervention that creates a
portosystemic tract through the liver parenchyma, through
which an 8-12 mm expandable metal stent is inserted. In
the 8 years since its introduction into clinical practice,
TIPSS has become the treatment of choice as rescue
therapy for the 10-20% of patients with variceal
haemorrhage unresponsive to endoscopic management.
Failure of emergency endoscopic therapy has been defined
as further variceal bleeding after two endoscopic treatments
during a single hospital admission for an acute bleeding
episode.18 Treatment with balloon tamponade should
be followed by TIPSS or, less commonly, surgery in
this situation.
Although few trials have been done, TIPSS is easier to
carry out than surgical shunt procedures or oesophageal
transection, has lower associated morbidity and mortality,
and does not compromise subsequent liver transplantation.
A study suggested benefits from small-diameter H-graft
portacaval shunts compared with TIPSS for refractory
variceal bleeding," but TIPSS can be used for patients who
are too ill for major surgery.
The main limitations of TIPSS are the development of
encephalopathy in about 20% of patients and progressive
development of shunt insufficiency.20 Encephalopathy is
generally easy to manage with lactulose and protein
restriction, although some patients require a reduction in
the size of the shunt. Shunt insufficiency is more difficult to
manage and requires regular, long-term Doppler and
portographic surveillance and treatment.
Surgery
TIPSS has in many cases replaced surgery for variceal
haemorrhage unresponsive to endoscopic treatment.
However, technical failure occurs in 5-10% of cases. In
these patients, the options are shunt surgery or oesophageal
transection with or without devascularisation, but the
mortality rate is high, particularly among patients with
decompensated liver disease.
Gastric or ectopic varices and portal hypertensive
gastropathy
Gastric varices are the source of bleeding in 10-36% of
patients with variceal haemorrhage. Higher rates are
reported for patients with "sinistral" or left-sided portal
hypertension due to portal-vein or splenic-vein thrombosis.
Unless the gastric varices are located in a hiatus hernia or
on the proximal lesser curve in continuation with
oesophageal varices, endoscopic bleeding control is
generally unhelpful. For this reason, and because of the
difficulty in obtaining adequate endoscopic vision, early
TIPSS or shunt surgery have been advocated for gastric
variceal bleeding.
The management of gastric variceal haemorrhage with
endoscopic injection of thrombin or tissue adhesives needs
further study.21 Ideally, randomised trials should compare
endoscopic methods, TIPSS, and surgery. In the
meantime, control of any active bleeding with
pharmacological agents or endoscopy, if possible, seems
valid before proceeding to TIPSS. For similar reasons, the
3% of patients who have troublesome bleeding from ectopic
varices are probably best managed by TIPSS.
Bleeding from portal hypertensive gastropathy or
enteropathy accounts for 5-8% of bleeding episodes in
cirrhosis. Although major bleeding from these sources is
uncommon, when it occurs, its diffuse nature precludes the
use of endoscopic therapy and the treatment options are
pharmacological therapy, TIPSS, or surgery, dependent on
the severity of bleeding, the degree of liver impairment, and
likely compliance with drug therapy.
Prevention of rebleeding
After an initial variceal bleed, most patients will rebleed,
commonly within the first few weeks. To reduce this risk,
further treatment, such as endoscopic variceal eradication,
pharmacological therapy, or portosystemic shunt creation,
is necessary.
Endoscopy
After a variceal haemorrhage, most units enrol patients into
an endoscopic sclerotherapy or band ligation programme
to eradicate the varices. A meta-analysis of eight trials
comparing sclerotherapy with non-active treatment in the
prevention of variceal rebleeding showed reductions in
rebleeding and mortality in the sclerotherapy group.13
However, band ligation has advantages over sclerotherapy,"
and banding should now be the endoscopic treatment of
choice for variceal eradication. Generally, band ligation is
done every 1-2 weeks until varices are eradicated.
Thereafter, periodic endoscopic surveillance is necessary.
Unsuccessful long-term endoscopic management has been
defined as either recurrent bleeding, despite adequate
endoscopic therapy, or oesophageal varices that are difficult
to eradicate by endoscopy. For these cases, TIPSS or
selective shunt surgery should be undertaken.
Pharmacological agents
The most widely used drugs to prevent rebleeding are
(3-blockers. The most commonly investigated ^-blocker is
propranolol, although some studies have assessed nadolol,
which can be given once daily and, unlike propranolol, is
not metabolised by the liver. 13 randomised trials and three
meta-analyses have confirmed the efficacy of ^-blockers
and have suggested an improvement in survival compared
with placebo. Overall, (3-blockers seem to lower the risk of
rebleeding by about 40% and mortality by 20%.22'23
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Ideally, reduction in portal pressure in response to drug
therapy should be haemodynamically assessed by hepatic
venous catheterisation, with measurement of the hepatic
venous-pressure gradient. Such assessment is especially
important in patients with alcoholic cirrhosis in whom a
spontaneous fall of more than 20% is possible with
abstinence. Although a reduction of 25% in the resting
pulse rate is commonly used to guide the dosage of
3-blockers, the splanchnic haemodynamic effects of
3-blockers are unpredictable and correlate poorly with
systemic effects.
Most studies have shown that (3-blockers and
sclerotherapy have similar efficacy in the prevention of
variceal rebleeding, although complications are more
frequent and severe with sclerotherapy. There is no clear
evidence of a benefit from combined (3-blocker therapy and
sclerotherapy compared with either treatment alone.
The addition of nitrates (generally isosorbide-5-
mononitrate) to 3-blockers improves the portal hypotensive
response. Reduced rebleeding has been reported with
this drug combination compared with endosopic
sclerotherapy.24
Studies are needed to compare pharmacological therapy
with band ligation for the prevention of rebleeding, since
this is now the endoscopic treatment of choice and is widely
used by hepatologists.
TIPSS
Although TIPSS is an accepted treatment for recurrent
variceal haemorrhage unresponsive to endoscopic therapy,
current debate centres on whether or not TIPSS should be
placed after an initial variceal haemorrhage to prevent
rebleeding. Ten randomised studies have been published
(including six in abstract form) comparing TIPSS with
endoscopic treatment, with or without 3-blockers, to
prevent variceal rebleeding (table). Generally, the studies
show reduced rebleeding in the TIPSS group, but higher
rates of encephalopathy and no difference in survival. Data
on cost and quality of life are awaited before advice can be
given about the optimum treatment for this patient
population.
Surgery
Early randomised trials comparing portacaval shunt surgery
with non-specific treatment in the prevention of variceal
rebleeding reported reductions in rates of bleeding but
increased rates of encephalopathy in surgical groups. The
use of more selective distal-splenorenal or small portacaval
H-shunts seems to lower the incidence of encephalopathy.
A meta-analysis of trials comparing shunt surgery with
sclerotherapy to prevent variceal rebleeding found reduced
bleeding rates but higher encephalopathy rates in the
surgical group.13 No difference in mortality was detected.
Orthotopic liver transplantation
Liver transplantation is the definitive treatment for
deteriorating liver disease. Any patient with advanced
cirrhosis and a variceal haemorrhage should be considered
for transplantation. Unlike most surgical shunts, TIPSS
does not seem to compromise subsequent transplant
surgery and has been successfully used as a bridging therapy
in patients with variceal bleeding.25
Primary prophylaxis of variceal haemorrhage
Because of the availability of proven primary prophylactic
therapies, all patients with cirrhosis should have a screening
endoscopy to confirm the presence of varices. If no varices
are found, surveillance endoscopy should be done every 1-2
years, dependent on the severity of liver disease. If varices
are present and thought to have a high risk of bleeding, the
patient should be offered primary prophylactic therapy.
Treatment should probably be limited to patients with such
varices, because many studies have excluded patients with
varices with low bleeding risk. If varices at low risk of
bleeding are found, surveillance endoscopies should be
more frequent to assess any changes.
Pharmacological agents
Nine controlled studies and three meta-analyses have
confirmed the efficacy of 3-blockers compared with placebo
in the prevention of a first variceal haemorrhage. The risk of
bleeding is reduced by about 45% with 3-blocker therapy
and in most studies there is a trend towards improved
survival. Benefits seem to have been consistently found for
patients with moderate or large oesophageal varices from all
forms of liver disease. Side-effects of 3-blockers are
reported in about 15% of patients, requiring withdrawal of
therapy in less than half of these cases.26
Nitrates may be as effective as 3-blockers in the primary
prophylaxis of variceal bleeding and offer an alternative to
patients who are intolerant of 3-blockers.27 A reduced
incidence of first variceal haemorrhage among patients
given combined nitrates and 3-blockers has been reported,
compared with those given 3-blockers alone.28 No effect on
survival was seen. This drug combination may, therefore,
be the optimum therapy in the primary prophylaxis of
variceal bleeding, but confirmatory studies are awaited.
Various other drugs have been shown to reduce portal
pressure in haemodynamic studies, including diuretics,
a-adrenoreceptor antagonists, endothelin antagonists, and
vasodilating 3-blockers. However, clinical studies of these
drugs for primary prophylaxis of variceal bleeding are
limited.
Endoscopy
19 trials have compared sclerotherapy with non-active
treatment in the primary prophylaxis of variceal bleeding.
Although meta-analysis shows reduced bleeding risk and
improved survival, there is substantial heterogeneity
between the trials and a higher mortality in the
sclerotherapy group in the largest study.25 In addition,
complications of sclerotherapy seem to outweigh the
benefits, especially among patients with smaller varices at
low risk of bleeding.
Two studies have compared sclerotherapy with
propranolol to prevent first variceal haemorrhage. One
study showed a lower rate of bleeding in the propranolol
group but no difference was found in the other study.
Propranolol is also superior to combined propranolol and
sclerotherapy in this situation.30
Trials are needed to compare band ligation with drug
therapy for the primary prophylaxis of variceal
haemorrhage. However, at present, patients with known
high-risk varices should receive non-selective 3-blockers (or
nitrates if 3-blockers are contraindicated or not tolerated) as
primary prophylaxis against bleeding.
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Vaccine series
Applications of molecular microbiology to vaccinology
E Richard Moxon
Genetics, cell biology, and whole-genome sequencing of pathogens have changed dramatically the opportunities to
investigate the epidemiology, pathogenesis, diagnosis, and control of microbial diseases. For example, recombinant
DNA and PCR are powerful tools used to isolate genes whose role in pathogenicity can be investigated in biologically
relevant virulence assays. Vaccines that target one or more of these genes can then be developed. Complete genome
sequences of microbes provide an inventory of the genes encoding every virulence factor and potential immunogen.
Candidate vaccines can be selected and developed using various approaches, including the recent innovation of
immunisation with nucleic acids. Although many successful vaccines have been and will continue to be developed
through empirical approaches, molecular microbiology provides a rational basis for discovery, development, and
implementation of safer, more effective and, potentially cheaper vaccines.
In the Golden Age of microbiology (the latter part of the
19th and early part of the 20th Century), it was
discovered that particular microbes were responsible for
specific diseases. Allied with the concept of host
immunity, this eventually led to the development of
vaccines which have controlled several major microbial
diseases (yellow fever, diphtheria, tetanus, pertussis,
poliomyelitis, measles, mumps, and rubella) and
eradicated small pox.
Starting with sulphonamides and penicillin, the
decades of 1930, 1940, 1950, and 1960 witnessed the
discovery of most of the important classes of
antimicrobial drugs. By the middle of the 1990s,
improved socioeconomic circumstances, immunisation,
and antibiotics had transformed our capacity to treat,
control, and even prevent the ravages ofmany of the most
common and serious microbial diseases, at least in
relatively affluent societies. In retrospect, this seems to
have caused an inappropriate complacency concerning
the impact of infections. Towards the end of this century,
there has been appropriate recognition of the continuing
public-health challenges posed by microbes, including the
emergence of new pathogens, or old foes with novel
attributes, antibiotic resistance, and of the vast unmet
challenges of many infections for which vaccines are not
available.
Over the past three decades, the Golden Age of
molecular biology, genetics, and cell biology have been
used to dissect the details of host microbial interactions.
This has brought about a revolution which has
transformed our knowledge of epidemiology, patho¬
genesis, diagnosis, and prevention of microbial diseases.
This article attempts to place in perspective some of the
opportunities and the challenges, especially those
emanating from the impact of molecular microbiology, in
the field of vaccinology.
From birth until death, man is besieged by a myriad of
viruses, bacteria, fungi, and parasites competing to stay
alive and to perpetuate their genes. Starting at birth, a
variety of microbes establish themselves on the skin,
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mucous membranes, or gastrointestinal tract in the
process of colonisation. In most instances, microbes and
man coexist in a mutually benign or even beneficial
partnership since these commensal microflora stimulate
host immunity to protect against other invading
organisms and may contribute micronutrients or growth
factors. Rarely, colonisation by these living invasive
organisms results in infectious disease and the
impairment of health. This potential to injure or kill hosts
(pathogenicity) is a general characteristic of all microbes
and, directly or indirectly, is a constant challenge to
human health. Pathogenicity is dependent on both the
state of the host and a variety of microbial factors, and
this mutuality and the implicit co-evolutionary
implications are key concepts.
Molecular approaches to vaccinology
The application of molecular biology to the identification
of virulence genes has opened the door to understanding
the fundamental basis of the pathogenic personality of
virulent microbes. Starting from the classical version of
Koch's postulates, the new genetics has given us the
molecular tools to help our understanding of virulence, as
follows:1 identify a gene, or group of genes, responsible
for virulence; isolate the gene through recombinant DNA
technology (cloning) or PCR; make many copies of these
genes in vitro; and show the essential role of this gene in
pathogenicity by showing that a mutation of a specific
gene results in attenuation of virulence in an appropriate
model or that a monoclonal antibody specific to this gene
product can protect against disease.
The major functions of virulence genes include:
tropism for the host species, or even for specific cells of
individual hosts; mechanisms for the microbe to survive
host clearance and multiply in the host; and the capacity
to cause tissue damage or cytoxicity. For each of these,
there are examples of vaccines which are effective because
they target one or more of the virulence molecules
responsible for these virulence functions (table).
The molecular genetic definition of virulence has
enormous implications for vaccinology. Although the
concept of inducing immunity to essential virulence
determinants is not new, the use of molecular techniques
has helped in the discovery of many more ways of
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Summary
The relationship between the various haemodynamic
abnormalities observed in cirrhosis and their pro¬
gnostic value remains unclear. We report haemo¬
dynamic measurements on 96 patients with
alcoholic cirrhosis (mean Childs-Pugh Score, CPS,
9.0 + 0.2, mean age 55.6 + 1.0 years) and assess
their value in predicting variceal bleeding and death
during a mean follow-up of 19.3 + 1.5 months.
Baseline CPS correlated with hepatic venous pres¬
sure gradient (HVPG) (p= 0.001), azygos blood
flow (p<0.05), cardiac index (p<0.05), and
inversely with mean arterial pressure (p<0.01) and
systemic vascular resistance index (p<0.05). Renal
blood flow was not related to any haemodynamic
parameter or CPS. Thirty-eight patients died during
follow-up, and 16 had a variceal bleed. Death (p=
0.001) and variceal bleeding (p<0.05) were more
likely in patients with HVPG >16 mmHg than in
those with HVPG <16 mmHg, and variceal bleed¬
ing was more likely in patients with HVPG
>12 mmHg (vs. HVPG <12 mmHg, p<0.05).
HVPG also predicted death and variceal haemor¬
rhage on univariate and multivariate analyses. No
other haemodynamic parameter predicted death or
bleeding. In alcoholic cirrhosis, severity of liver
disease is related to HVPG, collateral blood flow
and degree of systemic circulatory abnormalities.
HVPG is a useful predictor of survival and variceal
bleeding in these patients.
Introduction
Cirrhotic patients exhibit a hyperdynamic circulation
with raised cardiac output and low systemic vascular
resistance, but paradoxical renal vasoconstriction.1 The
exact relationship of these circulatory abnormalities to
each other and to the degree of portal hypertension
and severity of liver disease remains unclear.
The majority of patients with cirrhosis develop
oesophageal varices secondary to the development
of portal hypertension, and approximately one third
will eventually bleed from these varices with an
associated mortality of up to 50%.2 It is therefore
important to identify patients at high risk of variceal
haemorrhage, to target treatment strategies.
The prognosis of cirrhotic patients depends largely
on the severity of the liver disease. However, it has
been suggested that haemodynamic assessment of
the systemic, cardiopulmonary, and particularly the
portal circulation, may offer additional indicators of
prognosis.3
The aim of this study was to clarify the relationships
between systemic, cardiopulmonary and portal
haemodynamic parameters in patients with alcohol-
related cirrhosis, and assess their prognostic value
with regard to variceal bleeding and survival.
Methods
Patients
From November 1992 to September 1996, 96
patients with alcohol-related cirrhosis underwent
haemodynamic assessment either as baseline meas¬
urements prior to acute pharmacological intervention
trials, or as part of a detailed assessment of their
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Table 1 Patient characteristics at time of haemodynamic




Mean + SEM 55.6+1.0
Range 35-80
Childs-Pugh score





liver disease. Cirrhosis was diagnosed by liver biopsy
or by clinical assessment (varices or ascites in the
absence of other causes and in the presence of
chronic biochemical derangement of liver function
tests). Full patient characteristics are shown in
Table 1.
Twenty-four patients had suffered a previous var-
iceal bleed and were on long-term variceal oblitera¬
tion programmes with band ligation. Three patients
were in a similar programme as part of a study
assessing band ligation in the primary prophylaxis of
variceal haemorrhage. No patient was encephalo-
pathic, and none had suffered a variceal bleed in
the 10 days prior to haemodynamic assessment. All
patients were haemodynamically stable at the time
of study, and none were taking haemodynamic
altering medications except for diuretic therapy
(n = 51).
Haemodynamic measurements
On the day of study, a full clinical examination was
undertaken and blood taken for measurement of
serum bilirubin and albumin, and prothrombin time.
Ethical approval was given by Lothian Ethics
Committee, and all patients gave witnessed, informed
written consent.
Mean arterial pressure (MAP) was recorded and a
right femoral venous introducer sheath inserted after
infiltration of local anaesthetic (2% lignocaine). All
catheters were placed under fluoroscopic guidance,
and due to the complexities of multiple catheter
placement, not all measurements were undertaken
at each study. Through the introducer, a Sidewinder
II torque balloon catheter (Cordis) was positioned in
the right hepatic vein, and free and wedged hepatic
venous pressures (FHVP and WHVP) were measured
in 82 patients. The hepatic venous pressure gradient
(HVPG) was calculated as WHVP minus FHVP.
Azygos blood flow (AzBF) (n = 62) and left renal
vein flow (RBF) (n = 42) were recorded using a
double-thermister reverse-thermodilution catheter
(Webster Laboratories) via the introducer sheath as
previously reported.4,5 In 28 patients, a Swan-Ganz
catheter (Baxter Healthcare) was inserted through the
introducer into the right pulmonary artery after
measurement of the right atrial pressure (RAP).
Cardiac output (CO) was then measured by the
thermodilution technique and systemic vascular
resistance (SVR) was calculated as:
SVR = 79.96(MAP-RAP)/CO
Cardiac index and systemic vascular resistance index
were calculated, respectively, as:
CO/m2 and SVR/m2
Patients were followed up at 3-monthly intervals or
earlier if complications arose. Mean + SEM follow-
up to most recent clinical review, death or liver
transplantation (n = 2) was 19.3 + 1.5, months and
episodes of endoscopically-proven variceal haemor¬
rhage during follow-up were recorded.
Data analysis
Results are expressed as means+ SEM. Relationship
between variables was assessed using Spearman's
correlation, and comparisons between groups were
analysed by the unpaired Students t-test and Mann-
U-Whitney test, for parametric and non-parametric
data, respectively.
Patients were grouped into Childs Class A/B and
Childs Class C for survival analysis, into HVPG
<12 mmHg and >12 mmHg for bleeding analysis,
and into HVPG <16 mmHg or >16 mmHg for
both bleeding and survival analysis. These groups
were chosen because it has been suggested that
variceal bleeding does not occur at HVPG
<12 mmHg,6 and that HVPG of 16 mmHg may be
a threshold value above which bleeding and death
is more likely.7 Survival and bleeding were compared
between groups using the Kaplan-Meier method with
log rank test.
Cox's regression was used to test the univariate
and multivariate significance of the haemodynamic
parameters described above, in addition to serum
albumin, bilirubin, prothrombin time, the presence
of ascites, the CPS, diuretic therapy and the occur¬
rence of a previous variceal bleed in predicting
variceal bleeding and death.
Results
The baseline values of the haemodynamic measure¬
ments are shown in Table 2. Both the HVPG and
AzBF correlated with CPS (r= 0.38, p= 0.001 and
r = 0.29, p<0.05 respectively; Figures 1 and 2) but
not with other haemodynamic parameters. CPS was
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Table 2
Baseline haemodynamic measurements
Measurement Mean + SEM
MAP (mmHg) 90.51 ±1.38
CI (l/min/m2) 3.94 + 0.20
SVRI (dynes.s/cm5/m2) 1858.43 + 124.97
HVPG (mmHg) 16.69 + 0.59
AzBF (ml/min) 474.68 + 43.07
RBF (ml/min) 398.98 + 38.83
also related to HR, MAP, CI and SVRI (r = 0.38,
p<0.001; r = -0.28, p<0.01; r = 0.40, p<0.05;
r = -0.44, p<0.05 respectively, Figure 3). CI and
SVRI also both correlated with HR (r = 0.55,
p<0.005 and r = -0.62, p<0.005 respectively) but
not with other haemodynamic measurements. There
was no relationship between RBF and any other
haemodynamic parameter or CPS.
During follow-up, 16 patients suffered a variceal
haemorrhage (only one of whom had a baseline
HVPG of <12 mmHg). Variceal bleeding occurred
in seven (29.2%) patients who had previously bled
and nine (12.5%) who had not (p = NS). Baseline
HVPG was higher in those patients who subsequently
bled compared with those who did not (18.7+1.2
vs. 16.3 +0.7 mmHg; p<0.02) and bleeding was
more likely to occur in those with a baseline HVPG
>12 mmHg compared with those with HVPG
<12 mmHg (p<0.05; Figure 4), and also in those
with HVPG >16 mmHg vs. those with HVPG
<16 mmHg (p<0.05). Variceal bleeding was only
predicted in the univariate or multivariate analysis
by HVPG (p<0.01).
Baseline CI was higher in those patients who bled
during follow-up compared with those who did not
(6.1 +0.5 vs. 3.8 + 0.2 l/min/m2; p <0.01), but AzBF,
RBF, SVRI, HR, MAP and CPS were no different
between those who subsequently bled and those
who did not.
During follow-up, 38 patients died. Survival was
significantly greater in patients with Childs grade A
or B compared with grade C disease (p< 0.0001)
(Figure 5), and in those with baseline HVPG
<16 mmHg compared with HVPG >16 mmHg
(p = 0.001) (Figure 6). Baseline CPS and HVPG were
HVPG (mmHg)
Figure 1. Correlation between Childs-Pugh Score and hepatic venous pressure gradient (HVPG) (r= 0.38, p= 0.001)
o
Azygos Blood Flow (ml/min)
Figure 2. Correlation between Childs-Pugh Score and Azygos blood flow (r = 0.29, p<0.05).
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Figure 4. Kaplan-Meier analysis comparing variceal bleeding during follow-up between patients with HVPG <12 mmHg

















Figure 5. Kaplan-Meier analysis comparing cumulative survival between patients with Childs grade A or B liver disease
with those with grade C disease (p<0.0001).
higher in patients who died during follow-up then
in those who survived (10.3+0.3 vs. 8.2 + 0.3
(p<0.001); and 19.2 + 1.0 vs. 15.1 +0.7 mmHg
(p= 0.001), respectively). Baseline AzBF, RBF, CI,
SVRI or MAP was not different between those who
died and survived on follow-up.
Variables predicting death in the univariate ana¬
lysis were CPS (p<0.0001), prothrombin time







Figure 6. Kaplan-Meier analysis comparing cumulative survival between patients with HVPG <16 mmHg and those with
HVPG > 1 6 mmHg (p = 0.001).
(p<0.0001), HVPG (p = 0.0001), presence of asci¬
tes (p<0.001), serum albumin (p<0.001), serum
bilirubin (p<0.05), and diuretic therapy (p<0.05).
No other haemodynamic parameter predicted death.
On multivariate analysis, only the CPS and HVPG
retained independent predictive significance
(p<0.0001 and p<0.05, respectively).
Discussion
This large study indicates a strong relationship
between severity of liver disease and the associated
haemodynamic changes, including a fall in MAP
and SVRI, and a rise in HVPG, CI and AzBF. We
also confirm the prognostic value of HVPG measure¬
ment in patients with alcoholic cirrhosis.
The haemodynamic changes in cirrhosis have long
been recognized, but the relationship between the
systemic, renal and portal circulations in these
patients remains unclear. These alterations in sys¬
temic haemodynamics are thought to arise secondary
to vasodilators of splanchnic origin gaining access
to the systemic vasculature via collateral vessels and
reduced hepatic clearance.8 It has also been sug¬
gested that the splanchnic circulation is the main
site of reduced vascular resistance in cirrhosis.9 This
leads to activation of neurohumoral systems, causing
sodium and water retention and renal vasoconstric¬
tion, which in turn can lead to ascites formation and
functional renal abnormalities.8,10
We have shown that the severity of the hyperdyn¬
amic circulatory disturbances observed in cirrhosis
is related to the degree of hepatic impairment as
assessed by the CPS. The relationship between sys¬
temic hypotension and disease severity has previ¬
ously been noted, and Llach and colleagues reported
that MAP independently predicts survival on multiva¬
riate analysis in cirrhotic patients with ascites.11
The HVPG is an indirect measurement of portal
pressure which accurately reflects the pressure gradi¬
ent between the portal and hepatic veins in patients
with sinusoidal portal hypertension such as alcoholic
cirrhosis, but not in those with pre- or post-sinusoidal
portal hypertension.12 Consistent with earlier studies,
we have found that HVPG correlates with CPS.13
Recently, a number of studies have assessed the
prognostic usefulness of HVPG measurement in cir¬
rhosis, with some authors suggesting it should be
used much more frequently in such patients.14 In
addition, early reports of a 'bleeding threshold' of
an HVPG of 12 mmHg, below which variceal bleed¬
ing did not occur,6 have subsequently been con¬
firmed.15,16 In our study, only one patient with an
HVPG <12 mmHg went on to have a variceal
bleed. However, this patient was studied when
abstinent from alcohol, then subsequently returned
to drinking prior to the variceal haemorrhage. Active
drinking has been shown to increase the HVPG and
therefore the risk of variceal bleeding.17 Obviously
other patients in our study may have returned to or
continued drinking during follow-up, but we did not
analyse this factor with regard to its effect on patient
outcome, as it is difficult to be entirely sure of
abstinence in this patient group.
Although a number of patients were on a band
ligation surveillance programme and others were on
diuretic therapy at the time of study, endoscopic
treatment of varices does not appear to affect HVPG18
and it remains unclear whether diuretics have an
effect.19,20 There was no difference in the HVPG
between patients who were on diuretic therapy and
those not on diuretics in our study.
Using Cox's regression, we found that HVPG was
the only haemodynamic, laboratory or clinical para¬
meter to predict bleeding on multivariate analysis,
and in particular, had better predictive value than
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CPS. It is interesting that one measurement of HVPG
appears to predict variceal haemorrhage over the
next 2 years, despite the fact that a number of
patients subsequently had pharmacological interven¬
tion as attempted prophylaxis for variceal bleeding.
This study was designed to assess the prognostic
value of a 'snap-shot' haemodynamic assessment,
and we did not evaluate the individual benefit of
any subsequently administered drugs.
Endoscopic signs such as variceal size and the
presence of red spots on the varices have also been
shown to predict variceal bleeding.21 However, few
of our patients underwent endoscopy around the
time of the haemodynamic study, therefore we were
unable to include endoscopic signs in the analysis.
We found no relationship between AzBF, which
is a marker of collateral flow, and the risk of
bleeding. This finding has been previously reported
by Cales et al.,22 and is probably explained by the
fact that the azygos vein also drains mediastinal
channels in addition to the oesophageal submucosa.
Presumably for similar reasons, AzBF was not related
to survival. However, consistent with Braillon and
colleagues, we did find that AzBF correlated with
CPS.13
A number of studies have suggested that the
measurement of HVPG may predict survival in
cirrhosis above and beyond the information given
by the CPS.7,23,24 We have confirmed Merkel and
colleagues earlier report of a lower survival in
patients with HVPG >16 mmHg.7 HVPG has also
previously been shown to be an independent
predictor of survival on multiple regression
analysis.7,24,25
We found that only HVPG and the CPS predicted
survival on multivariate analysis. HVPG retained
independent significant predictive value for survival
even when patients with a previous history of variceal
bleeding, or those with death due to bleeding were
omitted from analysis. The CPS is of course a
composite score of five clinical and laboratory para¬
meters. When HVPG was compared with these
individual parameters on multivariate analysis with
the exclusion of the CPS, only the prothrombin time
and the presence of ascites were superior to HVPG
in predicting death. Therefore, incorporation of
HVPG into a scoring system including some or all
of the current CPS parameters is likely to lead to an
improved prognostic score.
Implications for management
Measurement of HVPG is a relatively simple and
safe procedure that takes less than 20 min to perform.
In our patients, five had self-limiting bruising over
the femoral venous site, but no other complications
were encountered. Apart from its possible prognostic
value for survival, HVPG measurement can help
target therapy for patients at high risk of bleeding.
We believe measurement of HVPG should become
part of the routine assessment of patients with
cirrhosis and certainly those with varices.
Patients with an HVPG >12 mmHg who have
not previously bled should receive primary prophy¬
laxis with beta-blockers with or without nitrates, as
these have been shown to reduce the risk of variceal
bleeding.26 Although sclerotherapy is not recom¬
mended as a primary prophylactic therapy for var¬
iceal haemorrhage, due to its complication rate,27
band ligation has been shown to be at least as
effective as sclerotherapy but with fewer complica¬
tions.28 A recent report has suggested a role for band
ligation in the primary prophylaxis of variceal bleed¬
ing,29 although randomized trials comparing this with
drug therapy are required.
Although band ligation is now considered the
gold standard for the endoscopic eradication of
varices in patients who have suffered a variceal
bleed,30 studies are currently underway to compare
pharmacological agents and transjugular intrahepatic
portosystemic stent-shunts (TIPSS) with band ligation
in this situation.31 Ideally, any patient undergoing
pharmacological therapy as primary or secondary
prophylaxis for variceal haemorrhage should undergo
serial measurements of HVPG, which can act as a
'splanchnic sphygmomanometer'.14 This will identify
patients not responding to treatment, who can then
be offered alternative therapeutic strategies.15,16
In conclusion, we have shown a relationship
between the severity of liver disease and HVPG,
AzBF and the systemic haemodynamic abnormalities
observed in alcohol-related cirrhosis. In addition,
HVPG measurement predicts variceal bleeding and
survival in this patient group, and merits more
widespread use.
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Acute effect of propranolol and
isosorbide-5-mononitrate administration on renal
blood flow in cirrhotic patients

















5-mononitrate (ISMN) are increasingly
used in the prophylaxis ofvariceal haemor¬
rhage in cirrhosis. However, recent studies
have suggested that these drugs may com¬
promise renal function, possibly by reduc¬
ing renal blood flow.
Aims—To assess the acute effects of
propranolol and ISMN on renal blood flow
and other haemodynamic parameters in
cirrhosis.
Patients and methods—Twenty six cir¬
rhotic patients were given either 80 mg
propranolol, 20 mg ISMN, or a combina¬
tion of the two drugs. Unilateral renal
blood flow (RBF), azygos blood flow
(AZBF), hepatic venous pressure gradient
(HVPG), mean arterial pressure (MAP),
and heart rate (HR) were recorded prior
to and one hour after drug administra¬
tion.
Results—Propranolol caused a reduction
in HR (p<0.005), AZBF (p<0.01), and
HVPG (p=0.05), but no change in MAP or
RBF (454.1 (77.3) versus 413.9 (60.3)
ml/min). ISMN reduced MAP (p<0.005)
and HVPG (p<0.01), but had no effect on
HR, AZBF, or RBF (302.5 (49.4) versus
301.7 (58.8) ml/min). Combined treatment
reduced MAP (p<0.005), AZBF (p<0.05),
and HVPG (p=0.002), but HR and RBF
(419.2 (62.6) versus 415.1 (61.1) ml/min)
remained unchanged.
Conclusions—Despite the anticipated
changes in other haemodynamic param¬
eters, acute propranolol and/or ISMN
administration did not reduce RBF. These
drugs do not seem to compromise RBF in
cirrhosis.
{Gut 1998;42:283-287)
Keywords: cirrhosis; portal hypertension; renal blood
flow; propranolol; nitrates
Propranolol is widely used in the primary and
secondary prophylaxis of variceal haemorrhage
in cirrhotic patients. It reduces portal pressure
and collateral blood flow in cirrhosis and
numerous studies have confirmed its efficacy as
prophylaxis against portal hypertensive related
gastrointestinal bleeding.'"' Isosorbide-5-
mononitrate (ISMN) is a long acting venodila-
tor that reduces portal pressure and hepatic
vascular resistance.0"8 It has been shown to
reduce the risk of variceal bleeding,'1 10 and can
be used as an alternative treatment for patients
with portal hypertension who are intolerant to
(3 blockade. More recently, reports have
suggested that the combination of propranolol
and ISMN may be the optimum treatment to
reduce portal pressure and overcome the prob¬
lem of non-response to propranolol." 12
Several recent studies have suggested that P
blockers and particularly nitrates may compro¬
mise renal function in cirrhosis, possibly due to
a reduction in renal perfusion secondary to the
associated reduced systemic blood
pressure.12"1' The aim of our study was to
investigate the effect of propranolol, ISMN,
and the combination of both drugs on renal
blood flow and systemic and splanchnic
haemodynamics in cirrhotic patients.
Patients and methods
Twenty six patients (12 female, mean age 51.1
years (range 33-70), mean Child-Pugh score
(CPS) 9.2 (0.6)) with cirrhosis were studied.
Eighteen patients had ascites at the time of
study which was clinically graded as mild,
moderate, or severe. Diagnosis of cirrhosis was
based on liver biopsy (20 patients) or the pres¬
ence of chronic liver biochemical abnormalities
and endoscopicallv proven varices (six pa¬
tients). Cirrhosis was alcohol related in 21
patients, and secondary to primary biliary
cirrhosis in two, primary sclerosing cholangitis
in one, sarcoid in one, and a, antitrypsin
deficiency in one. No patient had biochemical
evidence of renal dysfunction prior to study
(serum urea greater than 6.6 mmol/1 or serum
creatinine greater than 150 pmol/l) and none
was receiving vasoactive medication at the time
of study. In addition, no patient had suffered a
gastrointestinal haemorrhage within the previ¬
ous four months. All patients gave informed
consent and the study was approved by the
Lothian Ethics Committee.
Studies were undertaken in the Department
of Medicine catheter laboratory, on fasted
patients in the supine position. Vascular
catheters were positioned under fluoroscopic
guidance via an 8.5 FG right femoral venous
introducer (Baxter Healthcare Corporation,
USA), inserted after local infiltration with 2%
lignocaine. A balloon catheter (Sidewinder II,
Cordis Corporation, USA) was inserted
through the introducer to record both the free
(FHVP) and wedged (WHVP) hepatic venous
pressure. Hepatic venous pressure gradient
(HVPG) was calculated as WHVP minus
FHVP.
A double thermister, reverse thermodilution
catheter (Webster Laboratories, California,
USA) was then inserted through the introducer
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Table 1 Patient characteristics
Combined treatment
Propanolol (n—9) ISMN (n-S) (n—9)
Age (y) 52.7 (2.3) 50.5 (2.8) 51.1 (1.9)
Child-Pugh score 9.2 (1.0) 9.4 (1.5) 9.1 (l.D
No with ascites (mild or
moderate/severe) 5-0 4/1 7 1
Serum creatinine (fimol. 1),
mean (range) 83.1 (63-136) 92.1 (65-142) 88.8 (66-126)
Aetiology (ALD/other) 8/1 6/2 7 • 2









and positioned in the left renal vein. The
proximal thermister was confirmed to be
within the lumen of the renal vein by injection
of 5 ml dilute contrast media (Conray 280,
May & Baker Ltd, Dagenham, UK). Record¬
ings of unilateral renal blood flow (RBF) were
made using a custom built interface (B55724
type CF) and an IBM microcomputer proces¬
sor (PS2-286) as previously reported.18 Mean
blood flows were recorded over a 30 second
period with the patient breathing normally at
rest.
Finally, the reverse thermodilution catheter
was positioned in the azygos vein and azvgos
blood flow (AZBF) recorded in a similar man¬
ner to RBF. The catheter was then left in posi¬
tion for the duration of the study.
When recruited for the study, patients were
matched for age and CPS for each therapeutic
regimen (table 1). Nine patients were then
given 80 mg oral propranolol, eight patients 20
mg oral ISMN, and nine patients both
treatments. One hour later AZBF was again
recorded, then the reverse thermodilution
catheter was manouevred back into the initial
position in the left renal vein and repeat RBF
measurement made as described above. Fi¬
nally, repeat measurements of the WHVP and
FHVP were recorded using the balloon cath¬
eter. The sheath was then removed and firm
pressure applied until haemostasis was ob¬
Table 2 Systemic haemodynamic effects
tained. Heart rate (HR) and mean arterial
pressure (MAP) were also recorded for the
duration of the study and for four hours there¬
after. In all patients, the duration of the study
was less than 3.5 hours.
STATISTICAL ANALYSIS
Results are expressed as mean (SEM) or range
where indicated. For parametric data, the
paired Student's t test and Pearson's correla¬
tion were used. The Wilcoxon signed ranked
test and Kendall correlation were used for
non-parametric variables. A p value of less than
0.05 was taken to be significant.
Results
All patients completed the study without diffi¬
culty and no side effects were observed or
reported. There was no statistical difference
between the three therapeutic groups with
regard to baseline RBF or other haemody¬
namic parameters. Baseline RBF did not
correlate with CPS, HVPG, or ascites severity.
Table 2 shows changes in HR and MAP for
each treatment group at one hour following
medication.
Following administration of propranolol,
there was a fall in HVPG from 16.3 (2.2) to
12.9 (1.9) mm Hg (p=0.05) and in AZBF from
471.5 (85.8) to 293.4 (42.6) ml/min (p<0.01)
(fig 1). There was no effect on RBF (454.1
(77.3) versus 413.9 (60.3) ml/min) (fig 2).
ISMN treatment led to a fall in HVPG from
14.9 (1.9) to 11.0 (1.3) mm Hg (p<0.01), but
had no effect on either AZBF (573.4 (183.1)
versus 576.0 (145.1) ml/min) (fig 1) or RBF
(302.5 (49.4) versus 301.7 (58.8) ml/min) (fig
2).
Following administration of the combination
of propranolol and ISMN, HVPG fell from
15.1 (1.8) to 8.9 (1.1) mm Hg (p=0.002) and
AZBF fell from 612.5 (187.6) to 358.2 (57.0)
Propanolol ISMN Combined treatment
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Figure 1 Changes in HVPG and AZBF one hour after a Single dose of (A) propranolol, (B) ISMN, or (C) combined treatment.
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Figure 2 Unilateral RBF one hour after a single dose of (A) propranolol, (B) ISMN, or (C) combined treatment.
After
ml/min (p<0.05) (fig 1). Again, there was no
effect on RBF (419.2 (62.6) versus 415.1
(61.1) ml/min) (fig 2).
When the 18 patients with ascites were con¬
sidered alone, there remained no effect on RBF
of any treatment when these patients were
grouped together, or when analysed in treat¬
ment subgroups.
Discussion
We undertook this study to assess the acute
effect of propranolol, ISMN, and the combina¬
tion of both drugs on RBF in cirrhotic patients.
Despite the anticipated changes in other
haemodynamic parameters, no change in RBF
was detected.
Any reduction in renal function is critical in
cirrhotic patients, because they are already at
risk of renal impairment due to reduced RBF,
glomerular filtration rate (GFR), and sodium
and water excretion." Recent suggestions that
P blockers and nitrates may have deleterious
renal effects in cirrhosis include reports of
reduced renal sodium excretion12 13 16 and
reduced renal perfusion14"17 following adminis¬
tration of these drugs. This is important in view
of their increasing use as prophylaxis against
variceal haemorrhage.1"'9 10
Generally, autoregulation in the kidney
maintains a constant RBF over a wide range of
arterial blood pressures.20 Henriksen and Ring-
Larsen suggest that in cirrhosis, a pharmaco¬
logically induced fall in MAP may compromise
renal perfusion and GFR, leading to a
subsequent reduction in sodium and water
excretion, partly due to a shift in this
autoregulation.17
P Blockers are the most widely used drugs in
the prophylaxis of variceal haemorrhage. Most
investigators have studied propranolol in this
role, although nadolol has been used by some
researchers. In addition to their portal hypo¬
tensive action, these drugs reduce cardiac out¬
put and increase systemic vascular resistance
but have less effect on MAP.21
The renal effects of P blockers are complex
due to their haemodynamic and neurohumoral
actions. Propranolol treatment leads to in¬
creased circulating concentrations of nor¬
adrenaline which can cause sodium and water
retention22; however, reduced levels of renin,
angiotensin, and aldosterone (p, blockade) are
also observed which increase salt and water
excretion.23 In addition, renal vasoconstriction
due to P: blockade has been suggested as a
mechanism by which P blockers may impair
RBF and GFR.20 However, the clinical signifi¬
cance of these changes remains unclear and
data on cirrhotic patients are limited.
P Blockers have been shown to reduce the
frusemide stimulated increase in renal inter¬
lobular arterial flow,14 and reduce estimated
RBF in cirrhosis as assessed by Doppler
ultrasonography.1' However, Bataille et al
found no effect on RBF of acute propranolol
treatment when given to cirrhotic patients,24
and no difference in creatinine clearance was
detected between cirrhotic patients given
diuretics alone and those given propranolol
and diuretics.13 In addition, propranolol has
been reported as having no effect on GFR in
cirrhosis despite suppressing renin secretion,25
and Bernardi et al found that propranolol actu¬
ally increased GFR and natriuresis in ascitic
cirrhotics with high sympathetic tone.23 Other
studies have reported both decreased13 and
increased26 natriuresis in cirrhotic patients in
response to propranolol.
Up to 40% of cirrhotic patients do not have
a reduction in portal pressure in response to
propranolol despite a fall in AZBF and are
termed "non-responders". In addition, ap¬
proximately 15% of patients are intolerant of
the drug.27 28 Therefore, nitrates are commonly
used as an alternative treatment, or in combi¬
nation with propranolol.
Nitrates are venodilators that reduce cardiac
output and MAP in cirrhosis.7 16 29 They are
effective in reducing portal pressure and can
convert propranolol non-responders into re-
sponders. This is consistent with our findings
of only a mild reduction in HVPG following
propranolol, but a significant reduction follow¬
ing ISMN and particularly the combination
treatment. Recent studies have suggested that
the combination of ISMN and P blockers may
be the optimum treatment in portal
hypertension." 12
There has been concern that nitrates may
compromise renal function in patients with
advanced liver disease, due to the associated
fall in blood pressure and activation of the
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sympathetic and renin-angiotensin-aldo¬
sterone systems. Vorobioff ei al found that 57%
of cirrhotic patients with ascites or a history of
ascites developed worsening of ascites when
given propranolol and nitrates, compared with
no worsening of ascites in any patient given
propranolol alone.1' ISMN has also been
shown to reduce renal plasma flow, GFR, and
sodium and water excretion and increase renin
and aldosterone values in cirrhosis."* The fall in
GFR and free water clearance was greater in
those patients who had ascites.
However, Morrillos et al found no effect on
inulin clearance, free water clearance, plasma
renin activity, aldosterone concentration, or
ascites outcome in cirrhotic patients given long
term propranolol and ISMN, despite a reduc¬
tion in blood pressure.'0 In addition, Merkel et
al found no deterioration in renal function in
cirrhotic patients given six months of ISMN
and nadolol compared with patients given nad¬
olol alone." Although there was a correlation
between the fall in blood pressure and the rise
in serum creatinine in the group as a whole, it
was only the patients given combination treat¬
ment who had a reduction in their ascites.
More recently, Salerno et al reported that
acute ISMN treatment in cirrhosis reduced
diuresis and natriuresis, and reduced GFR in
patients with ascites.'2 However, the same
study also showed that chronic administration
of ISMN did not affect renal function if
patients did not have ascites, but reduced diu¬
resis and natriuresis in ascitic patients. No
effect on GFR or renal plasma flow was
detected.
It is clear that there are conflicting data in the
literature on this subject which may be due to
differences in the study populations or in the
duration of treatment. Although we did not
assess sodium and water excretion or GFR in
this study, we found no change in RBF despite
the expected changes in MAP, HVPG, and
AZBF following administration of propranolol
and/or ISMN. Despite the fact that all patients
in our study had normal serum creatinine con¬
centrations, it is possible that some may have
had a degree of renal impairment not evident
from their serum creatinine. However, when
ascitic patients alone were assessed, there was
still no effect on RBF. We assessed only the
acute effect of these drugs on RBF, therefore
we cannot draw conclusions regarding pro¬
longed treatment. It is possible that administra¬
tion of these drugs to cirrhotic patients may
compromise renal function by mechanisms
other than a reduction in RBF, such as neuro¬
humoral or tubular effects. However, the main
concern of many of the above studies was a
possible reduction in renal perfusion conse¬
quent on the systemic haemodynamic changes
induced by these drugs.
In view of our desire to assess both AZBF
and RBF in this study, we had to move the
thermodilution catheter out of the renal vein
between the two recordings of RBF. The initial
position of the catheter in the left renal vein was
recorded fiuoroscopically and the catheter
repositioned to the exact same position for the
one hour recording of RBF using fluoroscopic
guidance. To ensure validity of these measure¬
ments, three other cirrhotic patients had multi¬
ple RBF recordings made over one hour, with
the catheter moved in and out of the left renal
vein under similar conditions. The coefficient
of variation in RBF recordings was less than
10%.
Most studies assessing renal plasma flow and
GFR rely on clearance ofp-aminohippuric acid
and inulin respectively, but such methods rely
on high renal extraction of these substances. In
the presence of sepsis or other pathological
conditions leading to tissue hypoxia, micro-
vasular abnormalities, and shunting of blood
such as in cirrhosis, these methods are largely
invalid." Although thermodilution measure¬
ment of RBF has been shown to correlate well
with half the renal blood flow as calculated
from p-aminohippuric acid infusion," ther¬
modilution methods may be more accurate
than clearance techniques in pathological
states.
Using the thermodilution technique, we
found no acute effect on RBF in patients given
propranolol and/or ISMN. The possibility of a
type II error exists, but the numbers studied
produced significant results with regard to the
other haemodynamic parameters, and particu¬
larly in the propranolol group, the patients with
the lower initial RBF (whose renal function
would be of most concern) actually had a rise
in RBF following treatment. Although the
patients given ISMN had slightly lower base¬
line RBF compared with those given pro¬
pranolol or combination treatment, this differ¬
ence was not significant, and as in the other
therapeutic groups, these patients had no
change in RBF after treatment.
In conclusion, we have detected no effect on
RBF following acute administration of pro¬
pranolol, ISMN, or a combination of the two
drugs to cirrhotic patients, despite the antici¬
pated changes in MAP, HVPG, and AZBF.
Therefore any effect of these drugs on renal
function in cirrhosis does not seem to be due to
an acute reduction in RBF.
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Natriuretic Effect of an Adenosine-1 Receptor Antagonist
in Cirrhotic Patients With Ascites
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Background & Aims: The sodium and water retention
and renal vasoconstriction exhibited by patients with
cirrhotic ascites are similar to the changes observed by
stimulation of renal adenosine 1 receptors. The aim of
this study was to investigate the effects of FK352 (an
adenosine 1 antagonist) on renal and systemic hemo¬
dynamics and renal function in cirrhotic patients with
ascites. Methods: p-Aminohippuric acid and inulin
clearance, urine flow rate, sodium and potassium
excretion, and free water clearance were measured for
2 hours before and after FK352 administration. Car¬
diac output, systemic vascular resistance, plasma
angiotensin II level, plasma renin activity, and nor¬
adrenaline, adrenaline, and adenosine 3',5'-cyclic
monophosphate (cAMP) levels were also measured
before and after FK352. Results: Urine sodium excre¬
tion and urine flow rate increased after FK352 by a
mean of 199.9% ± 43.0% (P < 0.001) and 51.2% ±
17.5% (P < 0.02), respectively. Plasma cAMP and
angiotensin II levels and plasma renin activity also
increased by 10.8% ± 3.2% (P < 0.01), 36.9% ±
11.3% (P < 0.01), and 247.9% ± 82.6% (P < 0.02),
respectively. No change was detected in any other
parameter. Conclusions: The isokaliuretic improve¬
ment in natriuresis and diuresis suggests a role for
adenosine 1 antagonism in the treatment of the renal
abnormalities found in advanced cirrhosis.
Patients with advanced cirrhosis have a hyperdynamiccirculation with increased cardi c output and low
systemic vascular resistance.1 However, they also have
evidence of renal vasoconstriction and tubular transport
abnormalities that can lead to a spectrum of renal effects
ranging from sodium and water retention to the develop¬
ment of the hepatorenal syndrome.2
Adenosine is an endogenous nucleoside produced
locally by the intracellular degradation of adenosine
triphosphate in response to hypoxia. It has potent
vasoactive properties with renal hemodynamic and tubu¬
lar effects.3'4 Adenosine 1 receptors are present on the
afferent renal artery and proximal renal tubule, and
stimulation of these inhibit adenyl cyclase, resulting in
renal vasoconstriction and sodium and water retention.5'6
Adenosine 2 receptors are found in the vasculature of the
systemic circulation, and stimulation leads to vasodilata¬
tion via activation of adenyl cyclase.7 These effects are
similar to the abnormalities found in cirrhotic patients,
and it has been suggested that adenosine has a role in the
hemodynamic and renal changes of cirrhosis.8'9
Methylxanthines are nonspecific adenosine antago¬
nists, and studies have shown that they improve renal
blood flow, glomerular filtration rate (GFR), urine vol¬
ume, and sodium and water excretion in cirrhosis, with
variable effects on systemic hemodynamics.8'10'11 How¬
ever, these drugs are far from ideal for use in cirrhosis
because of side effects including tachycardia, gastrointes¬
tinal disturbances, arrhythmias, and convulsions. Cir¬
rhotic patients also clear xanthines poorly, and the drugs
act via phosphodiesterase inhibition at high plasma levels
giving variable effects.12 However, specific adenosine 1
blockade may be beneficial in cirrhotic patients with
impaired sodium and water excretion or functional renal
impairment.
FK352 is a novel pyrazolopyridine derivative that has
been characterized in vitro as a highly selective adeno¬
sine-1 receptor antagonist. In animal studies, it has been
shown to increase renal blood flow, diuresis, and natriure¬
sis. We investigated its effect on renal and systemic




Twelve patients (8 men) with alcohol-induced cirrhosis
and ascites were studied. The mean age was 51.3 ± 2.4 years,
and the mean Child—Pugh score was 8.2 ± 0.5 (8 Child's class
B, 4 Child's class C). Cirrhosis was confirmed by biopsy in 9
patients and by the combination of esophageal varices and
Abbreviations used in this paper: AUC, area under the curve; ERPF,
estimated renal plasma flow; GFR, glomerular filtration rate; MAP,
mean arterial pressure; PAH, p-aminohippuric acid; PRA, plasma
renin activity; V, urine flow rate; UNa, urine sodium concentration;
UnaV, sodium excretion rate.
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chronic derangement in biochemical liver function test results
in the absence of portal vein thrombosis in 3 patients. All
patients had earlier confirmation of ascites by ultrasonography,
and at the time of study ascites was clinically graded as
moderate in 7 patients and mild in 5. No patient was taking
vasoactive medications, and all were on dietary salt restriction.
Ten patients were undergoing diuretic therapy before the
study. Eight patients were taking spironolactone at a mean dose
of 119 mg/day (1 of whom was also taking 40 mg frusemide
daily) and 2 amiloride at a mean dose of 6.7 mg/day (1 ofwhom
was also taking 40 mg frusemide daily). Spironolactone
administration was stopped 1 week before and amiloride and
frusemide 3 days before the study. No patient had biochemical
evidence of renal impairment (defined as serum urea of >6.6
mmol/L or serum creatinine of >120 pmol/L). Patients
abstained from alcohol, cigarettes, and caffeine-containing
substances for 24 hours before the study.
Study Protocol
This was a phase II open-labeled pilot study, designed
primarily to assess the efficacy and safety of FK352. A dose
escalation was built into the study to identify any dose
response. The study was approved by the Lothian Ethics
Committee, and all patients gave informed written consent.
On the morning of the study, patients received a light
breakfast (two slices of toast and half a pint of milk). At 8 AM,
they drank 1 L of water and were then transferred to the
hemodynamic suite where they remained supine until comple¬
tion of the study. A urinary catheter was inserted, and a loading
dose of/>-aminohippuric acid (PAH) (450 mg) and inulin (3.5
g) was administered via a peripheral vein. This was followed at
9 AM by a constant infusion of PAH (16 mg/min) and inulin
(20 mg/min). After local infiltration with 2% lignocaine, an
8.5F gauge right femoral venous introducer sheath (Baxter
Healthcare Corp., Irvine, CA) was inserted, through which the
renal venous and pulmonary artery catheters were positioned
(see below).
A single bolus injection of FK352 (10 mg for the first 4
patients, 25 mg the next 4 patients, and 50 mg the final 4
patients) was administered over a 2-minute period through a
separate peripheral vein at noon. PAH and inulin infusions
were continued for 120 minutes after drug administration.
Clinical Tests
Plasma and urine analyses. Sixty minutes after com¬
mencement of the PAH and inulin infusions, 30-minute urine
collections were obtained for the 2 hours before and the 2 hours
after administration of FK352. Patients were required to drink
100 mL of water during each of these 30-minute periods. The
urine collections were used to measure flow rate (V) and
concentrations of PAH and inulin. Peripheral blood was
sampled at the midpoint of these 30-minute urine collections
to measure PAH and inulin concentrations and therefore
calculate inulin clearance (estimated GFR) and PAH clearance
(estimated renal plasma flow [ERPF]) for each 30-minute
period as follows: {Clearance = (Urine Concentration) X
V/(Plasma Concentration)}.
Four patients also had renal venous PAH concentrations
measured before and after FK352 administration via a catheter
(Webster Laboratories, Baldwin Park, CA) positioned through
the femoral introducer sheath into the left renal vein under
fluoroscopic guidance. The catheter was confirmed to be within
the lumen of the renal vein by injection of 5 mL of dilute
contrast media (Conray 280, May & Baker Ltd., Dagenham,
England). The renal venous PAH levels were used to calculate
the PAH extraction coefficient as follows: {= (Peripheral PAH
Concentration — Renal Vein PAH Concentration)/(Peripheral
PAH Concentration)}. In these 4 patients, this was used to give
the corrected ERPF {= ERPF/PAH Extraction Coefficient}.
Plasma and urine osmolality and sodium and potassium
concentration were measured to calculate the sodium excretion
rate (UNaV, where UNa is the urine concentration of sodium),
potassium excretion rate, and free water clearance {= V —
(Urine Osmolality) X V/(Plasma Osmolality)} for each 30-
minute period.
Plasma and urine was also collected at 15 minutes before and
15, 45, and 105 minutes after administration of FK352 to
measure plasma angiotensin II level, plasma renin activity
(PRA), and adrenaline, noradrenaline, and plasma and urine
adenosine 3',5'-cyclic monophosphate (cAMP) levels.
At the end of the study, the PAH and inulin infusions were
discontinued and the urinary catheter was removed.
Hemodynamic measurements. Under fluoroscopic
guidance, pulmonary artery catheterization (Swan—Ganz cath¬
eter; Baxter Healthcare Corp.) was performed via the femoral
introducer sheath 30 minutes before administration of FK352,
to measure cardiac output and systemic vascular resistance.
These measurements were repeated 120 minutes after drug
administration. During the study, continuous electrocardio¬
graph monitoring was used and heart rate and mean arterial
blood pressure (MAP) were recorded at 15-minute intervals.
After completion of the study (<6 hours in all cases), the
femoral sheath was removed and pressure applied until hemo-
stasis was obtained. The patient was then transferred to the
ward, and monitoring of heart rate and MAP was undertaken
for a further 4 hours. The patients were observed overnight and
reviewed at 1 week for clinical and biochemical assessment.
Laboratory Analysis
Blood samples for PRA, angiotensin II, adrenaline,
noradrenaline, and cAMP determinations were collected on ice.
The supernatant serum from all blood samples and the urine
samples for cAMP measurement were stored at —70°C until
analysis. PRA was measured by I125-radioimmunoassay of
angiotensin I generation (Biodata Diagnostics, Rome, Italy),
and angiotensin II by radioisotope assay with solid-
phase separation step (Nichols Institute Ltd., Newport, Wales).
Catecholamines were measured by high-performance liquid
chromatography and cAMP by radioimmunoassay (Incstar
Ltd., Wokingham, England). PAH and inulin were measured
using high-performance liquid chromatography with fluoromet-
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ric detection and spectrophotometric technique, respectively, as
described previously.13
Data Analysis
Data are expressed as mean values ± SEM. In view of
the repeated measurements on each patient, the drug effect was
analyzed by area under the curve (AUC) based on percentage
change from the mean baseline value. If the AUC was
significant (P < 0.05), Student's t test was used to compare the
mean predrug level with the value at each postdose time point
using the Bonferroni correction. Therefore, the parameters with
four postdose time points (V, UNaV, potassium excretion rate,
and free water clearance) had a significance level of 0.05/4 =
0.0125, and those with three postdose time points (PAH and
inulin clearance and hormone parameters) had a significance
level of 0.05/3 = 0.0167.
Results
All patients tolerated the drug well and com¬
pleted the study without difficulty. No clinical or
biochemical abnormalities were detected at 24 hours or at
the 1-week review. No dose response was detected;
therefore, all results were analyzed for the 12 patients
together.
Changes in Renal Function
After FK352 administration, UNaV increased by
a mean of 199.9% — 43.0% (P < 0.001) from a baseline
mean of 185.9 ± 31.0 pmol/min, remaining elevated for
at least 2 hours (Figure 1). Urine flow rate increased by
51.2% ± 17.5% (P < 0.02) from a mean of 6.49 ± 0.80
mL/min with a maximal increase immediately after drug
administration (Figure 1). There was an increase in free
water clearance by 92.7% ± 53.8% from a mean of
3.56 ± 0.56 mL/min before FK352, but this did not
reach statistical significance (P = 0.11).
There was no change in potassium excretion rate after
FK352 with an increase of 10.0% ± 6.8% from a
baseline of 60.84 ± 9-88 pmol/min. Similarly, no change
was observed in PAH or inulin clearance over the study
period, with a change of 3.8% ± 10.6% and —3.8% ±
3.8% from baseline values of 592.2 ± 60.8 mL/min and
113.8 ± 12.8 mL/min, respectively. In the 4 patients in
whom it was measured, the PAH extraction coefificent
ranged from 0.21 to 0.81, with a mean change in
corrected ERPF after FK352 of— 1.3% — 12.6% from a
baseline value of 454.8 ± 150.3 mL/min.
Changes in Hemodynamics
There was no change in heart rate or MAP during
the study. Similarly, cardiac output (before FK352,
6.42 ± 0.45 L/min; after FK352, 6.38 ± 0.47 L/min)
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Figure 1. Graph showing changes in (A) UNaV (AUC, P < 0.001) and
(6) urine flow rate (AUC, P < 0.02) after administration of FK352.
Application of the Bonferroni correction for multiple comparisons at
individual postdose time points gives a significance level of P =
0.0125. Therefore, the only individual significant values are *P <
0.001 and 'P < 0.005 vs. mean pre-FK352 value.
92.7 dyne • s" 1 • cm-5; after FK352, 1020.2
dyne • s_1 • cm-5) remained unchanged.
102.0
Measurements of Angiotensin II, PRA,
Catecholamines, and cAMP
Plasma cAMP and angiotensin II levels and PRA
increased after FK352 by a mean of 10.8% ± 3.2% (P <
0.01), 36.9% ± 11.3% (P < 0.01), and 247.9% ±
82.6% (P < 0.02), respectively, but no change was
observed in plasma adrenaline or noradrenaline or urine
cAMP levels (Table 1).
Discussion
We have shown an improvement in urine flow and
natriuresis after administration of an adenosine 1—specific
antagonist (FK352) to cirrhotic patients with ascites.
This is the first use of this drug in cirrhotic patients.
The renal abnormalities associated with cirrhosis are
characterized by renal vasoconstriction and an impaired
ability to excrete sodium and water,2,14 but the exact
mechanisms by which such "functional" renal abnormali¬
ties arise remain unclear. Increased oxygen demand and
tissue hypoxia are found in cirrhosis,15,16 which lead to
release of vasodilating substances including adeno-
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Table 1. Percentage Change From Baseline for Angiotensin II, PRA, Catecholamines, and cAMP After FK352 Administration
Time after FK352 administration (mini)
Baseline value 15 45 105 P value (AUC)
PRA 4.14 ± 1.75 ng- mL-1 • h-1 202.7 ± 63.7C 243.7 87.0 349.9 117.7" <0.02
Angiotensin II 30.80 ± 7.67 pg/mL 35.8 ± 10.2a 41.1 ± 17.8 40.7 9.7" <0.01
Adrenaline 0.18 ± 0.04 nmol/L -2.2 ± 12.8 30.3 27.5 30.4 26.0 NS
Noradrenaline 2.76 ± 0.41 nmol/L 0.2 ± 6.3 2.5 5.6 -1.9 9.1 NS
Plasma cAMP 7.53 ± 0.46 nmol/L 8.9 ± 5.3 13.2 3.2" 11.2 4.1 <0.01
Urine cAMP 1072.00 ± 468.37 nmol/L -14.4 ± 9.3 -15.5 11.3 14.6 + 27.2 NS
NOTE. Application of Bonferroni correction for multiple comparisons at individual postdose time points gives a significance level of P = 0.0167.
Therefore, the only individual significant values are aP < 0.005, bP < 0.002, °P < 0.01, and dP = 0.013.
sine.17,18 However, in the kidney, adenosine acts as a
vasoconstrictor, reducing renal perfusion, GFR, and
sodium excretion.4-6,19 Cirrhotic patients seem to have an
increased number of adenosine receptors and increased
sensitivity to adenosine.20-22
Balakrishnan et al.4 reported a decline in urine flow,
natriuresis, free water clearance, and GFR after adminis¬
tration of adenosine to healthy subjects.4 Llach et al.9
showed that increasing extracellular adenosine levels by
administration of dipyridamole to cirrhotic patients
reduced sodium and free water excretion. In their study,
ERPF and GFR were also reduced in patients with ascites
and high basal renin levels. Animal studies have shown
that stimulation of adenosine 1 receptors leads to renal
hemodynamic and tubular effects similar to those found
in cirrhosis.5'6,23 These findings suggest that adenosine
1—specific antagonism may be beneficial in the treatment
of the renal abnormalities of cirrhosis.
Previous use of adenosine 1 antagonists in animal
studies has led to increased diuresis and natriuresis with
minimal systemic effects24 and amelioration of the acute
renal failure induced by glycerol, endotoxin, and cis-
platin.25-27 Adenosine 1 antagonism has also been shown
to attenuate the oliguria, hypofiltration, and electrolyte
disturbance induced by adenosine in an animal model,
suggesting that adenosine 1 antagonists may protect the
kidney from the undesirable hemodynamic and tubular
effects of adenosine.28
After administration of the adenosine 1 antagonist
FK352, we observed an immediate isokaliuretic improve¬
ment in urine flow rate, an increase in natriuresis, and a
tendency for free water clearance to increase. These effects
are of obvious benefit to cirrhotic patients with ascites in
whom sodium and water excretion is impaired and
diuretic therapy often leads to potassium imbalance.29
Little effect on systemic hemodynamics was observed,
possibly reflecting the renal specificity of adenosine 1
receptors, although right heart catheterization was re¬
peated 120 minutes after drug administration, which
may have missed an earlier effect.
A potential holdover from spironolactone, water load¬
ing, and commencement of the supine position may have
led to the relatively high baseline natriuresis and urine
volumes. However, spironolactone was stopped in all
patients 1 week before the study, and urine flow rate,
natriuresis, and free water clearance remained stable for
the 2 hours before FK352 administration. This was
followed by an immediate increase in urine flow and
natriuresis. Any relation of this effect to the fluid load
and posture change 4 hours earlier is improbable and
inconsistent with previous reports.30,31
Although the patients in our study all had clinical
evidence of ascites, none had biochemical renal impair¬
ment or true refractory ascites as defined by Arroyo et
al.32; we therefore cannot extend our findings to these
patient groups. However, there was a consistent increase
in urine flow rate and natriuresis when only patients with
Child's grade C disease were considered. Therapeutic
options for patients with refractory ascites or hepatorenal
syndrome are limited, and any possible therapy requires
evaluation.
The standard method for measuring renal blood flow is
PAH clearance, but in the presence of hypoxia and
shunting of blood (such as occurs in sepsis or cirrhosis),
this method may be invalid because of low renal PAH
extraction.33 In normal subjects, PAH extraction should
be >0.9, but in the 4 patients in whom we measured
this, the PAH extraction ranged from 0.21 to 0.81.
Allowing for this reduced extraction, the corrected ERPF
was lower than the ERPF measured by the standard
method, but there remained no obvious effect of FK352
administration. Inulin clearance remains the gold stan¬
dard for GFR measurement, and no increase in GFR was
detected despite the increased diuresis and natriuresis. It
is possible that FK352 leads to tubular transport changes
via antagonism of adenosine 1 receptors on the tubule
cells, with little effect on renal plasma flow or GFR,
which may be under greater influence from other humeral
control mechanisms.
We observed an increase in plasma angiotensin II and
410 STANLEY ET AL. GASTROENTEROLOGY Vol. 115, No. 2
cAMP levels and in PRA but no change in plasma
catecholamines or urinary cAMP after FK352 administra¬
tion. Stimulation of adenosine 1 receptors inhibits renin
release,34'35 and suppression of this inhibition by theoph¬
ylline or an adenosine-1 receptor antagonist has been
reported to increase PRA.36'37 It has been suggested that
the activity of the renin-angiotensin-aldosterone system
is closely related to impaired natriuresis in cirrhosis.38
However, after administration of FK352 to cirrhotic
patients, we observed an improvement in natriuresis and
urine flow rate despite an increase in PRA and angioten¬
sin II level. This suggests that adenosine 1 antagonism is
unique in being able to counter the detrimental effects on
the kidney of overactivity of the renin-angiotensin-
aldosterone system without a deleterious effect on the
peripheral vasculature.
Stimulation ofadenosine 1 receptors leads to a decrease
in cAMP via adenyl cyclase inhibition,39 and antagonism
of these receptors has been shown to inhibit this decrease
in human glomeruli.40 Therefore, adenosine 1 antago¬
nism by FK352 may explain the observed increase in
plasma cAMP levels. No effect of FK352 on peripheral
catecholamine levels was observed, which may reflect a
limited effect on systemic hemodynamics.
In conclusion, we have demonstrated efficacy and
safety of a novel adenosine 1—specific antagonist in
cirrhotic patients with ascites. Adenosine 1 antagonism
offers a novel approach to the management of cirrhotic
ascites and the spectrum of renal abnormalities found in
cirrhosis. Further studies are required to assess its
potential role in this condition.
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